<TABLE border="1" cellpading="0" cellspacing="0">
<TR><TH>P-value</TH><TD>ln(P)</TD><TD>Term</TD><TD>GO Tree</TD><TD>GO ID</TD><TD># of Genes in Term</TD><TD># of Target Genes in Term</TD><TD># of Total Genes</TD><TD># of Target Genes</TD><TD>Common Genes</TD></TR>
<tr><td>4.193e-14</td><td>-30.80</td><td>WU CELL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>179</td><td>10</td><td>17621</td><td>26</td><td>
KRT7, IGFBP6, GPR87, MAGEA3, SLPI, TGM2, RBPMS, MAGEA6, THBS1, IGFBP3</td></tr><tr><td>1.188e-10</td><td>-22.85</td><td>MODULE 6</td><td>MSigDB lists</td><td>&nbsp;</td><td>398</td><td>10</td><td>17621</td><td>26</td><td>
CEACAM6, KRT7, IGFBP6, SLPI, TGM2, CEACAM5, RBPMS, PI3, ELF3, IGFBP3</td></tr><tr><td>3.025e-10</td><td>-21.92</td><td>DELYS THYROID CANCER UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>438</td><td>10</td><td>17621</td><td>26</td><td>
CEACAM6, TNFAIP6, IGFBP6, SCG5, TGFA, SLPI, TGM2, THBS1, IGFBP3, ELF3</td></tr><tr><td>1.323e-09</td><td>-20.44</td><td>GOZGIT ESR1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>687</td><td>11</td><td>17621</td><td>26</td><td>
GPR37, CEACAM6, IGFBP6, TGFA, INPP4B, TNFRSF11B, CEACAM5, TGM2, ATP1B1, RBPMS, THBS1</td></tr><tr><td>8.226e-09</td><td>-18.62</td><td>ONDER CDH1 TARGETS 2 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>445</td><td>9</td><td>17621</td><td>26</td><td>
DST, CEACAM6, CXCL3, TGFA, GPR87, INPP4B, SLPI, ANO1, PI3</td></tr><tr><td>1.400e-08</td><td>-18.08</td><td>ONDER CDH1 TARGETS 3 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>54</td><td>5</td><td>17621</td><td>26</td><td>
CEACAM6, CXCL3, TGFA, ANO1, PI3</td></tr><tr><td>7.082e-08</td><td>-16.46</td><td>MCBRYAN PUBERTAL BREAST 4 5WK UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>259</td><td>7</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, TGM2, KRT7, IGFBP6, ANO1, THBS1</td></tr><tr><td>8.207e-08</td><td>-16.32</td><td>BOQUEST STEM CELL CULTURED VS FRESH UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>407</td><td>8</td><td>17621</td><td>26</td><td>
TNFAIP6, KRT7, CXCL3, SCG5, TNFRSF11B, TGM2, ANO1, THBS1</td></tr><tr><td>1.049e-07</td><td>-16.07</td><td>ONDER CDH1 TARGETS 1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>161</td><td>6</td><td>17621</td><td>26</td><td>
CEACAM6, ANO1, CXCL3, TGFA, PI3, IGFBP3</td></tr><tr><td>3.516e-07</td><td>-14.86</td><td>LIN SILENCED BY TUMOR MICROENVIRONMENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>102</td><td>5</td><td>17621</td><td>26</td><td>
CEACAM6, KRT7, PI3, INPP4B, ELF3</td></tr><tr><td>1.075e-06</td><td>-13.74</td><td>KOINUMA TARGETS OF SMAD2 OR SMAD3</td><td>MSigDB lists</td><td>&nbsp;</td><td>788</td><td>9</td><td>17621</td><td>26</td><td>
DST, PCDH1, KRT7, TGFA, GPR87, TGM2, ANO1, THBS1, IGFBP3</td></tr><tr><td>1.627e-06</td><td>-13.33</td><td>extracellular region part</td><td>cellular component</td><td>GO:0044421</td><td>3790</td><td>17</td><td>17744</td><td>26</td><td>
CEACAM6, TNFAIP6, KRT7, IGFBP6, CXCL3, TGFA, SLPI, ATP1B1, TFF2, ANO1, PI3, THBS1, DST, TNFRSF11B, TGM2, CEACAM5, IGFBP3</td></tr><tr><td>1.914e-06</td><td>-13.17</td><td>MAGEA3/MAGEA6</td><td>interpro domains</td><td>IPR030097</td><td>2</td><td>2</td><td>18428</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.968e-06</td><td>-13.14</td><td>MODULE 5</td><td>MSigDB lists</td><td>&nbsp;</td><td>424</td><td>7</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, TGM2, RBPMS, KRT7, IGFBP6, THBS1</td></tr><tr><td>1.998e-06</td><td>-13.12</td><td>KRAS.600.LUNG.BREAST UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>266</td><td>6</td><td>17621</td><td>26</td><td>
MAGEA6, CXCL3, SCG5, ANO1, MAGEA3, IGFBP3</td></tr><tr><td>2.423e-06</td><td>-12.93</td><td>HELLER SILENCED BY METHYLATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>275</td><td>6</td><td>17621</td><td>26</td><td>
TNFAIP6, TFF2, MAGEA6, KRT7, MAGEA3, IGFBP3</td></tr><tr><td>2.873e-06</td><td>-12.76</td><td>extracellular region</td><td>cellular component</td><td>GO:0005576</td><td>4466</td><td>18</td><td>17744</td><td>26</td><td>
CEACAM6, TNFAIP6, KRT7, IGFBP6, CXCL3, TGFA, SLPI, ATP1B1, TFF2, ANO1, PI3, THBS1, DST, SCG5, TNFRSF11B, TGM2, CEACAM5, IGFBP3</td></tr><tr><td>3.073e-06</td><td>-12.69</td><td>SENGUPTA NASOPHARYNGEAL CARCINOMA WITH LMP1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>158</td><td>5</td><td>17621</td><td>26</td><td>
CEACAM6, MAGEA6, KRT7, PI3, MAGEA3</td></tr><tr><td>3.689e-06</td><td>-12.51</td><td>ELVIDGE HYPOXIA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>164</td><td>5</td><td>17621</td><td>26</td><td>
DST, KRT7, GPR87, ELF3, IGFBP3</td></tr><tr><td>4.140e-06</td><td>-12.39</td><td>IGF2 (insulin like growth factor 2)</td><td>protein interactions</td><td>3481</td><td>21</td><td>3</td><td>16330</td><td>25</td><td>
RBPMS, IGFBP6, IGFBP3</td></tr><tr><td>4.151e-06</td><td>-12.39</td><td>GSE41867 DAY6 VS DAY15 LCMV ARMSTRONG EFFECTOR CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>168</td><td>5</td><td>17621</td><td>26</td><td>
TNFAIP6, CEACAM5, MAGEA6, CXCL3, MAGEA3</td></tr><tr><td>4.383e-06</td><td>-12.34</td><td>WONG ADULT TISSUE STEM MODULE</td><td>MSigDB lists</td><td>&nbsp;</td><td>689</td><td>8</td><td>17621</td><td>26</td><td>
DST, TNFAIP6, SCG5, TNFRSF11B, TGM2, RBPMS, IGFBP3, THBS1</td></tr><tr><td>4.571e-06</td><td>-12.30</td><td>LEI MYB TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>307</td><td>6</td><td>17621</td><td>26</td><td>
DST, CEACAM6, TNFAIP6, TGM2, KRT7, PI3</td></tr><tr><td>4.658e-06</td><td>-12.28</td><td>LI AMPLIFIED IN LUNG CANCER</td><td>MSigDB lists</td><td>&nbsp;</td><td>172</td><td>5</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5, ATP1B1, KRT7, IGFBP3</td></tr><tr><td>5.068e-06</td><td>-12.19</td><td>TURASHVILI BREAST DUCTAL CARCINOMA VS DUCTAL NORMAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>175</td><td>5</td><td>17621</td><td>26</td><td>
DST, RBPMS, KRT7, TGFA, ELF3</td></tr><tr><td>5.659e-06</td><td>-12.08</td><td>GSE9006 HEALTHY VS TYPE 1 DIABETES PBMC AT DX DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>179</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, MAGEA6, PI3, MAGEA3</td></tr><tr><td>6.023e-06</td><td>-12.02</td><td>HOOI ST7 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>82</td><td>4</td><td>17621</td><td>26</td><td>
TGFA, PI3, GPR87, INPP4B</td></tr><tr><td>6.303e-06</td><td>-11.97</td><td>ERB2 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>5</td><td>17621</td><td>26</td><td>
CEACAM6, TNFRSF11B, CEACAM5, PCDH1, KRT7</td></tr><tr><td>7.187e-06</td><td>-11.84</td><td>MEK UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>5</td><td>17621</td><td>26</td><td>
CEACAM6, TNFRSF11B, CEACAM5, PCDH1, KRT7</td></tr><tr><td>8.031e-06</td><td>-11.73</td><td>NABA MATRISOME</td><td>MSigDB lists</td><td>&nbsp;</td><td>1006</td><td>9</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, CXCL3, TGFA, SLPI, TGM2, PI3, THBS1, IGFBP3</td></tr><tr><td>8.585e-06</td><td>-11.67</td><td>HALLMARK EPITHELIAL MESENCHYMAL TRANSITION</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>5</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, TGM2, IGFBP3, THBS1</td></tr><tr><td>9.838e-06</td><td>-11.53</td><td>WANG SMARCE1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>351</td><td>6</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGM2, MAGEA6, CXCL3, MAGEA3, INPP4B</td></tr><tr><td>9.999e-06</td><td>-11.51</td><td>MODULE 12</td><td>MSigDB lists</td><td>&nbsp;</td><td>352</td><td>6</td><td>17621</td><td>26</td><td>
DST, SLPI, TGM2, IGFBP6, SCG5, IGFBP3</td></tr><tr><td>1.084e-05</td><td>-11.43</td><td>MODULE 1</td><td>MSigDB lists</td><td>&nbsp;</td><td>357</td><td>6</td><td>17621</td><td>26</td><td>
DST, SLPI, TGM2, RBPMS, IGFBP6, IGFBP3</td></tr><tr><td>1.288e-05</td><td>-11.26</td><td>MODULE 33</td><td>MSigDB lists</td><td>&nbsp;</td><td>368</td><td>6</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, KRT7, IGFBP6, ELF3, THBS1</td></tr><tr><td>1.385e-05</td><td>-11.19</td><td>ELANE (elastase, neutrophil expressed)</td><td>protein interactions</td><td>1991</td><td>31</td><td>3</td><td>16330</td><td>25</td><td>
SLPI, TGFA, THBS1</td></tr><tr><td>1.390e-05</td><td>-11.18</td><td>MODULE 2</td><td>MSigDB lists</td><td>&nbsp;</td><td>373</td><td>6</td><td>17621</td><td>26</td><td>
DST, SLPI, TGM2, IGFBP6, RBPMS, IGFBP3</td></tr><tr><td>1.441e-05</td><td>-11.15</td><td>MODULE 47</td><td>MSigDB lists</td><td>&nbsp;</td><td>217</td><td>5</td><td>17621</td><td>26</td><td>
TNFRSF11B, TNFAIP6, SCG5, IGFBP3, THBS1</td></tr><tr><td>1.574e-05</td><td>-11.06</td><td>SENESE HDAC1 AND HDAC2 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>221</td><td>5</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGM2, SCG5, CXCL3, PI3</td></tr><tr><td>1.592e-05</td><td>-11.05</td><td>extracellular space</td><td>cellular component</td><td>GO:0005615</td><td>1411</td><td>10</td><td>17744</td><td>26</td><td>
CEACAM6, TNFAIP6, IGFBP6, CXCL3, TGFA, SLPI, TNFRSF11B, TFF2, THBS1, IGFBP3</td></tr><tr><td>1.908e-05</td><td>-10.87</td><td>WINTER HYPOXIA METAGENE</td><td>MSigDB lists</td><td>&nbsp;</td><td>230</td><td>5</td><td>17621</td><td>26</td><td>
TGM2, TGFA, ELF3, IGFBP3, THBS1</td></tr><tr><td>2.143e-05</td><td>-10.75</td><td>GEISS RESPONSE TO DSRNA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>37</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, ELF3</td></tr><tr><td>2.150e-05</td><td>-10.75</td><td>LENAOUR DENDRITIC CELL MATURATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>113</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, ATP1B1, TGM2, TGFA</td></tr><tr><td>2.224e-05</td><td>-10.71</td><td>SMID BREAST CANCER BASAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>614</td><td>7</td><td>17621</td><td>26</td><td>
GPR37, SLPI, TNFRSF11B, TFF2, MAGEA6, PI3, MAGEA3</td></tr><tr><td>2.325e-05</td><td>-10.67</td><td>chr20q12</td><td>MSigDB lists</td><td>&nbsp;</td><td>38</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TGM2, PI3</td></tr><tr><td>2.861e-05</td><td>-10.46</td><td>IGFBP 1-6 chordata</td><td>interpro domains</td><td>IPR022321</td><td>6</td><td>2</td><td>18428</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.861e-05</td><td>-10.46</td><td>IGFBP1-6</td><td>interpro domains</td><td>IPR009168</td><td>6</td><td>2</td><td>18428</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.943e-05</td><td>-10.43</td><td>CHARAFE BREAST CANCER LUMINAL VS BASAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>426</td><td>6</td><td>17621</td><td>26</td><td>
DST, SLPI, IGFBP6, CXCL3, TGFA, PI3</td></tr><tr><td>3.014e-05</td><td>-10.41</td><td>MODULE 112</td><td>MSigDB lists</td><td>&nbsp;</td><td>253</td><td>5</td><td>17621</td><td>26</td><td>
TNFRSF11B, CEACAM5, CXCL3, TGFA, THBS1</td></tr><tr><td>3.129e-05</td><td>-10.37</td><td>CHOI ATL ACUTE STAGE</td><td>MSigDB lists</td><td>&nbsp;</td><td>6</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>3.298e-05</td><td>-10.32</td><td>ELVIDGE HYPOXIA BY DMOG UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>126</td><td>4</td><td>17621</td><td>26</td><td>
DST, GPR87, ELF3, IGFBP3</td></tr><tr><td>3.372e-05</td><td>-10.30</td><td>KRAS.600 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>259</td><td>5</td><td>17621</td><td>26</td><td>
GPR37, TGM2, SCG5, ANO1, CXCL3</td></tr><tr><td>3.958e-05</td><td>-10.14</td><td>KRAS.LUNG UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>132</td><td>4</td><td>17621</td><td>26</td><td>
MAGEA6, SCG5, ANO1, MAGEA3</td></tr><tr><td>4.152e-05</td><td>-10.09</td><td>LIU PROSTATE CANCER DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>453</td><td>6</td><td>17621</td><td>26</td><td>
DST, CEACAM6, RBPMS, KRT7, ANO1, GPR87</td></tr><tr><td>4.415e-05</td><td>-10.03</td><td>LIM MAMMARY STEM CELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>458</td><td>6</td><td>17621</td><td>26</td><td>
DST, IGFBP6, RBPMS, GPR87, THBS1, IGFBP3</td></tr><tr><td>4.703e-05</td><td>-9.96</td><td>CEACAM6 (carcinoembryonic antigen related cell adhesion molecule 6)</td><td>protein interactions</td><td>4680</td><td>7</td><td>2</td><td>16330</td><td>25</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>5.023e-05</td><td>-9.90</td><td>HALMOS CEBPA TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>49</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, CXCL3, IGFBP3</td></tr><tr><td>5.023e-05</td><td>-9.90</td><td>TSUNODA CISPLATIN RESISTANCE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>49</td><td>3</td><td>17621</td><td>26</td><td>
MAGEA6, KRT7, MAGEA3</td></tr><tr><td>5.338e-05</td><td>-9.84</td><td>LI WILMS TUMOR VS FETAL KIDNEY 2 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>50</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, TGFA, THBS1</td></tr><tr><td>6.007e-05</td><td>-9.72</td><td>HUPER BREAST BASAL VS LUMINAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>52</td><td>3</td><td>17621</td><td>26</td><td>
DST, SLPI, PI3</td></tr><tr><td>6.025e-05</td><td>-9.72</td><td>MODULE 92</td><td>MSigDB lists</td><td>&nbsp;</td><td>147</td><td>4</td><td>17621</td><td>26</td><td>
CEACAM6, TFF2, PCDH1, TGFA</td></tr><tr><td>6.073e-05</td><td>-9.71</td><td>DUTERTRE ESTRADIOL RESPONSE 24HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>485</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, CEACAM6, ATP1B1, PCDH1, ELF3, IGFBP3</td></tr><tr><td>6.166e-05</td><td>-9.69</td><td>SMID BREAST CANCER RELAPSE IN BONE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>294</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, TNFRSF11B, MAGEA6, PI3, MAGEA3</td></tr><tr><td>6.526e-05</td><td>-9.64</td><td>insulin-like growth factor II binding</td><td>molecular function</td><td>GO:0031995</td><td>8</td><td>2</td><td>16652</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>7.592e-05</td><td>-9.49</td><td>PETROVA ENDOTHELIUM LYMPHATIC VS BLOOD DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>156</td><td>4</td><td>17621</td><td>26</td><td>
ATP1B1, PCDH1, TGM2, KRT7</td></tr><tr><td>8.062e-05</td><td>-9.43</td><td>extracellular matrix</td><td>cellular component</td><td>GO:0031012</td><td>514</td><td>6</td><td>17744</td><td>26</td><td>
DST, SLPI, TNFRSF11B, TGM2, PI3, THBS1</td></tr><tr><td>8.338e-05</td><td>-9.39</td><td>CROONQUIST STROMAL STIMULATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>58</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, CXCL3, IGFBP3</td></tr><tr><td>9.229e-05</td><td>-9.29</td><td>BOSCO EPITHELIAL DIFFERENTIATION MODULE</td><td>MSigDB lists</td><td>&nbsp;</td><td>60</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5, ELF3</td></tr><tr><td>9.229e-05</td><td>-9.29</td><td>LEE LIVER CANCER MYC TGFA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>60</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, IGFBP6, ELF3</td></tr><tr><td>9.315e-05</td><td>-9.28</td><td>SMID BREAST CANCER LUMINAL B DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>524</td><td>6</td><td>17621</td><td>26</td><td>
DST, SLPI, TNFRSF11B, KRT7, PI3, IGFBP3</td></tr><tr><td>1.012e-04</td><td>-9.20</td><td>TAKEDA TARGETS OF NUP98 HOXA9 FUSION 3D UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>168</td><td>4</td><td>17621</td><td>26</td><td>
DST, ATP1B1, RBPMS, INPP4B</td></tr><tr><td>1.035e-04</td><td>-9.18</td><td>BROWNE HCMV INFECTION 18HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>169</td><td>4</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, RBPMS, THBS1</td></tr><tr><td>1.042e-04</td><td>-9.17</td><td>IGFBPFAMILY</td><td>prints domains</td><td>PR01976</td><td>6</td><td>2</td><td>4725</td><td>13</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.068e-04</td><td>-9.14</td><td>GRAHAM NORMAL QUIESCENT VS NORMAL DIVIDING UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>63</td><td>3</td><td>17621</td><td>26</td><td>
DST, RBPMS, CXCL3</td></tr><tr><td>1.119e-04</td><td>-9.10</td><td>WILCOX RESPONSE TO PROGESTERONE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>64</td><td>3</td><td>17621</td><td>26</td><td>
DST, IGFBP3, THBS1</td></tr><tr><td>1.185e-04</td><td>-9.04</td><td>GSE29615 CTRL VS LAIV FLU VACCINE PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>175</td><td>4</td><td>17621</td><td>26</td><td>
CEACAM6, TNFAIP6, ATP1B1, PI3</td></tr><tr><td>1.227e-04</td><td>-9.01</td><td>HLA-DRB4 (major histocompatibility complex, class II, DR beta 4)</td><td>protein interactions</td><td>3126</td><td>11</td><td>2</td><td>16330</td><td>25</td><td>
ATP1B1, MAGEA6</td></tr><tr><td>1.265e-04</td><td>-8.98</td><td>TAKEDA TARGETS OF NUP98 HOXA9 FUSION 10D UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, RBPMS, INPP4B, THBS1</td></tr><tr><td>1.283e-04</td><td>-8.96</td><td>MARTINEZ RESPONSE TO TRABECTEDIN UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>67</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, CXCL3, SCG5</td></tr><tr><td>1.300e-04</td><td>-8.95</td><td>plasma membrane part</td><td>cellular component</td><td>GO:0044459</td><td>2613</td><td>12</td><td>17744</td><td>26</td><td>
GPR37, DST, CEACAM6, PCDH1, TGFA, GPR87, TNFRSF11B, TGM2, ATP1B1, CEACAM5, ANO1, THBS1</td></tr><tr><td>1.369e-04</td><td>-8.90</td><td>MODULE 190</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.467e-04</td><td>-8.83</td><td>GSE16450 CTRL VS IFNA 12H STIM MATURE NEURON CELL LINE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>4</td><td>17621</td><td>26</td><td>
IGFBP6, GPR87, ELF3, IGFBP3</td></tr><tr><td>1.532e-04</td><td>-8.78</td><td>insulin-like growth factor I binding</td><td>molecular function</td><td>GO:0031994</td><td>12</td><td>2</td><td>16652</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.590e-04</td><td>-8.75</td><td>SEITZ NEOPLASTIC TRANSFORMATION BY 8P DELETION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>72</td><td>3</td><td>17621</td><td>26</td><td>
MAGEA6, IGFBP6, MAGEA3</td></tr><tr><td>1.617e-04</td><td>-8.73</td><td>WACKER HYPOXIA TARGETS OF VHL</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, IGFBP3</td></tr><tr><td>1.626e-04</td><td>-8.72</td><td>NABA ECM GLYCOPROTEINS</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, IGFBP3, THBS1</td></tr><tr><td>1.693e-04</td><td>-8.68</td><td>GSE18281 CORTICAL VS MEDULLARY THYMOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, TFF2, TGM2, CXCL3</td></tr><tr><td>1.796e-04</td><td>-8.62</td><td>HALLMARK KRAS SIGNALING UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, SCG5, ANO1, IGFBP3</td></tr><tr><td>1.819e-04</td><td>-8.61</td><td>basolateral plasma membrane</td><td>cellular component</td><td>GO:0016323</td><td>197</td><td>4</td><td>17744</td><td>26</td><td>
DST, CEACAM5, ATP1B1, TGFA</td></tr><tr><td>1.820e-04</td><td>-8.61</td><td>functioning</td><td>COSMIC cancer mutations</td><td>functioning</td><td>1862</td><td>10</td><td>17630</td><td>26</td><td>
GPR37, PCDH1, SCG5, INPP4B, SLPI, TNFRSF11B, TGM2, CEACAM5, THBS1, IGFBP3</td></tr><tr><td>1.820e-04</td><td>-8.61</td><td>adrenal gland-adrenal gland-adrenal cortical carcinoma-functioning</td><td>COSMIC cancer mutations</td><td>adrenal_gland-adrenal_gland-adrenal_cortical_carcinoma-functioning</td><td>1862</td><td>10</td><td>17630</td><td>26</td><td>
GPR37, PCDH1, SCG5, INPP4B, SLPI, TNFRSF11B, TGM2, CEACAM5, THBS1, IGFBP3</td></tr><tr><td>1.868e-04</td><td>-8.59</td><td>HALLMARK GLYCOLYSIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>197</td><td>4</td><td>17621</td><td>26</td><td>
TGFA, GPR87, ELF3, IGFBP3</td></tr><tr><td>1.939e-04</td><td>-8.55</td><td>4DISULPHCORE</td><td>prints domains</td><td>PR00003</td><td>8</td><td>2</td><td>4725</td><td>13</td><td>
SLPI, PI3</td></tr><tr><td>1.940e-04</td><td>-8.55</td><td>FRIDMAN SENESCENCE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>77</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3, THBS1</td></tr><tr><td>1.951e-04</td><td>-8.54</td><td>adrenal gland</td><td>COSMIC cancer mutations</td><td>adrenal_gland</td><td>2706</td><td>12</td><td>17630</td><td>26</td><td>
GPR37, CEACAM6, PCDH1, SCG5, INPP4B, SLPI, TNFRSF11B, TGM2, CEACAM5, ANO1, IGFBP3, THBS1</td></tr><tr><td>1.980e-04</td><td>-8.53</td><td>MODULE 342</td><td>MSigDB lists</td><td>&nbsp;</td><td>200</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, KRT7, ELF3</td></tr><tr><td>2.023e-04</td><td>-8.51</td><td>WAP</td><td>pfam domains</td><td>PF00095</td><td>15</td><td>2</td><td>16832</td><td>24</td><td>
SLPI, PI3</td></tr><tr><td>2.056e-04</td><td>-8.49</td><td>MIYAGAWA TARGETS OF EWSR1 ETS FUSIONS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>202</td><td>4</td><td>17621</td><td>26</td><td>
TNFRSF11B, SCG5, INPP4B, IGFBP3</td></tr><tr><td>2.062e-04</td><td>-8.49</td><td>extracellular exosome</td><td>cellular component</td><td>GO:0070062</td><td>2739</td><td>12</td><td>17744</td><td>26</td><td>
DST, KRT7, IGFBP6, SLPI, CEACAM5, TFF2, TGM2, ATP1B1, ANO1, PI3, THBS1, IGFBP3</td></tr><tr><td>2.093e-04</td><td>-8.47</td><td>HARRIS HYPOXIA</td><td>MSigDB lists</td><td>&nbsp;</td><td>79</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, TGFA, IGFBP3</td></tr><tr><td>2.172e-04</td><td>-8.43</td><td>MATTIOLI MULTIPLE MYELOMA SUBGROUPS</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.173e-04</td><td>-8.43</td><td>BASSO HAIRY CELL LEUKEMIA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>80</td><td>3</td><td>17621</td><td>26</td><td>
DST, THBS1, IGFBP3</td></tr><tr><td>2.174e-04</td><td>-8.43</td><td>extracellular vesicle</td><td>cellular component</td><td>GO:1903561</td><td>2754</td><td>12</td><td>17744</td><td>26</td><td>
DST, KRT7, IGFBP6, SLPI, CEACAM5, TFF2, TGM2, ATP1B1, ANO1, PI3, THBS1, IGFBP3</td></tr><tr><td>2.182e-04</td><td>-8.43</td><td>extracellular organelle</td><td>cellular component</td><td>GO:0043230</td><td>2755</td><td>12</td><td>17744</td><td>26</td><td>
DST, KRT7, IGFBP6, SLPI, CEACAM5, TFF2, TGM2, ATP1B1, ANO1, PI3, THBS1, IGFBP3</td></tr><tr><td>2.300e-04</td><td>-8.38</td><td>GO BASOLATERAL PLASMA MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>208</td><td>4</td><td>17621</td><td>26</td><td>
DST, ATP1B1, CEACAM5, TGFA</td></tr><tr><td>2.423e-04</td><td>-8.33</td><td>HINATA NFKB TARGETS FIBROBLAST UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>83</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, KRT7, CXCL3</td></tr><tr><td>2.480e-04</td><td>-8.30</td><td>REACTOME REGULATION OF INSULIN LIKE GROWTH FACTOR IGF ACTIVITY BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.570e-04</td><td>-8.27</td><td>Thyroglobulin 1</td><td>interpro domains</td><td>IPR000716</td><td>17</td><td>2</td><td>18428</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.570e-04</td><td>-8.27</td><td>WAP dom</td><td>interpro domains</td><td>IPR008197</td><td>17</td><td>2</td><td>18428</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>2.616e-04</td><td>-8.25</td><td>Thyroglobulin 1</td><td>pfam domains</td><td>PF00086</td><td>17</td><td>2</td><td>16832</td><td>24</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.665e-04</td><td>-8.23</td><td>IGF1 (insulin like growth factor 1)</td><td>protein interactions</td><td>3479</td><td>16</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.701e-04</td><td>-8.22</td><td>GO INTRINSIC COMPONENT OF PLASMA MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>1573</td><td>9</td><td>17621</td><td>26</td><td>
GPR37, CEACAM6, PCDH1, TGFA, GPR87, TNFRSF11B, TGM2, ATP1B1, CEACAM5</td></tr><tr><td>2.784e-04</td><td>-8.19</td><td>NAKAYAMA SOFT TISSUE TUMORS PCA2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>87</td><td>3</td><td>17621</td><td>26</td><td>
MAGEA6, SCG5, MAGEA3</td></tr><tr><td>2.809e-04</td><td>-8.18</td><td>ZEMBUTSU SENSITIVITY TO FLUOROURACIL</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.809e-04</td><td>-8.18</td><td>LOPEZ MBD TARGETS IMPRINTED AND X LINKED</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.809e-04</td><td>-8.18</td><td>INGA TP53 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>2.809e-04</td><td>-8.18</td><td>MODULE 474</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.809e-04</td><td>-8.18</td><td>ZEMBUTSU SENSITIVITY TO CYCLOPHOSPHAMIDE</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ELF3</td></tr><tr><td>2.891e-04</td><td>-8.15</td><td>GO EXTRACELLULAR MATRIX</td><td>MSigDB lists</td><td>&nbsp;</td><td>409</td><td>5</td><td>17621</td><td>26</td><td>
DST, SLPI, TNFRSF11B, PI3, THBS1</td></tr><tr><td>2.930e-04</td><td>-8.14</td><td>WAP</td><td>smart domains</td><td>SM00217</td><td>13</td><td>2</td><td>9480</td><td>19</td><td>
SLPI, PI3</td></tr><tr><td>2.930e-04</td><td>-8.14</td><td>-</td><td>gene3d domains</td><td>4.10.75.10</td><td>17</td><td>2</td><td>10485</td><td>16</td><td>
SLPI, PI3</td></tr><tr><td>2.930e-04</td><td>-8.14</td><td>-</td><td>gene3d domains</td><td>4.10.800.10</td><td>17</td><td>2</td><td>10485</td><td>16</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.977e-04</td><td>-8.12</td><td>HINATA NFKB TARGETS KERATINOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>89</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, KRT7, CXCL3</td></tr><tr><td>3.017e-04</td><td>-8.11</td><td>COL5A1 (collagen type V alpha 1 chain)</td><td>protein interactions</td><td>1289</td><td>17</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, THBS1</td></tr><tr><td>3.143e-04</td><td>-8.07</td><td>CXCR chemokine receptor binding</td><td>molecular function</td><td>GO:0045236</td><td>17</td><td>2</td><td>16652</td><td>26</td><td>
TFF2, CXCL3</td></tr><tr><td>3.157e-04</td><td>-8.06</td><td>ALONSO METASTASIS NEURAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>3.282e-04</td><td>-8.02</td><td>SMID BREAST CANCER RELAPSE IN BONE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>92</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5, INPP4B</td></tr><tr><td>3.340e-04</td><td>-8.00</td><td>SENESE HDAC1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>422</td><td>5</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGM2, CXCL3, SCG5, PI3</td></tr><tr><td>3.391e-04</td><td>-7.99</td><td>LTBP1 (latent transforming growth factor beta binding protein 1)</td><td>protein interactions</td><td>4052</td><td>18</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, IGFBP3</td></tr><tr><td>3.581e-04</td><td>-7.93</td><td>MAGE N</td><td>interpro domains</td><td>IPR021072</td><td>20</td><td>2</td><td>18428</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>3.581e-04</td><td>-7.93</td><td>IGFBP-like</td><td>interpro domains</td><td>IPR000867</td><td>20</td><td>2</td><td>18428</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>3.589e-04</td><td>-7.93</td><td>GO EXTRACELLULAR SPACE</td><td>MSigDB lists</td><td>&nbsp;</td><td>1278</td><td>8</td><td>17621</td><td>26</td><td>
CEACAM6, IGFBP6, CXCL3, TGFA, SLPI, TNFRSF11B, THBS1, IGFBP3</td></tr><tr><td>3.644e-04</td><td>-7.92</td><td>MAGE N</td><td>pfam domains</td><td>PF12440</td><td>20</td><td>2</td><td>16832</td><td>24</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>3.644e-04</td><td>-7.92</td><td>IGFBP</td><td>pfam domains</td><td>PF00219</td><td>20</td><td>2</td><td>16832</td><td>24</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>3.835e-04</td><td>-7.87</td><td>WINZEN DEGRADED VIA KHSRP</td><td>MSigDB lists</td><td>&nbsp;</td><td>97</td><td>3</td><td>17621</td><td>26</td><td>
SCG5, CXCL3, TGFA</td></tr><tr><td>3.921e-04</td><td>-7.84</td><td>GO INFLAMMATORY RESPONSE</td><td>MSigDB lists</td><td>&nbsp;</td><td>437</td><td>5</td><td>17621</td><td>26</td><td>
TNFRSF11B, TNFAIP6, CXCL3, ELF3, THBS1</td></tr><tr><td>3.995e-04</td><td>-7.83</td><td>response to magnesium ion</td><td>biological process</td><td>GO:0032026</td><td>19</td><td>2</td><td>16543</td><td>26</td><td>
TNFRSF11B, THBS1</td></tr><tr><td>4.140e-04</td><td>-7.79</td><td>negative regulation of endopeptidase activity</td><td>biological process</td><td>GO:0010951</td><td>228</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>4.142e-04</td><td>-7.79</td><td>NUYTTEN EZH2 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>979</td><td>7</td><td>17621</td><td>26</td><td>
GPR37, ATP1B1, TGM2, GPR87, PI3, THBS1, IGFBP3</td></tr><tr><td>4.180e-04</td><td>-7.78</td><td>WAP</td><td>prosite domains</td><td>PS51390</td><td>16</td><td>2</td><td>11955</td><td>23</td><td>
SLPI, PI3</td></tr><tr><td>4.204e-04</td><td>-7.77</td><td>CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1)</td><td>protein interactions</td><td>634</td><td>20</td><td>2</td><td>16330</td><td>25</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>4.305e-04</td><td>-7.75</td><td>MODULE 38</td><td>MSigDB lists</td><td>&nbsp;</td><td>446</td><td>5</td><td>17621</td><td>26</td><td>
PCDH1, TGM2, RBPMS, KRT7, IGFBP3</td></tr><tr><td>4.321e-04</td><td>-7.75</td><td>ROY WOUND BLOOD VESSEL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, ATP1B1</td></tr><tr><td>4.556e-04</td><td>-7.69</td><td>JAEGER METASTASIS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>249</td><td>4</td><td>17621</td><td>26</td><td>
DST, SLPI, GPR87, PI3</td></tr><tr><td>4.576e-04</td><td>-7.69</td><td>GO POSITIVE REGULATION OF MAPK CASCADE</td><td>MSigDB lists</td><td>&nbsp;</td><td>452</td><td>5</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, TGFA, IGFBP3, THBS1</td></tr><tr><td>4.731e-04</td><td>-7.66</td><td>THYROGLOBULIN 1 2</td><td>prosite domains</td><td>PS51162</td><td>17</td><td>2</td><td>11955</td><td>23</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>4.731e-04</td><td>-7.66</td><td>THYROGLOBULIN 1 1</td><td>prosite domains</td><td>PS00484</td><td>17</td><td>2</td><td>11955</td><td>23</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>4.749e-04</td><td>-7.65</td><td>ZIRN TRETINOIN RESPONSE WT1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>4.749e-04</td><td>-7.65</td><td>GO REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>4.749e-04</td><td>-7.65</td><td>HINATA NFKB TARGETS KERATINOCYTE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, THBS1</td></tr><tr><td>4.838e-04</td><td>-7.63</td><td>BRUECKNER TARGETS OF MIRLET7A3 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>105</td><td>3</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3, ELF3</td></tr><tr><td>4.945e-04</td><td>-7.61</td><td>intrinsic component of plasma membrane</td><td>cellular component</td><td>GO:0031226</td><td>1717</td><td>9</td><td>17744</td><td>26</td><td>
GPR37, CEACAM6, PCDH1, TGFA, GPR87, TNFRSF11B, TGM2, ATP1B1, CEACAM5</td></tr><tr><td>4.946e-04</td><td>-7.61</td><td>negative regulation of peptidase activity</td><td>biological process</td><td>GO:0010466</td><td>239</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>5.084e-04</td><td>-7.58</td><td>TY</td><td>smart domains</td><td>SM00211</td><td>17</td><td>2</td><td>9480</td><td>19</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>5.101e-04</td><td>-7.58</td><td>KLK3 (kallikrein related peptidase 3)</td><td>protein interactions</td><td>354</td><td>22</td><td>2</td><td>16330</td><td>25</td><td>
SLPI, IGFBP3</td></tr><tr><td>5.113e-04</td><td>-7.58</td><td>SENESE HDAC2 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>107</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGM2, SCG5</td></tr><tr><td>5.197e-04</td><td>-7.56</td><td>GO RESPONSE TO MAGNESIUM ION</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, THBS1</td></tr><tr><td>5.210e-04</td><td>-7.56</td><td>vesicle</td><td>cellular component</td><td>GO:0031982</td><td>4013</td><td>14</td><td>17744</td><td>26</td><td>
DST, KRT7, IGFBP6, SCG5, TGFA, SLPI, CEACAM5, ATP1B1, TFF2, TGM2, ANO1, PI3, THBS1, IGFBP3</td></tr><tr><td>5.293e-04</td><td>-7.54</td><td>Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)</td><td>REACTOME pathways</td><td>R-HSA-381426</td><td>21</td><td>2</td><td>10293</td><td>17</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>5.311e-04</td><td>-7.54</td><td>SWEET LUNG CANCER KRAS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>467</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, KRT7, IGFBP3, THBS1</td></tr><tr><td>5.582e-04</td><td>-7.49</td><td>SPARC (secreted protein acidic and cysteine rich)</td><td>protein interactions</td><td>6678</td><td>23</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, THBS1</td></tr><tr><td>5.664e-04</td><td>-7.48</td><td>HOFMANN MYELODYSPLASTIC SYNDROM RISK UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>5.691e-04</td><td>-7.47</td><td>EPPERT HSC R</td><td>MSigDB lists</td><td>&nbsp;</td><td>111</td><td>3</td><td>17621</td><td>26</td><td>
DST, RBPMS, INPP4B</td></tr><tr><td>5.713e-04</td><td>-7.47</td><td>IB</td><td>smart domains</td><td>SM00121</td><td>18</td><td>2</td><td>9480</td><td>19</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>5.889e-04</td><td>-7.44</td><td>regulation of insulin-like growth factor receptor signaling pathway</td><td>biological process</td><td>GO:0043567</td><td>23</td><td>2</td><td>16543</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>6.083e-04</td><td>-7.40</td><td>HLA-DRB1 (major histocompatibility complex, class II, DR beta 1)</td><td>protein interactions</td><td>3123</td><td>24</td><td>2</td><td>16330</td><td>25</td><td>
ATP1B1, MAGEA3</td></tr><tr><td>6.093e-04</td><td>-7.40</td><td>NABA CORE MATRISOME</td><td>MSigDB lists</td><td>&nbsp;</td><td>269</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, IGFBP3, THBS1</td></tr><tr><td>6.151e-04</td><td>-7.39</td><td>GO INSULIN LIKE GROWTH FACTOR BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>6.310e-04</td><td>-7.37</td><td>AZARE NEOPLASTIC TRANSFORMATION BY STAT3 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>115</td><td>3</td><td>17621</td><td>26</td><td>
SCG5, TGFA, THBS1</td></tr><tr><td>6.406e-04</td><td>-7.35</td><td>inflammatory response</td><td>biological process</td><td>GO:0006954</td><td>457</td><td>5</td><td>16543</td><td>26</td><td>
TNFRSF11B, TNFAIP6, CXCL3, THBS1, ELF3</td></tr><tr><td>6.587e-04</td><td>-7.33</td><td>IGFBP N 2</td><td>prosite domains</td><td>PS51323</td><td>20</td><td>2</td><td>11955</td><td>23</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>6.802e-04</td><td>-7.29</td><td>YEGNASUBRAMANIAN PROSTATE CANCER</td><td>MSigDB lists</td><td>&nbsp;</td><td>118</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, MAGEA6, MAGEA3</td></tr><tr><td>7.011e-04</td><td>-7.26</td><td>regulation of smooth muscle cell proliferation</td><td>biological process</td><td>GO:0048660</td><td>112</td><td>3</td><td>16543</td><td>26</td><td>
TGM2, IGFBP3, THBS1</td></tr><tr><td>7.077e-04</td><td>-7.25</td><td>MAGE N</td><td>smart domains</td><td>SM01392</td><td>20</td><td>2</td><td>9480</td><td>19</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>7.143e-04</td><td>-7.24</td><td>MISSIAGLIA REGULATED BY METHYLATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>120</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, IGFBP3</td></tr><tr><td>7.176e-04</td><td>-7.24</td><td>BROWNE HCMV INFECTION 14HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>281</td><td>4</td><td>17621</td><td>26</td><td>
DST, RBPMS, INPP4B, THBS1</td></tr><tr><td>7.183e-04</td><td>-7.24</td><td>GO REGULATION OF ANION TRANSMEMBRANE TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>7.183e-04</td><td>-7.24</td><td>GO FIBRONECTIN BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>2</td><td>17621</td><td>26</td><td>
THBS1, IGFBP3</td></tr><tr><td>7.183e-04</td><td>-7.24</td><td>DACOSTA ERCC3 ALLELE XPCS VS TTD UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, IGFBP6</td></tr><tr><td>7.183e-04</td><td>-7.24</td><td>GO APOPTOTIC CELL CLEARANCE</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>7.445e-04</td><td>-7.20</td><td>fibronectin binding</td><td>molecular function</td><td>GO:0001968</td><td>26</td><td>2</td><td>16652</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>7.494e-04</td><td>-7.20</td><td>GO GROWTH FACTOR BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>122</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3, THBS1</td></tr><tr><td>7.519e-04</td><td>-7.19</td><td>MARTENS TRETINOIN RESPONSE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>772</td><td>6</td><td>17621</td><td>26</td><td>
TFF2, PCDH1, TGM2, CXCL3, ELF3, IGFBP3</td></tr><tr><td>7.998e-04</td><td>-7.13</td><td>positive regulation of MAPK cascade</td><td>biological process</td><td>GO:0043410</td><td>480</td><td>5</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, TGFA, IGFBP3, THBS1</td></tr><tr><td>8.272e-04</td><td>-7.10</td><td>MAGE</td><td>pfam domains</td><td>PF01454</td><td>30</td><td>2</td><td>16832</td><td>24</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>8.421e-04</td><td>-7.08</td><td>KRAS.BREAST UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>127</td><td>3</td><td>17621</td><td>26</td><td>
SCG5, CXCL3, IGFBP3</td></tr><tr><td>8.565e-04</td><td>-7.06</td><td>env (gp160; envelope glycoprotein)</td><td>protein interactions</td><td>155971</td><td>1409</td><td>8</td><td>16330</td><td>25</td><td>
TNFAIP6, SCG5, CXCL3, SLPI, TGM2, PI3, THBS1, ELF3</td></tr><tr><td>8.602e-04</td><td>-7.06</td><td>bone-humerus-chondrosarcoma</td><td>COSMIC cancer mutations</td><td>bone-humerus-chondrosarcoma</td><td>128</td><td>3</td><td>17630</td><td>26</td><td>
CEACAM6, MAGEA3, THBS1</td></tr><tr><td>8.615e-04</td><td>-7.06</td><td>TAKEDA TARGETS OF NUP98 HOXA9 FUSION 10D DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>128</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, CXCL3</td></tr><tr><td>8.639e-04</td><td>-7.05</td><td>MODULE 100</td><td>MSigDB lists</td><td>&nbsp;</td><td>520</td><td>5</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6, SCG5, ELF3, IGFBP3</td></tr><tr><td>8.643e-04</td><td>-7.05</td><td>insulin-like growth factor binding</td><td>molecular function</td><td>GO:0005520</td><td>28</td><td>2</td><td>16652</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>8.756e-04</td><td>-7.04</td><td>apoptotic cell clearance</td><td>biological process</td><td>GO:0043277</td><td>28</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>8.865e-04</td><td>-7.03</td><td>MODULE 137</td><td>MSigDB lists</td><td>&nbsp;</td><td>523</td><td>5</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6, SCG5, ELF3, IGFBP3</td></tr><tr><td>8.865e-04</td><td>-7.03</td><td>MODULE 84</td><td>MSigDB lists</td><td>&nbsp;</td><td>523</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, TGM2, PI3, IGFBP3</td></tr><tr><td>8.878e-04</td><td>-7.03</td><td>LIANG SILENCED BY METHYLATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, SCG5</td></tr><tr><td>8.878e-04</td><td>-7.03</td><td>SEITZ NEOPLASTIC TRANSFORMATION BY 8P DELETION DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, TGFA</td></tr><tr><td>8.878e-04</td><td>-7.03</td><td>HOFMANN MYELODYSPLASTIC SYNDROM LOW RISK DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>8.934e-04</td><td>-7.02</td><td>SENGUPTA NASOPHARYNGEAL CARCINOMA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>298</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, KRT7, PI3, ELF3</td></tr><tr><td>9.252e-04</td><td>-6.99</td><td>MODULE 66</td><td>MSigDB lists</td><td>&nbsp;</td><td>528</td><td>5</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6, SCG5, ELF3, IGFBP3</td></tr><tr><td>9.331e-04</td><td>-6.98</td><td>CHICAS RB1 TARGETS SENESCENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>529</td><td>5</td><td>17621</td><td>26</td><td>
ATP1B1, SCG5, CXCL3, PI3, IGFBP3</td></tr><tr><td>9.362e-04</td><td>-6.97</td><td>NUYTTEN NIPP1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>805</td><td>6</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, TFF2, IGFBP6, ANO1, ELF3</td></tr><tr><td>9.418e-04</td><td>-6.97</td><td>KRAS.LUNG.BREAST UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>132</td><td>3</td><td>17621</td><td>26</td><td>
SCG5, CXCL3, IGFBP3</td></tr><tr><td>9.482e-04</td><td>-6.96</td><td>GNF2 MMP1</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>9.482e-04</td><td>-6.96</td><td>AMIT SERUM RESPONSE 40 MCF10A</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>9.482e-04</td><td>-6.96</td><td>DORSEY GAB2 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, THBS1</td></tr><tr><td>9.545e-04</td><td>-6.95</td><td>MODULE 88</td><td>MSigDB lists</td><td>&nbsp;</td><td>808</td><td>6</td><td>17621</td><td>26</td><td>
SLPI, TGM2, KRT7, IGFBP6, SCG5, IGFBP3</td></tr><tr><td>9.836e-04</td><td>-6.92</td><td>PROVENZANI METASTASIS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, ANO1, IGFBP3</td></tr><tr><td>9.836e-04</td><td>-6.92</td><td>KRAS.300 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>3</td><td>17621</td><td>26</td><td>
CXCL3, SCG5, ANO1</td></tr><tr><td>1.010e-03</td><td>-6.90</td><td>BAE BRCA1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>1.010e-03</td><td>-6.90</td><td>GO PEPTIDE CROSS LINKING</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>1.010e-03</td><td>-6.90</td><td>TSAI RESPONSE TO RADIATION THERAPY</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, THBS1</td></tr><tr><td>1.010e-03</td><td>-6.90</td><td>BANDRES RESPONSE TO CARMUSTIN MGMT 24HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B</td></tr><tr><td>1.014e-03</td><td>-6.89</td><td>growth factor binding</td><td>molecular function</td><td>GO:0019838</td><td>128</td><td>3</td><td>16652</td><td>26</td><td>
IGFBP6, IGFBP3, THBS1</td></tr><tr><td>1.035e-03</td><td>-6.87</td><td>FARMER BREAST CANCER APOCRINE VS LUMINAL</td><td>MSigDB lists</td><td>&nbsp;</td><td>310</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, KRT7, PI3, THBS1</td></tr><tr><td>1.044e-03</td><td>-6.86</td><td>MHD dom</td><td>interpro domains</td><td>IPR002190</td><td>34</td><td>2</td><td>18428</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.058e-03</td><td>-6.85</td><td>MODULE 23</td><td>MSigDB lists</td><td>&nbsp;</td><td>544</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, TFF2, PCDH1, TGM2, IGFBP3</td></tr><tr><td>1.074e-03</td><td>-6.84</td><td>regulation of anion transmembrane transport</td><td>biological process</td><td>GO:1903959</td><td>31</td><td>2</td><td>16543</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>1.074e-03</td><td>-6.84</td><td>regulation of signaling</td><td>biological process</td><td>GO:0023051</td><td>3039</td><td>12</td><td>16543</td><td>26</td><td>
GPR37, IGFBP6, SCG5, TGFA, MAGEA3, TNFRSF11B, ATP1B1, TGM2, RBPMS, ANO1, IGFBP3, THBS1</td></tr><tr><td>1.075e-03</td><td>-6.84</td><td>SCHOEN NFKB SIGNALING</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>1.075e-03</td><td>-6.84</td><td>SIMBULAN UV RESPONSE NORMAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>1.075e-03</td><td>-6.84</td><td>FRIDMAN IMMORTALIZATION DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.085e-03</td><td>-6.83</td><td>MODULE 44</td><td>MSigDB lists</td><td>&nbsp;</td><td>314</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, TGM2, PI3, IGFBP3</td></tr><tr><td>1.111e-03</td><td>-6.80</td><td>adrenal cortical carcinoma</td><td>COSMIC cancer mutations</td><td>adrenal_cortical_carcinoma</td><td>2326</td><td>10</td><td>17630</td><td>26</td><td>
GPR37, PCDH1, SCG5, INPP4B, SLPI, TNFRSF11B, TGM2, CEACAM5, THBS1, IGFBP3</td></tr><tr><td>1.113e-03</td><td>-6.80</td><td>GO DEFENSE RESPONSE</td><td>MSigDB lists</td><td>&nbsp;</td><td>1155</td><td>7</td><td>17621</td><td>26</td><td>
SLPI, TNFRSF11B, TNFAIP6, ATP1B1, CXCL3, ELF3, THBS1</td></tr><tr><td>1.141e-03</td><td>-6.78</td><td>GO CELLULAR RESPONSE TO HEAT</td><td>MSigDB lists</td><td>&nbsp;</td><td>34</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>1.154e-03</td><td>-6.76</td><td>TMSB4X (thymosin beta 4, X-linked)</td><td>protein interactions</td><td>7114</td><td>33</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, RBPMS</td></tr><tr><td>1.185e-03</td><td>-6.74</td><td>negative regulation of proteolysis</td><td>biological process</td><td>GO:0045861</td><td>302</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>1.217e-03</td><td>-6.71</td><td>negative regulation of protein maturation</td><td>biological process</td><td>GO:1903318</td><td>33</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>1.217e-03</td><td>-6.71</td><td>negative regulation of protein processing</td><td>biological process</td><td>GO:0010955</td><td>33</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>1.235e-03</td><td>-6.70</td><td>BROWNE HCMV INFECTION 24HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>145</td><td>3</td><td>17621</td><td>26</td><td>
DST, THBS1, IGFBP3</td></tr><tr><td>1.256e-03</td><td>-6.68</td><td>Heart rate variability traits(PMID:22174390)</td><td>GWAS genes</td><td>Heart rate variability traits(PMID:22174390)</td><td>1</td><td>1</td><td>2388</td><td>3</td><td>
RBPMS</td></tr><tr><td>1.260e-03</td><td>-6.68</td><td>TAKEDA TARGETS OF NUP98 HOXA9 FUSION 8D UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>146</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, RBPMS, THBS1</td></tr><tr><td>1.279e-03</td><td>-6.66</td><td>HUANG FOXA2 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>36</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, IGFBP6</td></tr><tr><td>1.340e-03</td><td>-6.62</td><td>Cell surface interactions at the vascular wall</td><td>REACTOME pathways</td><td>R-HSA-202733</td><td>136</td><td>3</td><td>10293</td><td>17</td><td>
CEACAM6, CEACAM5, ATP1B1</td></tr><tr><td>1.351e-03</td><td>-6.61</td><td>GO REGULATION OF GRANULOCYTE CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>37</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.351e-03</td><td>-6.61</td><td>EPPERT CE HSC LSC</td><td>MSigDB lists</td><td>&nbsp;</td><td>37</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, INPP4B</td></tr><tr><td>1.373e-03</td><td>-6.59</td><td>CTSG (cathepsin G)</td><td>protein interactions</td><td>1511</td><td>36</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP3, THBS1</td></tr><tr><td>1.409e-03</td><td>-6.57</td><td>SCHUETZ BREAST CANCER DUCTAL INVASIVE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>337</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2, SCG5, IGFBP3</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>ALP</td><td>interpro domains</td><td>IPR029712</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
SLPI</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>IGFBP-3</td><td>interpro domains</td><td>IPR012211</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Na/K ATPase sub beta chordates</td><td>interpro domains</td><td>IPR015565</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>SVP I</td><td>interpro domains</td><td>IPR002098</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
PI3</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Anoctamin-1</td><td>interpro domains</td><td>IPR031287</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
ANO1</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>IGFBP-6</td><td>interpro domains</td><td>IPR022326</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
IGFBP6</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>TNFR 11B</td><td>interpro domains</td><td>IPR017371</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Dystonin</td><td>interpro domains</td><td>IPR029926</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
DST</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Elf3</td><td>interpro domains</td><td>IPR033074</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
ELF3</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Trappin transglut-bd rpt</td><td>interpro domains</td><td>IPR019541</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
PI3</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Thrombospondin-1</td><td>interpro domains</td><td>IPR028499</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
THBS1</td></tr><tr><td>1.411e-03</td><td>-6.56</td><td>Secretogranin V</td><td>interpro domains</td><td>IPR007945</td><td>1</td><td>1</td><td>18428</td><td>26</td><td>
SCG5</td></tr><tr><td>1.419e-03</td><td>-6.56</td><td>negative regulation of catalytic activity</td><td>biological process</td><td>GO:0043086</td><td>819</td><td>6</td><td>16543</td><td>26</td><td>
SLPI, SCG5, GPR87, PI3, MAGEA3, THBS1</td></tr><tr><td>1.424e-03</td><td>-6.55</td><td>EPPERT LSC R</td><td>MSigDB lists</td><td>&nbsp;</td><td>38</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, RBPMS</td></tr><tr><td>1.424e-03</td><td>-6.55</td><td>NAKAMURA ADIPOGENESIS EARLY DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>38</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, IGFBP3</td></tr><tr><td>1.424e-03</td><td>-6.55</td><td>GU PDEF TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>38</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, THBS1</td></tr><tr><td>1.426e-03</td><td>-6.55</td><td>Cementoin</td><td>pfam domains</td><td>PF10511</td><td>1</td><td>1</td><td>16832</td><td>24</td><td>
PI3</td></tr><tr><td>1.426e-03</td><td>-6.55</td><td>Secretogranin V</td><td>pfam domains</td><td>PF05281</td><td>1</td><td>1</td><td>16832</td><td>24</td><td>
SCG5</td></tr><tr><td>1.441e-03</td><td>-6.54</td><td>GSE37336 LY6C POS VS NEG NAIVE CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>153</td><td>3</td><td>17621</td><td>26</td><td>
PCDH1, MAGEA6, MAGEA3</td></tr><tr><td>1.465e-03</td><td>-6.53</td><td>integral component of external side of plasma membrane</td><td>cellular component</td><td>GO:0071575</td><td>1</td><td>1</td><td>17744</td><td>26</td><td>
CEACAM5</td></tr><tr><td>1.465e-03</td><td>-6.53</td><td>H zone</td><td>cellular component</td><td>GO:0031673</td><td>1</td><td>1</td><td>17744</td><td>26</td><td>
DST</td></tr><tr><td>1.500e-03</td><td>-6.50</td><td>TOMLINS PROSTATE CANCER DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>39</td><td>2</td><td>17621</td><td>26</td><td>
DST, RBPMS</td></tr><tr><td>1.524e-03</td><td>-6.49</td><td>GSE13547 WT VS ZFX KO BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>156</td><td>3</td><td>17621</td><td>26</td><td>
DST, SLPI, INPP4B</td></tr><tr><td>1.524e-03</td><td>-6.49</td><td>PHONG TNF RESPONSE VIA P38 PARTIAL</td><td>MSigDB lists</td><td>&nbsp;</td><td>156</td><td>3</td><td>17621</td><td>26</td><td>
CXCL3, TGFA, THBS1</td></tr><tr><td>1.529e-03</td><td>-6.48</td><td>MMP2 (matrix metallopeptidase 2)</td><td>protein interactions</td><td>4313</td><td>38</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP3, THBS1</td></tr><tr><td>1.529e-03</td><td>-6.48</td><td>CTSL (cathepsin L)</td><td>protein interactions</td><td>1514</td><td>38</td><td>2</td><td>16330</td><td>25</td><td>
SLPI, IGFBP3</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>mal3 (EB1 family Mal3)</td><td>protein interactions</td><td>2542123</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>Hnrnpm (heterogeneous nuclear ribonucleoprotein M)</td><td>protein interactions</td><td>116655</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM5</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>Ltbp1 (latent transforming growth factor beta binding protein 1)</td><td>protein interactions</td><td>268977</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>Igf2 (insulin-like growth factor 2)</td><td>protein interactions</td><td>16002</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>LINC00588 (long intergenic non-protein coding RNA 588)</td><td>protein interactions</td><td>26138</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>ATP6V0E2 (ATPase H+ transporting V0 subunit e2)</td><td>protein interactions</td><td>155066</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>LINC00482 (long intergenic non-protein coding RNA 482)</td><td>protein interactions</td><td>284185</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>Jun (Jun proto-oncogene, AP-1 transcription factor subunit)</td><td>protein interactions</td><td>24516</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
ELF3</td></tr><tr><td>1.531e-03</td><td>-6.48</td><td>EB1a (microtubule end binding protein EB1A)</td><td>protein interactions</td><td>823923</td><td>1</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>1.535e-03</td><td>-6.48</td><td>COLINA TARGETS OF 4EBP1 AND 4EBP2</td><td>MSigDB lists</td><td>&nbsp;</td><td>345</td><td>4</td><td>17621</td><td>26</td><td>
TNFRSF11B, ATP1B1, TGM2, THBS1</td></tr><tr><td>1.561e-03</td><td>-6.46</td><td>CXCR4 chemokine receptor binding</td><td>molecular function</td><td>GO:0031723</td><td>1</td><td>1</td><td>16652</td><td>26</td><td>
TFF2</td></tr><tr><td>1.572e-03</td><td>-6.46</td><td>negative regulation of dendritic cell antigen processing and presentation</td><td>biological process</td><td>GO:0002605</td><td>1</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.572e-03</td><td>-6.46</td><td>negative regulation of cGMP-mediated signaling</td><td>biological process</td><td>GO:0010754</td><td>1</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.578e-03</td><td>-6.45</td><td>WEINMANN ADAPTATION TO HYPOXIA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>40</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, IGFBP3</td></tr><tr><td>1.595e-03</td><td>-6.44</td><td>regulation of cell proliferation</td><td>biological process</td><td>GO:0042127</td><td>1502</td><td>8</td><td>16543</td><td>26</td><td>
CEACAM6, IGFBP6, CXCL3, TGFA, TNFRSF11B, TGM2, THBS1, IGFBP3</td></tr><tr><td>1.647e-03</td><td>-6.41</td><td>Photodynamic therapy-induced HIF-1 survival signaling</td><td>WikiPathways</td><td>WP3614</td><td>37</td><td>2</td><td>5314</td><td>9</td><td>
TGFA, IGFBP3</td></tr><tr><td>1.694e-03</td><td>-6.38</td><td>TF (transferrin)</td><td>protein interactions</td><td>7018</td><td>40</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.698e-03</td><td>-6.38</td><td>regulation of granulocyte chemotaxis</td><td>biological process</td><td>GO:0071622</td><td>39</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.698e-03</td><td>-6.38</td><td>cellular response to heat</td><td>biological process</td><td>GO:0034605</td><td>39</td><td>2</td><td>16543</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>1.738e-03</td><td>-6.35</td><td>JAEGER METASTASIS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>42</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.738e-03</td><td>-6.35</td><td>ZUCCHI METASTASIS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>42</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, CXCL3</td></tr><tr><td>1.745e-03</td><td>-6.35</td><td>positive regulation of cell communication</td><td>biological process</td><td>GO:0010647</td><td>1523</td><td>8</td><td>16543</td><td>26</td><td>
GPR37, TGFA, TNFRSF11B, TGM2, RBPMS, ANO1, THBS1, IGFBP3</td></tr><tr><td>1.750e-03</td><td>-6.35</td><td>positive regulation of response to stimulus</td><td>biological process</td><td>GO:0048584</td><td>1905</td><td>9</td><td>16543</td><td>26</td><td>
GPR37, CXCL3, TGFA, TNFRSF11B, TGM2, RBPMS, ANO1, THBS1, IGFBP3</td></tr><tr><td>1.789e-03</td><td>-6.33</td><td>VECCHI GASTRIC CANCER ADVANCED VS EARLY UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>165</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1, IGFBP3</td></tr><tr><td>1.789e-03</td><td>-6.33</td><td>GSE24671 CTRL VS BAKIMULC INFECTED MOUSE SPLENOCYTES DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>165</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, CXCL3, INPP4B</td></tr><tr><td>1.805e-03</td><td>-6.32</td><td>positive regulation of signaling</td><td>biological process</td><td>GO:0023056</td><td>1531</td><td>8</td><td>16543</td><td>26</td><td>
GPR37, TGFA, TNFRSF11B, TGM2, RBPMS, ANO1, THBS1, IGFBP3</td></tr><tr><td>1.821e-03</td><td>-6.31</td><td>HALMOS CEBPA TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>43</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, ELF3</td></tr><tr><td>1.821e-03</td><td>-6.31</td><td>ZHAN MULTIPLE MYELOMA PR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>43</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.821e-03</td><td>-6.31</td><td>STREICHER LSM1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>43</td><td>2</td><td>17621</td><td>26</td><td>
INPP4B, ELF3</td></tr><tr><td>1.852e-03</td><td>-6.29</td><td>MCBRYAN PUBERTAL TGFB1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>167</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2, ANO1</td></tr><tr><td>1.884e-03</td><td>-6.27</td><td>integral component of plasma membrane</td><td>cellular component</td><td>GO:0005887</td><td>1653</td><td>8</td><td>17744</td><td>26</td><td>
GPR37, CEACAM6, PCDH1, TGFA, GPR87, TNFRSF11B, ATP1B1, CEACAM5</td></tr><tr><td>1.913e-03</td><td>-6.26</td><td>MAGE</td><td>prosite domains</td><td>PS50838</td><td>34</td><td>2</td><td>11955</td><td>23</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.916e-03</td><td>-6.26</td><td>GSE25502 WT VS KLF13 KO THYMIC MEMORY LIKE CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>169</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, MAGEA6, MAGEA3</td></tr><tr><td>1.924e-03</td><td>-6.25</td><td>SVP I</td><td>prosite domains</td><td>PS00313</td><td>1</td><td>1</td><td>11955</td><td>23</td><td>
PI3</td></tr><tr><td>2.046e-03</td><td>-6.19</td><td>F2 (coagulation factor II, thrombin)</td><td>protein interactions</td><td>2147</td><td>44</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP3, THBS1</td></tr><tr><td>2.049e-03</td><td>-6.19</td><td>positive regulation of protein phosphorylation</td><td>biological process</td><td>GO:0001934</td><td>880</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.055e-03</td><td>-6.19</td><td>MAGE</td><td>smart domains</td><td>SM01373</td><td>34</td><td>2</td><td>9480</td><td>19</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.082e-03</td><td>-6.17</td><td>GSE18804 BRAIN VS COLON TUMORAL MACROPHAGE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, MAGEA6, MAGEA3</td></tr><tr><td>2.125e-03</td><td>-6.15</td><td>regulation of cellular process</td><td>biological process</td><td>GO:0050794</td><td>10082</td><td>23</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, IGFBP6, CXCL3, TGFA, SLPI, ATP1B1, TFF2, ANO1, PI3, THBS1, ELF3, DST, GPR37, SCG5, GPR87, MAGEA3, INPP4B, TNFRSF11B, CEACAM5, TGM2, RBPMS, IGFBP3</td></tr><tr><td>2.200e-03</td><td>-6.12</td><td>GO REGULATION OF MAPK CASCADE</td><td>MSigDB lists</td><td>&nbsp;</td><td>642</td><td>5</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.221e-03</td><td>-6.11</td><td>GSE37301 COMMON LYMPHOID PROGENITOR VS PRO BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, KRT7, ELF3</td></tr><tr><td>2.221e-03</td><td>-6.11</td><td>LI WILMS TUMOR VS FETAL KIDNEY 1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>3</td><td>17621</td><td>26</td><td>
DST, ATP1B1, RBPMS</td></tr><tr><td>2.233e-03</td><td>-6.10</td><td>positive regulation of intracellular signal transduction</td><td>biological process</td><td>GO:1902533</td><td>895</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, TGM2, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.235e-03</td><td>-6.10</td><td>THBS1 (thrombospondin 1)</td><td>protein interactions</td><td>7057</td><td>46</td><td>2</td><td>16330</td><td>25</td><td>
TNFRSF11B, TNFAIP6</td></tr><tr><td>2.257e-03</td><td>-6.09</td><td>PRC2 EED UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>179</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, SLPI, SCG5</td></tr><tr><td>2.265e-03</td><td>-6.09</td><td>SASAI RESISTANCE TO NEOPLASTIC TRANSFROMATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>48</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, ATP1B1</td></tr><tr><td>2.293e-03</td><td>-6.08</td><td>PRC2 EZH2 UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, SLPI, TNFAIP6</td></tr><tr><td>2.293e-03</td><td>-6.08</td><td>GSE22886 NEUTROPHIL VS MONOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, MAGEA6, MAGEA3</td></tr><tr><td>2.293e-03</td><td>-6.08</td><td>GSE36888 UNTREATED VS IL2 TREATED TCELL 17H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, TGFA</td></tr><tr><td>2.314e-03</td><td>-6.07</td><td>MOREAUX MULTIPLE MYELOMA BY TACI UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>386</td><td>4</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5, TNFAIP6, PCDH1</td></tr><tr><td>2.314e-03</td><td>-6.07</td><td>THUM SYSTOLIC HEART FAILURE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>386</td><td>4</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGM2, IGFBP3, THBS1</td></tr><tr><td>2.329e-03</td><td>-6.06</td><td>LEF1 UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>181</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, SCG5, ELF3</td></tr><tr><td>2.332e-03</td><td>-6.06</td><td>ITGB3 (integrin subunit beta 3)</td><td>protein interactions</td><td>3690</td><td>47</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, THBS1</td></tr><tr><td>2.350e-03</td><td>-6.05</td><td>regulation of endopeptidase activity</td><td>biological process</td><td>GO:0052548</td><td>364</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>2.359e-03</td><td>-6.05</td><td>CROMER TUMORIGENESIS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>49</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>2.366e-03</td><td>-6.05</td><td>EGFR UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, TNFRSF11B, KRT7</td></tr><tr><td>2.403e-03</td><td>-6.03</td><td>KRAS.DF.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>3</td><td>17621</td><td>26</td><td>
SCG5, CXCL3, INPP4B</td></tr><tr><td>2.403e-03</td><td>-6.03</td><td>LEF1 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, IGFBP6, ANO1</td></tr><tr><td>2.403e-03</td><td>-6.03</td><td>GSE4811 CLASSSICALY ACTIVATED VS TYPE 2 ACTIVATED MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, TFF2, ELF3</td></tr><tr><td>2.440e-03</td><td>-6.02</td><td>GSE2706 UNSTIM VS 8H R848 DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, TNFAIP6, THBS1</td></tr><tr><td>2.440e-03</td><td>-6.02</td><td>GSE43700 UNTREATED VS IL10 TREATED PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, ELF3</td></tr><tr><td>2.455e-03</td><td>-6.01</td><td>BURTON ADIPOGENESIS PEAK AT 2HR</td><td>MSigDB lists</td><td>&nbsp;</td><td>50</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>2.466e-03</td><td>-6.01</td><td>CREIGHTON ENDOCRINE THERAPY RESISTANCE 3</td><td>MSigDB lists</td><td>&nbsp;</td><td>659</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, CEACAM5, ATP1B1, IGFBP3</td></tr><tr><td>2.478e-03</td><td>-6.00</td><td>GSE20366 CD103 POS VS CD103 KLRG1 DP TREG UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, SCG5, INPP4B</td></tr><tr><td>2.478e-03</td><td>-6.00</td><td>GSE41176 UNSTIM VS ANTI IGM STIM BCELL 3H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, RBPMS, CXCL3</td></tr><tr><td>2.478e-03</td><td>-6.00</td><td>ATF2 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>3</td><td>17621</td><td>26</td><td>
PCDH1, KRT7, INPP4B</td></tr><tr><td>2.478e-03</td><td>-6.00</td><td>GSE34205 HEALTHY VS RSV INF INFANT PBMC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, RBPMS</td></tr><tr><td>2.478e-03</td><td>-6.00</td><td>GSE29949 MICROGLIA VS DC BRAIN DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>3</td><td>17621</td><td>26</td><td>
PCDH1, SCG5, CXCL3</td></tr><tr><td>2.478e-03</td><td>-6.00</td><td>GSE24634 IL4 VS CTRL TREATED NAIVE CD4 TCELL DAY7 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, SCG5</td></tr><tr><td>2.516e-03</td><td>-5.98</td><td>GSE24634 IL4 VS CTRL TREATED NAIVE CD4 TCELL DAY3 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, THBS1</td></tr><tr><td>2.538e-03</td><td>-5.98</td><td>positive regulation of phosphorylation</td><td>biological process</td><td>GO:0042327</td><td>918</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.553e-03</td><td>-5.97</td><td>ZHENG IL22 SIGNALING UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>51</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CXCL3</td></tr><tr><td>2.553e-03</td><td>-5.97</td><td>NAGASHIMA NRG1 SIGNALING DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>51</td><td>2</td><td>17621</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>2.555e-03</td><td>-5.97</td><td>GSE3039 NKT CELL VS ALPHAALPHA CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, IGFBP6</td></tr><tr><td>2.555e-03</td><td>-5.97</td><td>GSE360 L DONOVANI VS L MAJOR MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, INPP4B</td></tr><tr><td>2.594e-03</td><td>-5.95</td><td>GSE28130 ACTIVATED VS INDUCEED TREG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM5, TFF2, CXCL3</td></tr><tr><td>2.609e-03</td><td>-5.95</td><td>REN ALVEOLAR RHABDOMYOSARCOMA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>399</td><td>4</td><td>17621</td><td>26</td><td>
TNFRSF11B, IGFBP6, IGFBP3, THBS1</td></tr><tr><td>2.633e-03</td><td>-5.94</td><td>GSE27786 LIN NEG VS ERYTHROBLAST DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, TNFAIP6, GPR87</td></tr><tr><td>2.633e-03</td><td>-5.94</td><td>GSE27670 CTRL VS BLIMP1 TRANSDUCED GC BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, SCG5, ELF3</td></tr><tr><td>2.633e-03</td><td>-5.94</td><td>GSE43955 TH0 VS TGFB IL6 TH17 ACT CD4 TCELL 20H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, TNFAIP6, CXCL3</td></tr><tr><td>2.633e-03</td><td>-5.94</td><td>GSE43863 TH1 VS TFH EFFECTOR CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, SCG5</td></tr><tr><td>2.633e-03</td><td>-5.94</td><td>GSE3982 NEUTROPHIL VS BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, PI3, GPR87</td></tr><tr><td>2.653e-03</td><td>-5.93</td><td>LIANG SILENCED BY METHYLATION 2</td><td>MSigDB lists</td><td>&nbsp;</td><td>52</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>2.673e-03</td><td>-5.92</td><td>GSE360 HIGH DOSE B MALAYI VS M TUBERCULOSIS MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, SCG5, INPP4B</td></tr><tr><td>2.673e-03</td><td>-5.92</td><td>GSE2405 HEAT KILLED LYSATE VS LIVE A PHAGOCYTOPHILUM STIM NEUTROPHIL 24H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>3</td><td>17621</td><td>26</td><td>
KRT7, SCG5, IGFBP3</td></tr><tr><td>2.673e-03</td><td>-5.92</td><td>GSE45365 NK CELL VS BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, THBS1</td></tr><tr><td>2.703e-03</td><td>-5.91</td><td>GO BIOLOGICAL ADHESION</td><td>MSigDB lists</td><td>&nbsp;</td><td>990</td><td>6</td><td>17621</td><td>26</td><td>
DST, CEACAM5, TNFAIP6, ATP1B1, PCDH1, THBS1</td></tr><tr><td>2.713e-03</td><td>-5.91</td><td>GSE360 L DONOVANI VS M TUBERCULOSIS MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, INPP4B</td></tr><tr><td>2.751e-03</td><td>-5.90</td><td>IGFBPFAMILY6</td><td>prints domains</td><td>PR01982</td><td>1</td><td>1</td><td>4725</td><td>13</td><td>
IGFBP6</td></tr><tr><td>2.751e-03</td><td>-5.90</td><td>TNFACTORR11B</td><td>prints domains</td><td>PR01975</td><td>1</td><td>1</td><td>4725</td><td>13</td><td>
TNFRSF11B</td></tr><tr><td>2.751e-03</td><td>-5.90</td><td>IGFBPFAMILY3</td><td>prints domains</td><td>PR01979</td><td>1</td><td>1</td><td>4725</td><td>13</td><td>
IGFBP3</td></tr><tr><td>2.753e-03</td><td>-5.90</td><td>GSE12392 IFNAR KO VS IFNB KO CD8 NEG SPLEEN DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>3</td><td>17621</td><td>26</td><td>
CXCL3, ELF3, THBS1</td></tr><tr><td>2.753e-03</td><td>-5.90</td><td>GSE20366 TREG VS NAIVE CD4 TCELL DEC205 CONVERSION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, CXCL3, INPP4B</td></tr><tr><td>2.753e-03</td><td>-5.90</td><td>TAKEDA TARGETS OF NUP98 HOXA9 FUSION 8D DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, CXCL3</td></tr><tr><td>2.772e-03</td><td>-5.89</td><td>GO POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>995</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.772e-03</td><td>-5.89</td><td>GO POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>995</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, THBS1, IGFBP3</td></tr><tr><td>2.794e-03</td><td>-5.88</td><td>GSE22886 DAY0 VS DAY1 MONOCYTE IN CULTURE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, PI3</td></tr><tr><td>2.794e-03</td><td>-5.88</td><td>GSE24634 IL4 VS CTRL TREATED NAIVE CD4 TCELL DAY10 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, SCG5</td></tr><tr><td>2.794e-03</td><td>-5.88</td><td>GSE8515 IL1 VS IL6 4H STIM MAC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, IGFBP3</td></tr><tr><td>2.820e-03</td><td>-5.87</td><td>GPR37 orph</td><td>interpro domains</td><td>IPR003909</td><td>2</td><td>1</td><td>18428</td><td>26</td><td>
GPR37</td></tr><tr><td>2.820e-03</td><td>-5.87</td><td>TNFR 11</td><td>interpro domains</td><td>IPR022323</td><td>2</td><td>1</td><td>18428</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>2.820e-03</td><td>-5.87</td><td>P2Y13 rcpt</td><td>interpro domains</td><td>IPR008109</td><td>2</td><td>1</td><td>18428</td><td>26</td><td>
GPR87</td></tr><tr><td>2.820e-03</td><td>-5.87</td><td>RRM U1 A/B''</td><td>interpro domains</td><td>IPR024888</td><td>2</td><td>1</td><td>18428</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.835e-03</td><td>-5.87</td><td>GSE19401 UNSTIM VS RETINOIC ACID AND PAM2CSK4 STIM FOLLICULAR DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>194</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, CXCL3, THBS1</td></tr><tr><td>2.835e-03</td><td>-5.87</td><td>GSE17721 PAM3CSK4 VS GADIQUIMOD 0.5H BMDC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>194</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, CXCL3, ANO1</td></tr><tr><td>2.847e-03</td><td>-5.86</td><td>COL1A1 (collagen type I alpha 1 chain)</td><td>protein interactions</td><td>1277</td><td>52</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP3, THBS1</td></tr><tr><td>2.858e-03</td><td>-5.86</td><td>PID TAP63 PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>54</td><td>2</td><td>17621</td><td>26</td><td>
DST, IGFBP3</td></tr><tr><td>2.876e-03</td><td>-5.85</td><td>PEDRIOLI MIR31 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, KRT7, IGFBP3</td></tr><tr><td>2.960e-03</td><td>-5.82</td><td>regulation of peptidase activity</td><td>biological process</td><td>GO:0052547</td><td>388</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>2.963e-03</td><td>-5.82</td><td>AMIT SERUM RESPONSE 240 MCF10A</td><td>MSigDB lists</td><td>&nbsp;</td><td>55</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>2.963e-03</td><td>-5.82</td><td>BORLAK LIVER CANCER EGF UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>55</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, ELF3</td></tr><tr><td>3.003e-03</td><td>-5.81</td><td>EBAUER TARGETS OF PAX3 FOXO1 FUSION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>198</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, TGM2, INPP4B</td></tr><tr><td>3.032e-03</td><td>-5.80</td><td>PURBEY TARGETS OF CTBP1 NOT SATB1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>416</td><td>4</td><td>17621</td><td>26</td><td>
CEACAM5, MAGEA6, PI3, MAGEA3</td></tr><tr><td>3.032e-03</td><td>-5.80</td><td>CHARAFE BREAST CANCER LUMINAL VS MESENCHYMAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>416</td><td>4</td><td>17621</td><td>26</td><td>
CEACAM6, PCDH1, ANO1, ELF3</td></tr><tr><td>3.043e-03</td><td>-5.79</td><td>negative regulation of hydrolase activity</td><td>biological process</td><td>GO:0051346</td><td>391</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>CEACAM8 (carcinoembryonic antigen related cell adhesion molecule 8)</td><td>protein interactions</td><td>1088</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM6</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>CARTPT (CART prepropeptide)</td><td>protein interactions</td><td>9607</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM6</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>LINC00908 (long intergenic non-protein coding RNA 908)</td><td>protein interactions</td><td>284276</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>CEACAM7 (carcinoembryonic antigen related cell adhesion molecule 7)</td><td>protein interactions</td><td>1087</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM6</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>TFF2 (trefoil factor 2)</td><td>protein interactions</td><td>7032</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
TFF2</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>LCORL (ligand dependent nuclear receptor corepressor like)</td><td>protein interactions</td><td>254251</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>LOC142937 (uncharacterized protein BC008131)</td><td>protein interactions</td><td>142937</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.060e-03</td><td>-5.79</td><td>RBM46 (RNA binding motif protein 46)</td><td>protein interactions</td><td>166863</td><td>2</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.120e-03</td><td>-5.77</td><td>phosphatidylinositol-3,4-bisphosphate 4-phosphatase activity</td><td>molecular function</td><td>GO:0016316</td><td>2</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>3.120e-03</td><td>-5.77</td><td>protein tyrosine phosphatase activator activity</td><td>molecular function</td><td>GO:0008160</td><td>2</td><td>1</td><td>16652</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.120e-03</td><td>-5.77</td><td>prosaposin receptor activity</td><td>molecular function</td><td>GO:0036505</td><td>2</td><td>1</td><td>16652</td><td>26</td><td>
GPR37</td></tr><tr><td>3.120e-03</td><td>-5.77</td><td>inositol-3,4-bisphosphate 4-phosphatase activity</td><td>molecular function</td><td>GO:0052828</td><td>2</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>3.120e-03</td><td>-5.77</td><td>inositol-1,3,4-trisphosphate 4-phosphatase activity</td><td>molecular function</td><td>GO:0017161</td><td>2</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>3.128e-03</td><td>-5.77</td><td>positive regulation of cell migration</td><td>biological process</td><td>GO:0030335</td><td>394</td><td>4</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, THBS1</td></tr><tr><td>3.141e-03</td><td>-5.76</td><td>protein transport into plasma membrane raft</td><td>biological process</td><td>GO:0044861</td><td>2</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.141e-03</td><td>-5.76</td><td>isopeptide cross-linking via N6-(L-isoglutamyl)-L-lysine</td><td>biological process</td><td>GO:0018153</td><td>2</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>3.141e-03</td><td>-5.76</td><td>negative regulation of odontogenesis of dentin-containing tooth</td><td>biological process</td><td>GO:0042489</td><td>2</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.141e-03</td><td>-5.76</td><td>positive regulation of calcium:sodium antiporter activity</td><td>biological process</td><td>GO:1903281</td><td>2</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.141e-03</td><td>-5.76</td><td>regulation of cGMP-mediated signaling</td><td>biological process</td><td>GO:0010752</td><td>2</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.141e-03</td><td>-5.76</td><td>isopeptide cross-linking</td><td>biological process</td><td>GO:0018262</td><td>2</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>3.179e-03</td><td>-5.75</td><td>CORDENONSI YAP CONSERVED SIGNATURE</td><td>MSigDB lists</td><td>&nbsp;</td><td>57</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>3.179e-03</td><td>-5.75</td><td>DASU IL6 SIGNALING UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>57</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>3.179e-03</td><td>-5.75</td><td>ISSAEVA MLL2 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>57</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, ELF3</td></tr><tr><td>3.212e-03</td><td>-5.74</td><td>p53 signaling pathway</td><td>KEGG pathways</td><td>hsa04115</td><td>69</td><td>2</td><td>7094</td><td>9</td><td>
IGFBP3, THBS1</td></tr><tr><td>3.212e-03</td><td>-5.74</td><td>p53 signaling pathway</td><td>KEGG pathways</td><td>ko04115</td><td>69</td><td>2</td><td>7094</td><td>9</td><td>
IGFBP3, THBS1</td></tr><tr><td>3.402e-03</td><td>-5.68</td><td>MODULE 164</td><td>MSigDB lists</td><td>&nbsp;</td><td>59</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>3.472e-03</td><td>-5.66</td><td>peptide cross-linking</td><td>biological process</td><td>GO:0018149</td><td>56</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>3.479e-03</td><td>-5.66</td><td>regulation of MAPK cascade</td><td>biological process</td><td>GO:0043408</td><td>670</td><td>5</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, TGFA, IGFBP3, THBS1</td></tr><tr><td>3.497e-03</td><td>-5.66</td><td>KIM WT1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>209</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, THBS1</td></tr><tr><td>3.500e-03</td><td>-5.66</td><td>regulation of cell communication</td><td>biological process</td><td>GO:0010646</td><td>2988</td><td>11</td><td>16543</td><td>26</td><td>
GPR37, IGFBP6, SCG5, TGFA, MAGEA3, TNFRSF11B, TGM2, RBPMS, ANO1, IGFBP3, THBS1</td></tr><tr><td>3.501e-03</td><td>-5.65</td><td>HELLER HDAC TARGETS SILENCED BY METHYLATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>433</td><td>4</td><td>17621</td><td>26</td><td>
ATP1B1, MAGEA6, MAGEA3, IGFBP3</td></tr><tr><td>3.516e-03</td><td>-5.65</td><td>MODULE 433</td><td>MSigDB lists</td><td>&nbsp;</td><td>60</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGFA</td></tr><tr><td>3.529e-03</td><td>-5.65</td><td>CTSD (cathepsin D)</td><td>protein interactions</td><td>1509</td><td>58</td><td>2</td><td>16330</td><td>25</td><td>
ATP1B1, IGFBP3</td></tr><tr><td>3.545e-03</td><td>-5.64</td><td>positive regulation of cell motility</td><td>biological process</td><td>GO:2000147</td><td>408</td><td>4</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, THBS1</td></tr><tr><td>3.637e-03</td><td>-5.62</td><td>single organism signaling</td><td>biological process</td><td>GO:0044700</td><td>5049</td><td>15</td><td>16543</td><td>26</td><td>
DST, GPR37, CEACAM6, TNFAIP6, PCDH1, IGFBP6, SCG5, CXCL3, GPR87, INPP4B, TNFRSF11B, TFF2, TGM2, ATP1B1, ANO1</td></tr><tr><td>3.660e-03</td><td>-5.61</td><td>GO LOCOMOTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>1052</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, DST, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>3.668e-03</td><td>-5.61</td><td>signaling</td><td>biological process</td><td>GO:0023052</td><td>5053</td><td>15</td><td>16543</td><td>26</td><td>
DST, GPR37, CEACAM6, TNFAIP6, PCDH1, IGFBP6, SCG5, CXCL3, GPR87, INPP4B, TNFRSF11B, ATP1B1, TFF2, TGM2, ANO1</td></tr><tr><td>3.684e-03</td><td>-5.60</td><td>regulation of cell migration</td><td>biological process</td><td>GO:0030334</td><td>679</td><td>5</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, IGFBP3, THBS1</td></tr><tr><td>3.737e-03</td><td>-5.59</td><td>COLDREN GEFITINIB RESISTANCE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>214</td><td>3</td><td>17621</td><td>26</td><td>
DST, GPR87, ELF3</td></tr><tr><td>3.786e-03</td><td>-5.58</td><td>ZHANG RESPONSE TO IKK INHIBITOR AND TNF UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>215</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3, PI3</td></tr><tr><td>3.789e-03</td><td>-5.58</td><td>GO POSITIVE REGULATION OF RESPONSE TO STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>1833</td><td>8</td><td>17621</td><td>26</td><td>
GPR37, CXCL3, TGFA, TNFRSF11B, RBPMS, ANO1, IGFBP3, THBS1</td></tr><tr><td>3.798e-03</td><td>-5.57</td><td>chemokine receptor binding</td><td>molecular function</td><td>GO:0042379</td><td>59</td><td>2</td><td>16652</td><td>26</td><td>
TFF2, CXCL3</td></tr><tr><td>3.823e-03</td><td>-5.57</td><td>human chr20q13.12</td><td>chromosome location</td><td>human chr20q13.12</td><td>93</td><td>2</td><td>26234</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>3.866e-03</td><td>-5.56</td><td>positive regulation of cellular component movement</td><td>biological process</td><td>GO:0051272</td><td>418</td><td>4</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, THBS1</td></tr><tr><td>3.990e-03</td><td>-5.52</td><td>DACOSTA UV RESPONSE VIA ERCC3 TTD UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>64</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, THBS1</td></tr><tr><td>3.995e-03</td><td>-5.52</td><td>NABA MATRISOME ASSOCIATED</td><td>MSigDB lists</td><td>&nbsp;</td><td>737</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, TGM2, CXCL3, TGFA, PI3</td></tr><tr><td>4.038e-03</td><td>-5.51</td><td>KONDO EZH2 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>220</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, ANO1, IGFBP3</td></tr><tr><td>4.038e-03</td><td>-5.51</td><td>BENPORATH MYC TARGETS WITH EBOX</td><td>MSigDB lists</td><td>&nbsp;</td><td>220</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM5, MAGEA6, MAGEA3</td></tr><tr><td>4.112e-03</td><td>-5.49</td><td>GO G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>1077</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TGM2, CXCL3, SCG5, ANO1, GPR87</td></tr><tr><td>4.113e-03</td><td>-5.49</td><td>OUELLET CULTURED OVARIAN CANCER INVASIVE VS LMP UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>65</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, KRT7</td></tr><tr><td>4.146e-03</td><td>-5.49</td><td>SCHAEFFER PROSTATE DEVELOPMENT 48HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>454</td><td>4</td><td>17621</td><td>26</td><td>
KRT7, IGFBP6, ANO1, ELF3</td></tr><tr><td>4.162e-03</td><td>-5.48</td><td>regulation of response to stimulus</td><td>biological process</td><td>GO:0048583</td><td>3535</td><td>12</td><td>16543</td><td>26</td><td>
GPR37, TNFAIP6, IGFBP6, CXCL3, TGFA, MAGEA3, TNFRSF11B, TGM2, RBPMS, ANO1, IGFBP3, THBS1</td></tr><tr><td>4.227e-03</td><td>-5.47</td><td>P trefoil chordata</td><td>interpro domains</td><td>IPR017994</td><td>3</td><td>1</td><td>18428</td><td>26</td><td>
TFF2</td></tr><tr><td>4.237e-03</td><td>-5.46</td><td>KEGG P53 SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>66</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>4.237e-03</td><td>-5.46</td><td>JECHLINGER EPITHELIAL TO MESENCHYMAL TRANSITION DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>66</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>4.237e-03</td><td>-5.46</td><td>PID INTEGRIN1 PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>66</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>4.237e-03</td><td>-5.46</td><td>YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 1</td><td>MSigDB lists</td><td>&nbsp;</td><td>66</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, IGFBP3</td></tr><tr><td>4.247e-03</td><td>-5.46</td><td>MODULE 176</td><td>MSigDB lists</td><td>&nbsp;</td><td>224</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, CXCL3, TGFA</td></tr><tr><td>4.323e-03</td><td>-5.44</td><td>GO POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>1088</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>4.355e-03</td><td>-5.44</td><td>cell communication</td><td>biological process</td><td>GO:0007154</td><td>5135</td><td>15</td><td>16543</td><td>26</td><td>
DST, GPR37, CEACAM6, TNFAIP6, PCDH1, IGFBP6, SCG5, CXCL3, GPR87, INPP4B, TNFRSF11B, ATP1B1, TFF2, TGM2, ANO1</td></tr><tr><td>4.364e-03</td><td>-5.43</td><td>GEORGANTAS HSC MARKERS</td><td>MSigDB lists</td><td>&nbsp;</td><td>67</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, INPP4B</td></tr><tr><td>4.412e-03</td><td>-5.42</td><td>PLG (plasminogen)</td><td>protein interactions</td><td>5340</td><td>65</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP3, THBS1</td></tr><tr><td>4.419e-03</td><td>-5.42</td><td>positive regulation of locomotion</td><td>biological process</td><td>GO:0040017</td><td>434</td><td>4</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, THBS1</td></tr><tr><td>4.517e-03</td><td>-5.40</td><td>DOANE RESPONSE TO ANDROGEN DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>229</td><td>3</td><td>17621</td><td>26</td><td>
DST, IGFBP3, THBS1</td></tr><tr><td>4.584e-03</td><td>-5.39</td><td>SENESE HDAC3 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>467</td><td>4</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, CXCL3, PI3</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>CSNK1G2-AS1 (CSNK1G2 antisense RNA 1)</td><td>protein interactions</td><td>255193</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>SLC7A9 (solute carrier family 7 member 9)</td><td>protein interactions</td><td>11136</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>VHLL (von Hippel-Lindau tumor suppressor like)</td><td>protein interactions</td><td>391104</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>KRTAP23-1 (keratin associated protein 23-1)</td><td>protein interactions</td><td>337963</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>ANKRD26P1 (ankyrin repeat domain 26 pseudogene 1)</td><td>protein interactions</td><td>124149</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>LRRC75A-AS1 (LRRC75A antisense RNA 1)</td><td>protein interactions</td><td>125144</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>FRMPD1 (FERM and PDZ domain containing 1)</td><td>protein interactions</td><td>22844</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>TNFAIP6 (TNF alpha induced protein 6)</td><td>protein interactions</td><td>7130</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>FCRL4 (Fc receptor like 4)</td><td>protein interactions</td><td>83417</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
TFF2</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>ELMOD3 (ELMO domain containing 3)</td><td>protein interactions</td><td>84173</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.586e-03</td><td>-5.38</td><td>LOC148413 (uncharacterized LOC148413)</td><td>protein interactions</td><td>148413</td><td>3</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.610e-03</td><td>-5.38</td><td>positive regulation of phosphorus metabolic process</td><td>biological process</td><td>GO:0010562</td><td>1035</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>4.610e-03</td><td>-5.38</td><td>positive regulation of phosphate metabolic process</td><td>biological process</td><td>GO:0045937</td><td>1035</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>4.622e-03</td><td>-5.38</td><td>DELPUECH FOXO3 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>69</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, TGFA</td></tr><tr><td>4.628e-03</td><td>-5.38</td><td>GO NEGATIVE REGULATION OF PEPTIDASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>231</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, PI3, THBS1</td></tr><tr><td>4.677e-03</td><td>-5.37</td><td>fibrinogen binding</td><td>molecular function</td><td>GO:0070051</td><td>3</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>4.677e-03</td><td>-5.37</td><td>iodide transmembrane transporter activity</td><td>molecular function</td><td>GO:0015111</td><td>3</td><td>1</td><td>16652</td><td>26</td><td>
ANO1</td></tr><tr><td>4.677e-03</td><td>-5.37</td><td>collagen V binding</td><td>molecular function</td><td>GO:0070052</td><td>3</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>4.684e-03</td><td>-5.36</td><td>ALFANO MYC TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>232</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, TGM2</td></tr><tr><td>4.684e-03</td><td>-5.36</td><td>MCLACHLAN DENTAL CARIES UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>232</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, PI3</td></tr><tr><td>4.708e-03</td><td>-5.36</td><td>regulation of calcium:sodium antiporter activity</td><td>biological process</td><td>GO:1903279</td><td>3</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.708e-03</td><td>-5.36</td><td>negative regulation of nitric oxide mediated signal transduction</td><td>biological process</td><td>GO:0010751</td><td>3</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.708e-03</td><td>-5.36</td><td>negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II</td><td>biological process</td><td>GO:0002581</td><td>3</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.708e-03</td><td>-5.36</td><td>positive regulation of potassium ion import</td><td>biological process</td><td>GO:1903288</td><td>3</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.724e-03</td><td>-5.36</td><td>ZWANG CLASS 1 TRANSIENTLY INDUCED BY EGF</td><td>MSigDB lists</td><td>&nbsp;</td><td>471</td><td>4</td><td>17621</td><td>26</td><td>
DST, SLPI, TGFA, THBS1</td></tr><tr><td>4.740e-03</td><td>-5.35</td><td>DAZARD RESPONSE TO UV NHEK UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>233</td><td>3</td><td>17621</td><td>26</td><td>
IGFBP6, SCG5, CXCL3</td></tr><tr><td>4.754e-03</td><td>-5.35</td><td>NATSUME RESPONSE TO INTERFERON BETA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>70</td><td>2</td><td>17621</td><td>26</td><td>
DST, IGFBP3</td></tr><tr><td>4.754e-03</td><td>-5.35</td><td>NAKAYAMA SOFT TISSUE TUMORS PCA1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>70</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>4.797e-03</td><td>-5.34</td><td>NABA ECM REGULATORS</td><td>MSigDB lists</td><td>&nbsp;</td><td>234</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TGM2, PI3</td></tr><tr><td>4.863e-03</td><td>-5.33</td><td>GO POSITIVE REGULATION OF CELL COMMUNICATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>1495</td><td>7</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, ANO1, THBS1, IGFBP3</td></tr><tr><td>4.887e-03</td><td>-5.32</td><td>MODULE 154</td><td>MSigDB lists</td><td>&nbsp;</td><td>71</td><td>2</td><td>17621</td><td>26</td><td>
DST, PI3</td></tr><tr><td>4.928e-03</td><td>-5.31</td><td>positive regulation of signal transduction</td><td>biological process</td><td>GO:0009967</td><td>1407</td><td>7</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, TGM2, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>4.931e-03</td><td>-5.31</td><td>signal transduction</td><td>biological process</td><td>GO:0007165</td><td>4644</td><td>14</td><td>16543</td><td>26</td><td>
DST, GPR37, CEACAM6, TNFAIP6, IGFBP6, SCG5, CXCL3, GPR87, INPP4B, TNFRSF11B, TFF2, TGM2, ATP1B1, ANO1</td></tr><tr><td>4.986e-03</td><td>-5.30</td><td>regulation of cell motility</td><td>biological process</td><td>GO:2000145</td><td>729</td><td>5</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, IGFBP3, THBS1</td></tr><tr><td>5.029e-03</td><td>-5.29</td><td>V$MYOD Q6 01</td><td>MSigDB lists</td><td>&nbsp;</td><td>238</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, DST, ATP1B1</td></tr><tr><td>5.116e-03</td><td>-5.28</td><td>human chr12q13.13</td><td>chromosome location</td><td>human chr12q13.13</td><td>108</td><td>2</td><td>26234</td><td>26</td><td>
IGFBP6, KRT7</td></tr><tr><td>5.159e-03</td><td>-5.27</td><td>HOSHIDA LIVER CANCER SURVIVAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>73</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, IGFBP6</td></tr><tr><td>5.164e-03</td><td>-5.27</td><td>BROWNE HCMV INFECTION 48HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>483</td><td>4</td><td>17621</td><td>26</td><td>
PCDH1, RBPMS, IGFBP6, IGFBP3</td></tr><tr><td>5.202e-03</td><td>-5.26</td><td>response to stress</td><td>biological process</td><td>GO:0006950</td><td>3139</td><td>11</td><td>16543</td><td>26</td><td>
DST, TNFAIP6, CXCL3, SLPI, TNFRSF11B, TFF2, ATP1B1, RBPMS, ANO1, ELF3, THBS1</td></tr><tr><td>5.207e-03</td><td>-5.26</td><td>Ig 2</td><td>pfam domains</td><td>PF13895</td><td>76</td><td>2</td><td>16832</td><td>24</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>5.207e-03</td><td>-5.26</td><td>BILD HRAS ONCOGENIC SIGNATURE</td><td>MSigDB lists</td><td>&nbsp;</td><td>241</td><td>3</td><td>17621</td><td>26</td><td>
CXCL3, TGFA, PI3</td></tr><tr><td>5.252e-03</td><td>-5.25</td><td>CUI TCF21 TARGETS 2 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>786</td><td>5</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, RBPMS, KRT7, THBS1</td></tr><tr><td>5.267e-03</td><td>-5.25</td><td>V$MYOD 01</td><td>MSigDB lists</td><td>&nbsp;</td><td>242</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, DST, PCDH1</td></tr><tr><td>5.272e-03</td><td>-5.25</td><td>DODD NASOPHARYNGEAL CARCINOMA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>1517</td><td>7</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6, PCDH1, CEACAM5, KRT7, PI3, ELF3</td></tr><tr><td>5.297e-03</td><td>-5.24</td><td>JACKSON DNMT1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>74</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, IGFBP6</td></tr><tr><td>5.339e-03</td><td>-5.23</td><td>receptor binding</td><td>molecular function</td><td>GO:0005102</td><td>1437</td><td>7</td><td>16652</td><td>26</td><td>
DST, TNFRSF11B, TFF2, IGFBP6, CXCL3, TGFA, THBS1</td></tr><tr><td>5.375e-03</td><td>-5.23</td><td>negative regulation of molecular function</td><td>biological process</td><td>GO:0044092</td><td>1068</td><td>6</td><td>16543</td><td>26</td><td>
SLPI, SCG5, GPR87, PI3, MAGEA3, THBS1</td></tr><tr><td>5.438e-03</td><td>-5.21</td><td>LIN APC TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>75</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>5.450e-03</td><td>-5.21</td><td>ONDER CDH1 TARGETS 2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>245</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, SCG5, IGFBP3</td></tr><tr><td>5.496e-03</td><td>-5.20</td><td>TNFACTORR11</td><td>prints domains</td><td>PR01961</td><td>2</td><td>1</td><td>4725</td><td>13</td><td>
TNFRSF11B</td></tr><tr><td>5.496e-03</td><td>-5.20</td><td>GPR37ORPHANR</td><td>prints domains</td><td>PR01421</td><td>2</td><td>1</td><td>4725</td><td>13</td><td>
GPR37</td></tr><tr><td>5.496e-03</td><td>-5.20</td><td>P2Y13PRNCPTR</td><td>prints domains</td><td>PR01735</td><td>2</td><td>1</td><td>4725</td><td>13</td><td>
GPR87</td></tr><tr><td>5.529e-03</td><td>-5.20</td><td>regulation of biological process</td><td>biological process</td><td>GO:0050789</td><td>10614</td><td>23</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, IGFBP6, CXCL3, TGFA, SLPI, ATP1B1, TFF2, ANO1, PI3, THBS1, ELF3, DST, GPR37, SCG5, GPR87, MAGEA3, INPP4B, TNFRSF11B, CEACAM5, TGM2, RBPMS, IGFBP3</td></tr><tr><td>5.539e-03</td><td>-5.20</td><td>GO CELL MOTILITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>796</td><td>5</td><td>17621</td><td>26</td><td>
DST, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>5.539e-03</td><td>-5.20</td><td>GO LOCALIZATION OF CELL</td><td>MSigDB lists</td><td>&nbsp;</td><td>796</td><td>5</td><td>17621</td><td>26</td><td>
DST, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>5.568e-03</td><td>-5.19</td><td>GO NEGATIVE REGULATION OF CATALYTIC ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>797</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, SCG5, PI3, GPR87, THBS1</td></tr><tr><td>5.580e-03</td><td>-5.19</td><td>MODULE 357</td><td>MSigDB lists</td><td>&nbsp;</td><td>76</td><td>2</td><td>17621</td><td>26</td><td>
DST, PI3</td></tr><tr><td>5.580e-03</td><td>-5.19</td><td>JIANG HYPOXIA CANCER</td><td>MSigDB lists</td><td>&nbsp;</td><td>76</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, TGM2</td></tr><tr><td>5.580e-03</td><td>-5.19</td><td>MODULE 297</td><td>MSigDB lists</td><td>&nbsp;</td><td>76</td><td>2</td><td>17621</td><td>26</td><td>
DST, PI3</td></tr><tr><td>5.580e-03</td><td>-5.19</td><td>THEILGAARD NEUTROPHIL AT SKIN WOUND UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>76</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, PI3</td></tr><tr><td>5.675e-03</td><td>-5.17</td><td>positive regulation of smooth muscle cell proliferation</td><td>biological process</td><td>GO:0048661</td><td>72</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>5.681e-03</td><td>-5.17</td><td>GRN (granulin precursor)</td><td>protein interactions</td><td>2896</td><td>74</td><td>2</td><td>16330</td><td>25</td><td>
SLPI, TGM2</td></tr><tr><td>5.804e-03</td><td>-5.15</td><td>locomotion</td><td>biological process</td><td>GO:0040011</td><td>1085</td><td>6</td><td>16543</td><td>26</td><td>
DST, GPR37, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>5.807e-03</td><td>-5.15</td><td>MODULE 55</td><td>MSigDB lists</td><td>&nbsp;</td><td>805</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, TGM2, KRT7, SCG5, IGFBP3</td></tr><tr><td>5.849e-03</td><td>-5.14</td><td>insulin-like growth factor ternary complex</td><td>cellular component</td><td>GO:0042567</td><td>4</td><td>1</td><td>17744</td><td>26</td><td>
IGFBP3</td></tr><tr><td>5.849e-03</td><td>-5.14</td><td>growth factor complex</td><td>cellular component</td><td>GO:0036454</td><td>4</td><td>1</td><td>17744</td><td>26</td><td>
IGFBP3</td></tr><tr><td>5.849e-03</td><td>-5.14</td><td>insulin-like growth factor binding protein complex</td><td>cellular component</td><td>GO:0016942</td><td>4</td><td>1</td><td>17744</td><td>26</td><td>
IGFBP3</td></tr><tr><td>5.868e-03</td><td>-5.14</td><td>HELLEBREKERS SILENCED DURING TUMOR ANGIOGENESIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>78</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, IGFBP3</td></tr><tr><td>5.868e-03</td><td>-5.14</td><td>ONDER CDH1 SIGNALING VIA CTNNB1</td><td>MSigDB lists</td><td>&nbsp;</td><td>78</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, IGFBP3</td></tr><tr><td>5.893e-03</td><td>-5.13</td><td>CAIRO HEPATOBLASTOMA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>252</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, ANO1, IGFBP3</td></tr><tr><td>5.958e-03</td><td>-5.12</td><td>GO LEUKOCYTE MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>253</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, ATP1B1, CXCL3</td></tr><tr><td>5.985e-03</td><td>-5.12</td><td>chemokine-mediated signaling pathway</td><td>biological process</td><td>GO:0070098</td><td>74</td><td>2</td><td>16543</td><td>26</td><td>
TFF2, CXCL3</td></tr><tr><td>6.012e-03</td><td>-5.11</td><td>protein binding</td><td>molecular function</td><td>GO:0005515</td><td>10733</td><td>23</td><td>16652</td><td>26</td><td>
CEACAM6, TNFAIP6, KRT7, IGFBP6, CXCL3, TGFA, SLPI, ATP1B1, TFF2, ANO1, THBS1, ELF3, DST, GPR37, SCG5, MAGEA3, INPP4B, TNFRSF11B, CEACAM5, TGM2, RBPMS, MAGEA6, IGFBP3</td></tr><tr><td>6.015e-03</td><td>-5.11</td><td>GO POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>79</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>6.015e-03</td><td>-5.11</td><td>SWEET KRAS TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>79</td><td>2</td><td>17621</td><td>26</td><td>
INPP4B, IGFBP3</td></tr><tr><td>6.015e-03</td><td>-5.11</td><td>DACOSTA UV RESPONSE VIA ERCC3 TTD DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>79</td><td>2</td><td>17621</td><td>26</td><td>
DST, RBPMS</td></tr><tr><td>6.080e-03</td><td>-5.10</td><td>HSPA1A (heat shock protein family A (Hsp70) member 1A)</td><td>protein interactions</td><td>3303</td><td>246</td><td>3</td><td>16330</td><td>25</td><td>
GPR37, TGM2, KRT7</td></tr><tr><td>6.089e-03</td><td>-5.10</td><td>BOQUEST STEM CELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>255</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6, IGFBP3</td></tr><tr><td>6.103e-03</td><td>-5.10</td><td>GO REGULATION OF PHOSPHORUS METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>1558</td><td>7</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, GPR87, IGFBP3, THBS1</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>NYNRIN (NYN domain and retroviral integrase containing)</td><td>protein interactions</td><td>57523</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>SMUG1 (single-strand-selective monofunctional uracil-DNA glycosylase 1)</td><td>protein interactions</td><td>23583</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>PCSK2 (proprotein convertase subtilisin/kexin type 2)</td><td>protein interactions</td><td>5126</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
SCG5</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>DISP3 (dispatched RND transporter family member 3)</td><td>protein interactions</td><td>57540</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM5</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>RASSF4 (Ras association domain family member 4)</td><td>protein interactions</td><td>83937</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>ARHGEF39 (Rho guanine nucleotide exchange factor 39)</td><td>protein interactions</td><td>84904</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>COL5A2 (collagen type V alpha 2 chain)</td><td>protein interactions</td><td>1290</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>LINC01588 (long intergenic non-protein coding RNA 1588)</td><td>protein interactions</td><td>283551</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>KRT27 (keratin 27)</td><td>protein interactions</td><td>342574</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
KRT7</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>TMEM176A (transmembrane protein 176A)</td><td>protein interactions</td><td>55365</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>Pick1 (protein interacting with PRKCA 1)</td><td>protein interactions</td><td>84591</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
GPR37</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>LINC01547 (long intergenic non-protein coding RNA 1547)</td><td>protein interactions</td><td>84536</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>6.110e-03</td><td>-5.10</td><td>RHBDF1 (rhomboid 5 homolog 1)</td><td>protein interactions</td><td>64285</td><td>4</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>6.164e-03</td><td>-5.09</td><td>MAHAJAN RESPONSE TO IL1A UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>80</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>6.231e-03</td><td>-5.08</td><td>phosphatidylinositol-4,5-bisphosphate 4-phosphatase activity</td><td>molecular function</td><td>GO:0034597</td><td>4</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>6.231e-03</td><td>-5.08</td><td>inositol bisphosphate phosphatase activity</td><td>molecular function</td><td>GO:0016312</td><td>4</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>regulation of sodium ion export from cell</td><td>biological process</td><td>GO:1903276</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>regulation of plasma membrane long-chain fatty acid transport</td><td>biological process</td><td>GO:0010746</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>negative regulation of odontogenesis</td><td>biological process</td><td>GO:0042483</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>regulation of sodium ion export</td><td>biological process</td><td>GO:1903273</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>iodide transport</td><td>biological process</td><td>GO:0015705</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ANO1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>regulation of potassium ion import</td><td>biological process</td><td>GO:1903286</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>protein localization to plasma membrane raft</td><td>biological process</td><td>GO:0044860</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>negative regulation of endothelial cell chemotaxis</td><td>biological process</td><td>GO:2001027</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>negative regulation of plasma membrane long-chain fatty acid transport</td><td>biological process</td><td>GO:0010748</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>peptidyl-glutamine modification</td><td>biological process</td><td>GO:0018199</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>positive regulation of sodium ion export</td><td>biological process</td><td>GO:1903275</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>positive regulation of sodium ion export from cell</td><td>biological process</td><td>GO:1903278</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>6.272e-03</td><td>-5.07</td><td>regulation of nitric oxide mediated signal transduction</td><td>biological process</td><td>GO:0010749</td><td>4</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>6.314e-03</td><td>-5.06</td><td>SCHUETZ BREAST CANCER DUCTAL INVASIVE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>81</td><td>2</td><td>17621</td><td>26</td><td>
DST, GPR87</td></tr><tr><td>6.356e-03</td><td>-5.06</td><td>V$AP1 Q2 01</td><td>MSigDB lists</td><td>&nbsp;</td><td>259</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, RBPMS, GPR87</td></tr><tr><td>6.450e-03</td><td>-5.04</td><td>ATF7IP (activating transcription factor 7 interacting protein)</td><td>protein interactions</td><td>55729</td><td>79</td><td>2</td><td>16330</td><td>25</td><td>
PCDH1, KRT7</td></tr><tr><td>6.513e-03</td><td>-5.03</td><td>ENK UV RESPONSE KERATINOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>516</td><td>4</td><td>17621</td><td>26</td><td>
TGM2, KRT7, IGFBP6, CXCL3</td></tr><tr><td>6.553e-03</td><td>-5.03</td><td>regulation of cell death</td><td>biological process</td><td>GO:0010941</td><td>1482</td><td>7</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, CEACAM5, TGM2, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>6.620e-03</td><td>-5.02</td><td>GO PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>83</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, ANO1</td></tr><tr><td>6.632e-03</td><td>-5.02</td><td>regulation of cellular protein metabolic process</td><td>biological process</td><td>GO:0032268</td><td>2312</td><td>9</td><td>16543</td><td>26</td><td>
GPR37, TGFA, MAGEA3, SLPI, TNFRSF11B, RBPMS, PI3, THBS1, IGFBP3</td></tr><tr><td>6.794e-03</td><td>-4.99</td><td>positive regulation of leukocyte chemotaxis</td><td>biological process</td><td>GO:0002690</td><td>79</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>6.841e-03</td><td>-4.98</td><td>YKACATTT UNKNOWN</td><td>MSigDB lists</td><td>&nbsp;</td><td>266</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, INPP4B, THBS1</td></tr><tr><td>6.912e-03</td><td>-4.97</td><td>POOLA INVASIVE BREAST CANCER UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>267</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, TNFAIP6, CEACAM5</td></tr><tr><td>6.914e-03</td><td>-4.97</td><td>regulation of locomotion</td><td>biological process</td><td>GO:0040012</td><td>788</td><td>5</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, IGFBP3, THBS1</td></tr><tr><td>6.918e-03</td><td>-4.97</td><td>CHICAS RB1 TARGETS CONFLUENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>525</td><td>4</td><td>17621</td><td>26</td><td>
TGM2, IGFBP6, ANO1, THBS1</td></tr><tr><td>6.933e-03</td><td>-4.97</td><td>LIU VAV3 PROSTATE CARCINOGENESIS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>85</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>6.933e-03</td><td>-4.97</td><td>GO RESPONSE TO HEAT</td><td>MSigDB lists</td><td>&nbsp;</td><td>85</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>6.933e-03</td><td>-4.97</td><td>BROWNE HCMV INFECTION 16HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>85</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>6.933e-03</td><td>-4.97</td><td>MVP (major vault protein)</td><td>protein interactions</td><td>9961</td><td>82</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, RBPMS</td></tr><tr><td>6.962e-03</td><td>-4.97</td><td>regulation of catalytic activity</td><td>biological process</td><td>GO:0050790</td><td>2329</td><td>9</td><td>16543</td><td>26</td><td>
SCG5, TGFA, GPR87, MAGEA3, SLPI, ATP1B1, PI3, THBS1, IGFBP3</td></tr><tr><td>6.973e-03</td><td>-4.97</td><td>defense response</td><td>biological process</td><td>GO:0006952</td><td>1127</td><td>6</td><td>16543</td><td>26</td><td>
SLPI, TNFRSF11B, TNFAIP6, CXCL3, THBS1, ELF3</td></tr><tr><td>6.973e-03</td><td>-4.97</td><td>positive regulation of protein modification process</td><td>biological process</td><td>GO:0031401</td><td>1127</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>7.035e-03</td><td>-4.96</td><td>TSP type-3 rpt</td><td>interpro domains</td><td>IPR028974</td><td>5</td><td>1</td><td>18428</td><td>26</td><td>
THBS1</td></tr><tr><td>7.035e-03</td><td>-4.96</td><td>Na/K ATPase sub beta</td><td>interpro domains</td><td>IPR000402</td><td>5</td><td>1</td><td>18428</td><td>26</td><td>
ATP1B1</td></tr><tr><td>7.035e-03</td><td>-4.96</td><td>Thrombospondin 3 rpt</td><td>interpro domains</td><td>IPR017897</td><td>5</td><td>1</td><td>18428</td><td>26</td><td>
THBS1</td></tr><tr><td>7.035e-03</td><td>-4.96</td><td>Protocadherin</td><td>interpro domains</td><td>IPR013585</td><td>5</td><td>1</td><td>18428</td><td>26</td><td>
PCDH1</td></tr><tr><td>7.035e-03</td><td>-4.96</td><td>Thrombospondin C</td><td>interpro domains</td><td>IPR008859</td><td>5</td><td>1</td><td>18428</td><td>26</td><td>
THBS1</td></tr><tr><td>7.035e-03</td><td>-4.96</td><td>Thrombospondin 3-like rpt</td><td>interpro domains</td><td>IPR003367</td><td>5</td><td>1</td><td>18428</td><td>26</td><td>
THBS1</td></tr><tr><td>7.061e-03</td><td>-4.95</td><td>regulation of cellular component movement</td><td>biological process</td><td>GO:0051270</td><td>792</td><td>5</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, CXCL3, IGFBP3, THBS1</td></tr><tr><td>7.104e-03</td><td>-4.95</td><td>FULCHER INFLAMMATORY RESPONSE LECTIN VS LPS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>529</td><td>4</td><td>17621</td><td>26</td><td>
ATP1B1, TGM2, CXCL3, TGFA</td></tr><tr><td>7.110e-03</td><td>-4.95</td><td>Protocadherin</td><td>pfam domains</td><td>PF08374</td><td>5</td><td>1</td><td>16832</td><td>24</td><td>
PCDH1</td></tr><tr><td>7.110e-03</td><td>-4.95</td><td>TSP C</td><td>pfam domains</td><td>PF05735</td><td>5</td><td>1</td><td>16832</td><td>24</td><td>
THBS1</td></tr><tr><td>7.110e-03</td><td>-4.95</td><td>TSP 3</td><td>pfam domains</td><td>PF02412</td><td>5</td><td>1</td><td>16832</td><td>24</td><td>
THBS1</td></tr><tr><td>7.110e-03</td><td>-4.95</td><td>Na K-ATPase</td><td>pfam domains</td><td>PF00287</td><td>5</td><td>1</td><td>16832</td><td>24</td><td>
ATP1B1</td></tr><tr><td>7.128e-03</td><td>-4.94</td><td>NAKAMURA TUMOR ZONE PERIPHERAL VS CENTRAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>270</td><td>3</td><td>17621</td><td>26</td><td>
KRT7, ANO1, THBS1</td></tr><tr><td>7.131e-03</td><td>-4.94</td><td>regulation of protein processing</td><td>biological process</td><td>GO:0070613</td><td>81</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>7.153e-03</td><td>-4.94</td><td>G-protein coupled receptor signaling pathway</td><td>biological process</td><td>GO:0007186</td><td>1133</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TGM2, SCG5, CXCL3, ANO1, GPR87</td></tr><tr><td>7.252e-03</td><td>-4.93</td><td>SASSON RESPONSE TO GONADOTROPHINS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>87</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, THBS1</td></tr><tr><td>7.252e-03</td><td>-4.93</td><td>GRAHAM CML DIVIDING VS NORMAL QUIESCENT DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>87</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, CXCL3</td></tr><tr><td>7.252e-03</td><td>-4.93</td><td>MODULE 426</td><td>MSigDB lists</td><td>&nbsp;</td><td>87</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, ELF3</td></tr><tr><td>7.302e-03</td><td>-4.92</td><td>negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</td><td>biological process</td><td>GO:0043154</td><td>82</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>7.302e-03</td><td>-4.92</td><td>regulation of protein maturation</td><td>biological process</td><td>GO:1903317</td><td>82</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>7.413e-03</td><td>-4.90</td><td>SASSON RESPONSE TO FORSKOLIN DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>88</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, THBS1</td></tr><tr><td>7.413e-03</td><td>-4.90</td><td>SANA TNF SIGNALING DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>88</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>7.413e-03</td><td>-4.90</td><td>ZHU CMV 24 HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>88</td><td>2</td><td>17621</td><td>26</td><td>
THBS1, IGFBP3</td></tr><tr><td>7.433e-03</td><td>-4.90</td><td>GO POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>854</td><td>5</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, TGFA, IGFBP3, THBS1</td></tr><tr><td>7.522e-03</td><td>-4.89</td><td>QT interval(PMID:19305409)</td><td>GWAS genes</td><td>QT interval(PMID:19305409)</td><td>6</td><td>1</td><td>2388</td><td>3</td><td>
ATP1B1</td></tr><tr><td>7.577e-03</td><td>-4.88</td><td>GO SERINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>89</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>7.608e-03</td><td>-4.88</td><td>-</td><td>gene3d domains</td><td>4.10.1080.10</td><td>5</td><td>1</td><td>10485</td><td>16</td><td>
THBS1</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>DOK6 (docking protein 6)</td><td>protein interactions</td><td>220164</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>PAPPA2 (pappalysin 2)</td><td>protein interactions</td><td>60676</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>DCDC2B (doublecortin domain containing 2B)</td><td>protein interactions</td><td>149069</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>IGFALS (insulin like growth factor binding protein acid labile subunit)</td><td>protein interactions</td><td>3483</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>PLAC8 (placenta specific 8)</td><td>protein interactions</td><td>51316</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>KRTAP8-1 (keratin associated protein 8-1)</td><td>protein interactions</td><td>337879</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>GCGR (glucagon receptor)</td><td>protein interactions</td><td>2642</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>GCM2 (glial cells missing homolog 2)</td><td>protein interactions</td><td>9247</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>CTF1 (cardiotrophin 1)</td><td>protein interactions</td><td>1489</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>7.632e-03</td><td>-4.88</td><td>KRTAP19-7 (keratin associated protein 19-7)</td><td>protein interactions</td><td>337974</td><td>5</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>7.650e-03</td><td>-4.87</td><td>response to heat</td><td>biological process</td><td>GO:0009408</td><td>84</td><td>2</td><td>16543</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>7.674e-03</td><td>-4.87</td><td>ATPASE NA K BETA 2</td><td>prosite domains</td><td>PS00391</td><td>4</td><td>1</td><td>11955</td><td>23</td><td>
ATP1B1</td></tr><tr><td>7.783e-03</td><td>-4.86</td><td>caspase binding</td><td>molecular function</td><td>GO:0089720</td><td>5</td><td>1</td><td>16652</td><td>26</td><td>
MAGEA3</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>negative regulation of plasminogen activation</td><td>biological process</td><td>GO:0010757</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>positive regulation of catecholamine metabolic process</td><td>biological process</td><td>GO:0045915</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>salivary gland cavitation</td><td>biological process</td><td>GO:0060662</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>tube lumen cavitation</td><td>biological process</td><td>GO:0060605</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>positive regulation of dopamine metabolic process</td><td>biological process</td><td>GO:0045964</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II</td><td>biological process</td><td>GO:0002580</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>7.835e-03</td><td>-4.85</td><td>engulfment of apoptotic cell</td><td>biological process</td><td>GO:0043652</td><td>5</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>7.882e-03</td><td>-4.84</td><td>positive regulation of response to external stimulus</td><td>biological process</td><td>GO:0032103</td><td>263</td><td>3</td><td>16543</td><td>26</td><td>
TGM2, CXCL3, THBS1</td></tr><tr><td>8.078e-03</td><td>-4.82</td><td>DE YY1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>92</td><td>2</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B</td></tr><tr><td>8.186e-03</td><td>-4.81</td><td>tissue remodeling</td><td>biological process</td><td>GO:0048771</td><td>87</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, ELF3</td></tr><tr><td>8.233e-03</td><td>-4.80</td><td>PTREFOIL</td><td>prints domains</td><td>PR00680</td><td>3</td><td>1</td><td>4725</td><td>13</td><td>
TFF2</td></tr><tr><td>8.419e-03</td><td>-4.78</td><td>GO REGULATION OF LEUKOCYTE CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>94</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>8.419e-03</td><td>-4.78</td><td>MODULE 128</td><td>MSigDB lists</td><td>&nbsp;</td><td>94</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>8.419e-03</td><td>-4.78</td><td>NIELSEN GIST</td><td>MSigDB lists</td><td>&nbsp;</td><td>94</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, ANO1</td></tr><tr><td>8.437e-03</td><td>-4.78</td><td>EGF rcpt ligand</td><td>interpro domains</td><td>IPR015497</td><td>6</td><td>1</td><td>18428</td><td>26</td><td>
TGFA</td></tr><tr><td>8.437e-03</td><td>-4.78</td><td>GAS dom</td><td>interpro domains</td><td>IPR003108</td><td>6</td><td>1</td><td>18428</td><td>26</td><td>
DST</td></tr><tr><td>8.526e-03</td><td>-4.76</td><td>GAS2</td><td>pfam domains</td><td>PF02187</td><td>6</td><td>1</td><td>16832</td><td>24</td><td>
DST</td></tr><tr><td>8.526e-03</td><td>-4.76</td><td>Plectin</td><td>pfam domains</td><td>PF00681</td><td>6</td><td>1</td><td>16832</td><td>24</td><td>
DST</td></tr><tr><td>8.642e-03</td><td>-4.75</td><td>leukocyte migration</td><td>biological process</td><td>GO:0050900</td><td>272</td><td>3</td><td>16543</td><td>26</td><td>
CEACAM6, ATP1B1, CXCL3</td></tr><tr><td>8.768e-03</td><td>-4.74</td><td>MODULE 79</td><td>MSigDB lists</td><td>&nbsp;</td><td>96</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>8.768e-03</td><td>-4.74</td><td>GO GLAND MORPHOGENESIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>96</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, ELF3</td></tr><tr><td>8.822e-03</td><td>-4.73</td><td>BERGER MBD2 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>6</td><td>1</td><td>17621</td><td>26</td><td>
TFF2</td></tr><tr><td>8.822e-03</td><td>-4.73</td><td>FOURNIER ACINAR DEVELOPMENT EARLY DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>6</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>8.822e-03</td><td>-4.73</td><td>JOHNSTONE PARVB TARGETS 1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>6</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>8.832e-03</td><td>-4.73</td><td>IVANOVA HEMATOPOIESIS STEM CELL LONG TERM</td><td>MSigDB lists</td><td>&nbsp;</td><td>292</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, PCDH1, KRT7</td></tr><tr><td>8.840e-03</td><td>-4.73</td><td>PRKAB2 (protein kinase AMP-activated non-catalytic subunit beta 2)</td><td>protein interactions</td><td>5565</td><td>93</td><td>2</td><td>16330</td><td>25</td><td>
DST, RBPMS</td></tr><tr><td>8.853e-03</td><td>-4.73</td><td>humerus</td><td>COSMIC cancer mutations</td><td>humerus</td><td>564</td><td>4</td><td>17630</td><td>26</td><td>
GPR37, CEACAM6, MAGEA3, THBS1</td></tr><tr><td>8.923e-03</td><td>-4.72</td><td>MODULE 45</td><td>MSigDB lists</td><td>&nbsp;</td><td>565</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6, TFF2, PI3</td></tr><tr><td>8.944e-03</td><td>-4.72</td><td>MODULE 170</td><td>MSigDB lists</td><td>&nbsp;</td><td>97</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>8.944e-03</td><td>-4.72</td><td>HIRSCH CELLULAR TRANSFORMATION SIGNATURE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>97</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>8.998e-03</td><td>-4.71</td><td>GO EXTRACELLULAR STRUCTURE ORGANIZATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>294</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, ELF3, THBS1</td></tr><tr><td>9.039e-03</td><td>-4.71</td><td>human chrXq28</td><td>chromosome location</td><td>human chrXq28</td><td>145</td><td>2</td><td>26234</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>9.123e-03</td><td>-4.70</td><td>-</td><td>gene3d domains</td><td>3.90.1290.10</td><td>6</td><td>1</td><td>10485</td><td>16</td><td>
DST</td></tr><tr><td>9.123e-03</td><td>-4.70</td><td>-</td><td>gene3d domains</td><td>3.30.920.20</td><td>6</td><td>1</td><td>10485</td><td>16</td><td>
DST</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>PAPD4 (poly(A) RNA polymerase D4, non-canonical)</td><td>protein interactions</td><td>167153</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>TEX37 (testis expressed 37)</td><td>protein interactions</td><td>200523</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>PRSS2 (protease, serine 2)</td><td>protein interactions</td><td>5645</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
SLPI</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>CELA1 (chymotrypsin like elastase family member 1)</td><td>protein interactions</td><td>1990</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
PI3</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>PDLIM4 (PDZ and LIM domain 4)</td><td>protein interactions</td><td>8572</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>KIR2DL4 (killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4)</td><td>protein interactions</td><td>3805</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>APLN (apelin)</td><td>protein interactions</td><td>8862</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>RIPPLY1 (ripply transcriptional repressor 1)</td><td>protein interactions</td><td>92129</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>SIRPB1 (signal regulatory protein beta 1)</td><td>protein interactions</td><td>10326</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>FXYD7 (FXYD domain containing ion transport regulator 7)</td><td>protein interactions</td><td>53822</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>9.152e-03</td><td>-4.69</td><td>Bace1 (beta-site APP cleaving enzyme 1)</td><td>protein interactions</td><td>23821</td><td>6</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>9.191e-03</td><td>-4.69</td><td>serine-type endopeptidase inhibitor activity</td><td>molecular function</td><td>GO:0004867</td><td>93</td><td>2</td><td>16652</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>9.302e-03</td><td>-4.68</td><td>QI PLASMACYTOMA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>99</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, IGFBP3</td></tr><tr><td>9.302e-03</td><td>-4.68</td><td>GO POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>99</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>9.315e-03</td><td>-4.68</td><td>GO PLASMA MEMBRANE REGION</td><td>MSigDB lists</td><td>&nbsp;</td><td>902</td><td>5</td><td>17621</td><td>26</td><td>
DST, CEACAM5, ATP1B1, ANO1, TGFA</td></tr><tr><td>9.326e-03</td><td>-4.67</td><td>response to stimulus</td><td>biological process</td><td>GO:0050896</td><td>7347</td><td>18</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, IGFBP6, CXCL3, SLPI, ATP1B1, TFF2, ANO1, ELF3, THBS1, DST, GPR37, SCG5, GPR87, INPP4B, TNFRSF11B, TGM2, RBPMS</td></tr><tr><td>9.349e-03</td><td>-4.67</td><td>regulation of localization</td><td>biological process</td><td>GO:0032879</td><td>2436</td><td>9</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, SCG5, CXCL3, ATP1B1, RBPMS, ANO1, THBS1, IGFBP3</td></tr><tr><td>9.394e-03</td><td>-4.67</td><td>positive regulation of transforming growth factor beta1 production</td><td>biological process</td><td>GO:0032914</td><td>6</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>9.394e-03</td><td>-4.67</td><td>protein transport into membrane raft</td><td>biological process</td><td>GO:0032596</td><td>6</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>9.394e-03</td><td>-4.67</td><td>mammary gland involution</td><td>biological process</td><td>GO:0060056</td><td>6</td><td>1</td><td>16543</td><td>26</td><td>
ELF3</td></tr><tr><td>9.394e-03</td><td>-4.67</td><td>locomotion involved in locomotory behavior</td><td>biological process</td><td>GO:0031987</td><td>6</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>9.394e-03</td><td>-4.67</td><td>negative regulation of antigen processing and presentation</td><td>biological process</td><td>GO:0002578</td><td>6</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>9.422e-03</td><td>-4.66</td><td>NAKAMURA TUMOR ZONE PERIPHERAL VS CENTRAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>574</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, PI3, ELF3, IGFBP3</td></tr><tr><td>9.483e-03</td><td>-4.66</td><td>GO INTEGRIN BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>100</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>9.584e-03</td><td>-4.65</td><td>TSP3</td><td>prosite domains</td><td>PS51234</td><td>5</td><td>1</td><td>11955</td><td>23</td><td>
THBS1</td></tr><tr><td>9.584e-03</td><td>-4.65</td><td>TSP CTER</td><td>prosite domains</td><td>PS51236</td><td>5</td><td>1</td><td>11955</td><td>23</td><td>
THBS1</td></tr><tr><td>9.584e-03</td><td>-4.65</td><td>ATPASE NA K BETA 1</td><td>prosite domains</td><td>PS00390</td><td>5</td><td>1</td><td>11955</td><td>23</td><td>
ATP1B1</td></tr><tr><td>9.658e-03</td><td>-4.64</td><td>GO ENZYME REGULATOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>910</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, SCG5, PI3, IGFBP3</td></tr><tr><td>9.666e-03</td><td>-4.64</td><td>ELVIDGE HIF1A AND HIF2A TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>101</td><td>2</td><td>17621</td><td>26</td><td>
DST, IGFBP3</td></tr><tr><td>9.667e-03</td><td>-4.64</td><td>regulation of phosphate metabolic process</td><td>biological process</td><td>GO:0019220</td><td>1593</td><td>7</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, GPR87, IGFBP3, THBS1</td></tr><tr><td>9.767e-03</td><td>-4.63</td><td>MODULE 19</td><td>MSigDB lists</td><td>&nbsp;</td><td>303</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, IGFBP6, RBPMS</td></tr><tr><td>9.775e-03</td><td>-4.63</td><td>PAK2 (p21 (RAC1) activated kinase 2)</td><td>protein interactions</td><td>5062</td><td>98</td><td>2</td><td>16330</td><td>25</td><td>
DST, TGM2</td></tr><tr><td>9.836e-03</td><td>-4.62</td><td>Anoct dimer</td><td>interpro domains</td><td>IPR032394</td><td>7</td><td>1</td><td>18428</td><td>26</td><td>
ANO1</td></tr><tr><td>9.836e-03</td><td>-4.62</td><td>Plectin repeat</td><td>interpro domains</td><td>IPR001101</td><td>7</td><td>1</td><td>18428</td><td>26</td><td>
DST</td></tr><tr><td>9.850e-03</td><td>-4.62</td><td>WESTON VEGFA TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>102</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, IGFBP3</td></tr><tr><td>9.871e-03</td><td>-4.62</td><td>Fibronectin matrix formation</td><td>REACTOME pathways</td><td>R-HSA-1566977</td><td>6</td><td>1</td><td>10293</td><td>17</td><td>
CEACAM6</td></tr><tr><td>9.893e-03</td><td>-4.62</td><td>negative regulation of cysteine-type endopeptidase activity</td><td>biological process</td><td>GO:2000117</td><td>96</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>9.940e-03</td><td>-4.61</td><td>Anoct dimer</td><td>pfam domains</td><td>PF16178</td><td>7</td><td>1</td><td>16832</td><td>24</td><td>
ANO1</td></tr><tr><td>1.004e-02</td><td>-4.60</td><td>IZADPANAH STEM CELL ADIPOSE VS BONE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>103</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, GPR87</td></tr><tr><td>1.008e-02</td><td>-4.60</td><td>plasma membrane region</td><td>cellular component</td><td>GO:0098590</td><td>926</td><td>5</td><td>17744</td><td>26</td><td>
DST, CEACAM5, ATP1B1, ANO1, TGFA</td></tr><tr><td>1.009e-02</td><td>-4.60</td><td>regulation of leukocyte chemotaxis</td><td>biological process</td><td>GO:0002688</td><td>97</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.009e-02</td><td>-4.60</td><td>regulation of phosphorus metabolic process</td><td>biological process</td><td>GO:0051174</td><td>1606</td><td>7</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, GPR87, IGFBP3, THBS1</td></tr><tr><td>1.028e-02</td><td>-4.58</td><td>WANG ESOPHAGUS CANCER PROGRESSION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>7</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>1.028e-02</td><td>-4.58</td><td>HE PTEN TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>7</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>1.029e-02</td><td>-4.58</td><td>response to lipopolysaccharide</td><td>biological process</td><td>GO:0032496</td><td>290</td><td>3</td><td>16543</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3</td></tr><tr><td>1.029e-02</td><td>-4.58</td><td>gland morphogenesis</td><td>biological process</td><td>GO:0022612</td><td>98</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, ELF3</td></tr><tr><td>1.031e-02</td><td>-4.57</td><td>regulation of protein metabolic process</td><td>biological process</td><td>GO:0051246</td><td>2473</td><td>9</td><td>16543</td><td>26</td><td>
GPR37, TGFA, MAGEA3, SLPI, TNFRSF11B, RBPMS, PI3, THBS1, IGFBP3</td></tr><tr><td>1.035e-02</td><td>-4.57</td><td>localization of cell</td><td>biological process</td><td>GO:0051674</td><td>869</td><td>5</td><td>16543</td><td>26</td><td>
DST, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>1.035e-02</td><td>-4.57</td><td>cell motility</td><td>biological process</td><td>GO:0048870</td><td>869</td><td>5</td><td>16543</td><td>26</td><td>
DST, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>1.040e-02</td><td>-4.57</td><td>human chr19q13.2</td><td>chromosome location</td><td>human chr19q13.2</td><td>156</td><td>2</td><td>26234</td><td>26</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>1.049e-02</td><td>-4.56</td><td>positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway</td><td>biological process</td><td>GO:0090100</td><td>99</td><td>2</td><td>16543</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>1.055e-02</td><td>-4.55</td><td>PAK1 (p21 (RAC1) activated kinase 1)</td><td>protein interactions</td><td>5058</td><td>102</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, ELF3</td></tr><tr><td>1.060e-02</td><td>-4.55</td><td>GO POSITIVE REGULATION OF LEUKOCYTE MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>106</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>GO RESPONSE TO MOLECULE OF BACTERIAL ORIGIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>313</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>TBX6 (T-box 6)</td><td>protein interactions</td><td>6911</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>EYA2 (EYA transcriptional coactivator and phosphatase 2)</td><td>protein interactions</td><td>2139</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>CRYBA1 (crystallin beta A1)</td><td>protein interactions</td><td>1411</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>TNFRSF11B (TNF receptor superfamily member 11b)</td><td>protein interactions</td><td>4982</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>C22orf39 (chromosome 22 open reading frame 39)</td><td>protein interactions</td><td>128977</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>FASTK (Fas activated serine/threonine kinase)</td><td>protein interactions</td><td>10922</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>CEACAM5 (carcinoembryonic antigen related cell adhesion molecule 5)</td><td>protein interactions</td><td>1048</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM6</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>TUSC2 (tumor suppressor candidate 2)</td><td>protein interactions</td><td>11334</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>EHF (ETS homologous factor)</td><td>protein interactions</td><td>26298</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
ELF3</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>WDR54 (WD repeat domain 54)</td><td>protein interactions</td><td>84058</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>CCER1 (coiled-coil glutamate rich protein 1)</td><td>protein interactions</td><td>196477</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.067e-02</td><td>-4.54</td><td>ZNF385C (zinc finger protein 385C)</td><td>protein interactions</td><td>201181</td><td>7</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.068e-02</td><td>-4.54</td><td>extracellular matrix organization</td><td>biological process</td><td>GO:0030198</td><td>294</td><td>3</td><td>16543</td><td>26</td><td>
TNFRSF11B, THBS1, ELF3</td></tr><tr><td>1.070e-02</td><td>-4.54</td><td>regulation of anion transport</td><td>biological process</td><td>GO:0044070</td><td>100</td><td>2</td><td>16543</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>1.077e-02</td><td>-4.53</td><td>extracellular structure organization</td><td>biological process</td><td>GO:0043062</td><td>295</td><td>3</td><td>16543</td><td>26</td><td>
TNFRSF11B, THBS1, ELF3</td></tr><tr><td>1.080e-02</td><td>-4.53</td><td>LAIHO COLORECTAL CANCER SERRATED UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>107</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, ATP1B1</td></tr><tr><td>1.088e-02</td><td>-4.52</td><td>GPI anchor binding</td><td>molecular function</td><td>GO:0034235</td><td>7</td><td>1</td><td>16652</td><td>26</td><td>
CEACAM5</td></tr><tr><td>1.094e-02</td><td>-4.51</td><td>GO NEGATIVE REGULATION OF PROTEOLYSIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>316</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, PI3, THBS1</td></tr><tr><td>1.095e-02</td><td>-4.51</td><td>negative regulation of fatty acid transport</td><td>biological process</td><td>GO:2000192</td><td>7</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.095e-02</td><td>-4.51</td><td>negative regulation of endoplasmic reticulum calcium ion concentration</td><td>biological process</td><td>GO:0032471</td><td>7</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>1.099e-02</td><td>-4.51</td><td>chrxq28</td><td>MSigDB lists</td><td>&nbsp;</td><td>108</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.116e-02</td><td>-4.50</td><td>ITGB1 (integrin subunit beta 1)</td><td>protein interactions</td><td>3688</td><td>105</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, THBS1</td></tr><tr><td>1.123e-02</td><td>-4.49</td><td>P trefoil CS</td><td>interpro domains</td><td>IPR017957</td><td>8</td><td>1</td><td>18428</td><td>26</td><td>
TFF2</td></tr><tr><td>1.135e-02</td><td>-4.48</td><td>Trefoil</td><td>pfam domains</td><td>PF00088</td><td>8</td><td>1</td><td>16832</td><td>24</td><td>
TFF2</td></tr><tr><td>1.137e-02</td><td>-4.48</td><td>Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol</td><td>KEGG pathways</td><td>M00131</td><td>9</td><td>1</td><td>7094</td><td>9</td><td>
INPP4B</td></tr><tr><td>1.137e-02</td><td>-4.48</td><td>Inositol phosphate metabolism, Ins(1,3,4,5)P4 => Ins(1,3,4)P3 => myo-inositol</td><td>KEGG pathways</td><td>hsa_M00131</td><td>9</td><td>1</td><td>7094</td><td>9</td><td>
INPP4B</td></tr><tr><td>1.138e-02</td><td>-4.48</td><td>GSE25123 ROSIGLITAZONE VS IL4 AND ROSIGLITAZONE STIM MACROPHAGE DAY10 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>110</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.149e-02</td><td>-4.47</td><td>GAR</td><td>prosite domains</td><td>PS51460</td><td>6</td><td>1</td><td>11955</td><td>23</td><td>
DST</td></tr><tr><td>1.158e-02</td><td>-4.46</td><td>HOSHIDA LIVER CANCER SURVIVAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>111</td><td>2</td><td>17621</td><td>26</td><td>
DST, SCG5</td></tr><tr><td>1.158e-02</td><td>-4.46</td><td>CERVERA SDHB TARGETS 1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>111</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.158e-02</td><td>-4.46</td><td>CHARAFE BREAST CANCER BASAL VS MESENCHYMAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>111</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ELF3</td></tr><tr><td>1.158e-02</td><td>-4.46</td><td>GSE32901 TH1 VS TH17 NEG CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>111</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, SLPI</td></tr><tr><td>1.158e-02</td><td>-4.46</td><td>response to molecule of bacterial origin</td><td>biological process</td><td>GO:0002237</td><td>303</td><td>3</td><td>16543</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3</td></tr><tr><td>1.160e-02</td><td>-4.46</td><td>integrin binding</td><td>molecular function</td><td>GO:0005178</td><td>105</td><td>2</td><td>16652</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>1.166e-02</td><td>-4.45</td><td>hemidesmosome</td><td>cellular component</td><td>GO:0030056</td><td>8</td><td>1</td><td>17744</td><td>26</td><td>
DST</td></tr><tr><td>1.175e-02</td><td>-4.44</td><td>NAKAMURA LUNG CANCER</td><td>MSigDB lists</td><td>&nbsp;</td><td>8</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>1.175e-02</td><td>-4.44</td><td>SIMBULAN UV RESPONSE NORMAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>8</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>1.175e-02</td><td>-4.44</td><td>CASTELLANO HRAS AND NRAS TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>8</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>1.178e-02</td><td>-4.44</td><td>MODULE 208</td><td>MSigDB lists</td><td>&nbsp;</td><td>112</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>1.183e-02</td><td>-4.44</td><td>human chr7q31.33</td><td>chromosome location</td><td>human chr7q31.33</td><td>12</td><td>1</td><td>26234</td><td>26</td><td>
GPR37</td></tr><tr><td>1.197e-02</td><td>-4.43</td><td>GAS2</td><td>smart domains</td><td>SM00243</td><td>6</td><td>1</td><td>9480</td><td>19</td><td>
DST</td></tr><tr><td>1.198e-02</td><td>-4.42</td><td>Extracellular matrix organization</td><td>REACTOME pathways</td><td>R-HSA-1474244</td><td>297</td><td>3</td><td>10293</td><td>17</td><td>
DST, CEACAM6, THBS1</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>SEMA4G (semaphorin 4G)</td><td>protein interactions</td><td>57715</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>CTSS (cathepsin S)</td><td>protein interactions</td><td>1520</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
SLPI</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>KLKB1 (kallikrein B1)</td><td>protein interactions</td><td>3818</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>FXYD1 (FXYD domain containing ion transport regulator 1)</td><td>protein interactions</td><td>5348</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>ARHGAP9 (Rho GTPase activating protein 9)</td><td>protein interactions</td><td>64333</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>NEU4 (neuraminidase 4)</td><td>protein interactions</td><td>129807</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>YPEL3 (yippee like 3)</td><td>protein interactions</td><td>83719</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>TULP3 (tubby like protein 3)</td><td>protein interactions</td><td>7289</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>FAM214A (family with sequence similarity 214 member A)</td><td>protein interactions</td><td>56204</td><td>8</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>MODULE 345</td><td>MSigDB lists</td><td>&nbsp;</td><td>114</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>1.218e-02</td><td>-4.41</td><td>KOKKINAKIS METHIONINE DEPRIVATION 96HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>114</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.239e-02</td><td>-4.39</td><td>CHEBOTAEV GR TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>115</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, IGFBP3</td></tr><tr><td>1.239e-02</td><td>-4.39</td><td>phospholipase C-activating G-protein coupled receptor signaling pathway</td><td>biological process</td><td>GO:0007200</td><td>108</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, ANO1</td></tr><tr><td>1.239e-02</td><td>-4.39</td><td>positive regulation of leukocyte migration</td><td>biological process</td><td>GO:0002687</td><td>108</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.243e-02</td><td>-4.39</td><td>protein phosphatase activator activity</td><td>molecular function</td><td>GO:0072542</td><td>8</td><td>1</td><td>16652</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.251e-02</td><td>-4.38</td><td>regulation of dendritic cell antigen processing and presentation</td><td>biological process</td><td>GO:0002604</td><td>8</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.251e-02</td><td>-4.38</td><td>positive regulation of cellular amine metabolic process</td><td>biological process</td><td>GO:0033240</td><td>8</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>1.251e-02</td><td>-4.38</td><td>protein transport within lipid bilayer</td><td>biological process</td><td>GO:0032594</td><td>8</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.252e-02</td><td>-4.38</td><td>Neutrophil count(PMID:21507922)</td><td>GWAS genes</td><td>Neutrophil count(PMID:21507922)</td><td>10</td><td>1</td><td>2388</td><td>3</td><td>
TGFA</td></tr><tr><td>1.263e-02</td><td>-4.37</td><td>Transglutaminase C</td><td>interpro domains</td><td>IPR008958</td><td>9</td><td>1</td><td>18428</td><td>26</td><td>
TGM2</td></tr><tr><td>1.263e-02</td><td>-4.37</td><td>Transglutaminase N</td><td>interpro domains</td><td>IPR001102</td><td>9</td><td>1</td><td>18428</td><td>26</td><td>
TGM2</td></tr><tr><td>1.263e-02</td><td>-4.37</td><td>Gln gamma-glutamylTfrase euk</td><td>interpro domains</td><td>IPR023608</td><td>9</td><td>1</td><td>18428</td><td>26</td><td>
TGM2</td></tr><tr><td>1.263e-02</td><td>-4.37</td><td>Transglutaminase AS</td><td>interpro domains</td><td>IPR013808</td><td>9</td><td>1</td><td>18428</td><td>26</td><td>
TGM2</td></tr><tr><td>1.276e-02</td><td>-4.36</td><td>Transglut C</td><td>pfam domains</td><td>PF00927</td><td>9</td><td>1</td><td>16832</td><td>24</td><td>
TGM2</td></tr><tr><td>1.276e-02</td><td>-4.36</td><td>Transglut N</td><td>pfam domains</td><td>PF00868</td><td>9</td><td>1</td><td>16832</td><td>24</td><td>
TGM2</td></tr><tr><td>1.282e-02</td><td>-4.36</td><td>regulation of protein phosphorylation</td><td>biological process</td><td>GO:0001932</td><td>1282</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>1.295e-02</td><td>-4.35</td><td>Senescence and Autophagy in Cancer</td><td>WikiPathways</td><td>WP615</td><td>106</td><td>2</td><td>5314</td><td>9</td><td>
IGFBP3, THBS1</td></tr><tr><td>1.301e-02</td><td>-4.34</td><td>GO LOCALIZATION WITHIN MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>118</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, TGFA</td></tr><tr><td>1.301e-02</td><td>-4.34</td><td>GO POSITIVE REGULATION OF CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>118</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.311e-02</td><td>-4.33</td><td>fibrinogen complex</td><td>cellular component</td><td>GO:0005577</td><td>9</td><td>1</td><td>17744</td><td>26</td><td>
THBS1</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>MATZUK CUMULUS EXPANSION</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>KOMMAGANI TP63 GAMMA TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>YIH RESPONSE TO ARSENITE C5</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>OXFORD RALA TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>NOUSHMEHR GBM SOMATIC MUTATED</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>FUNG IL2 TARGETS WITH STAT5 BINDING SITES T1</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>AGARWAL AKT PATHWAY TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>1.320e-02</td><td>-4.33</td><td>OXFORD RALA AND RALB TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>9</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.322e-02</td><td>-4.33</td><td>TAKEDA TARGETS OF NUP98 HOXA9 FUSION 16D DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>119</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6</td></tr><tr><td>1.322e-02</td><td>-4.33</td><td>RB DN.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>119</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, IGFBP3</td></tr><tr><td>1.324e-02</td><td>-4.32</td><td>cell adhesion</td><td>biological process</td><td>GO:0007155</td><td>1291</td><td>6</td><td>16543</td><td>26</td><td>
DST, CEACAM5, TNFAIP6, ATP1B1, PCDH1, THBS1</td></tr><tr><td>1.329e-02</td><td>-4.32</td><td>proteinaceous extracellular matrix</td><td>cellular component</td><td>GO:0005578</td><td>342</td><td>3</td><td>17744</td><td>26</td><td>
DST, TNFRSF11B, PI3</td></tr><tr><td>1.336e-02</td><td>-4.32</td><td>regulation of intracellular signal transduction</td><td>biological process</td><td>GO:1902531</td><td>1694</td><td>7</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, TGM2, TGFA, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>1.343e-02</td><td>-4.31</td><td>biological adhesion</td><td>biological process</td><td>GO:0022610</td><td>1295</td><td>6</td><td>16543</td><td>26</td><td>
DST, CEACAM5, TNFAIP6, ATP1B1, PCDH1, THBS1</td></tr><tr><td>1.360e-02</td><td>-4.30</td><td>positive regulation of cellular process</td><td>biological process</td><td>GO:0048522</td><td>4608</td><td>13</td><td>16543</td><td>26</td><td>
GPR37, CEACAM6, TNFAIP6, CXCL3, TGFA, TNFRSF11B, ATP1B1, TGM2, RBPMS, ANO1, IGFBP3, ELF3, THBS1</td></tr><tr><td>1.364e-02</td><td>-4.29</td><td>GO PROTEINACEOUS EXTRACELLULAR MATRIX</td><td>MSigDB lists</td><td>&nbsp;</td><td>343</td><td>3</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, PI3</td></tr><tr><td>1.366e-02</td><td>-4.29</td><td>-</td><td>gene3d domains</td><td>3.90.260.10</td><td>9</td><td>1</td><td>10485</td><td>16</td><td>
TGM2</td></tr><tr><td>1.370e-02</td><td>-4.29</td><td>AMMECR1 (Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1)</td><td>protein interactions</td><td>9949</td><td>9</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.370e-02</td><td>-4.29</td><td>NDRG2 (NDRG family member 2)</td><td>protein interactions</td><td>57447</td><td>9</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>1.370e-02</td><td>-4.29</td><td>C11orf87 (chromosome 11 open reading frame 87)</td><td>protein interactions</td><td>399947</td><td>9</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.370e-02</td><td>-4.29</td><td>CSN3 (casein kappa)</td><td>protein interactions</td><td>1448</td><td>9</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.375e-02</td><td>-4.29</td><td>Growth fac rcpt </td><td>interpro domains</td><td>IPR009030</td><td>127</td><td>2</td><td>18428</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.386e-02</td><td>-4.28</td><td>GSE13762 CTRL VS 125 VITAMIND DAY12 DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>122</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.395e-02</td><td>-4.27</td><td>PLEC</td><td>smart domains</td><td>SM00250</td><td>7</td><td>1</td><td>9480</td><td>19</td><td>
DST</td></tr><tr><td>1.397e-02</td><td>-4.27</td><td>CHEMNITZ RESPONSE TO PROSTAGLANDIN E2 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>346</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, KRT7, ELF3</td></tr><tr><td>1.397e-02</td><td>-4.27</td><td>phosphatidylinositol phosphate 4-phosphatase activity</td><td>molecular function</td><td>GO:0034596</td><td>9</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>1.397e-02</td><td>-4.27</td><td>protein-glutamine gamma-glutamyltransferase activity</td><td>molecular function</td><td>GO:0003810</td><td>9</td><td>1</td><td>16652</td><td>26</td><td>
TGM2</td></tr><tr><td>1.402e-02</td><td>-4.27</td><td>Anoctamin</td><td>interpro domains</td><td>IPR007632</td><td>10</td><td>1</td><td>18428</td><td>26</td><td>
ANO1</td></tr><tr><td>1.406e-02</td><td>-4.26</td><td>negative regulation of anion transmembrane transport</td><td>biological process</td><td>GO:1903960</td><td>9</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.406e-02</td><td>-4.26</td><td>protein localization to membrane raft</td><td>biological process</td><td>GO:1903044</td><td>9</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.406e-02</td><td>-4.26</td><td>regulation of transforming growth factor beta1 production</td><td>biological process</td><td>GO:0032908</td><td>9</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.406e-02</td><td>-4.26</td><td>type B pancreatic cell proliferation</td><td>biological process</td><td>GO:0044342</td><td>9</td><td>1</td><td>16543</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.406e-02</td><td>-4.26</td><td>potassium ion import across plasma membrane</td><td>biological process</td><td>GO:1990573</td><td>9</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.408e-02</td><td>-4.26</td><td>GSE40274 CTRL VS GATA1 TRANSDUCED ACTIVATED CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>123</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.417e-02</td><td>-4.26</td><td>Anoctamin</td><td>pfam domains</td><td>PF04547</td><td>10</td><td>1</td><td>16832</td><td>24</td><td>
ANO1</td></tr><tr><td>1.430e-02</td><td>-4.25</td><td>MODULE 292</td><td>MSigDB lists</td><td>&nbsp;</td><td>124</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>1.430e-02</td><td>-4.25</td><td>VECCHI GASTRIC CANCER ADVANCED VS EARLY DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>124</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TFF2</td></tr><tr><td>1.430e-02</td><td>-4.25</td><td>RB P107 DN.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>124</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, KRT7</td></tr><tr><td>1.430e-02</td><td>-4.25</td><td>REACTOME DIABETES PATHWAYS</td><td>MSigDB lists</td><td>&nbsp;</td><td>124</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>1.430e-02</td><td>-4.25</td><td>SMID BREAST CANCER BASAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>649</td><td>4</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5, ANO1, INPP4B</td></tr><tr><td>1.448e-02</td><td>-4.23</td><td>GO RECEPTOR BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>1402</td><td>6</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, IGFBP6, CXCL3, TGFA, THBS1</td></tr><tr><td>1.452e-02</td><td>-4.23</td><td>ZHU CMV ALL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>125</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>1.452e-02</td><td>-4.23</td><td>MODULE 436</td><td>MSigDB lists</td><td>&nbsp;</td><td>125</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>1.462e-02</td><td>-4.23</td><td>YOSHIMURA MAPK8 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>352</td><td>3</td><td>17621</td><td>26</td><td>
TFF2, IGFBP6, TGFA</td></tr><tr><td>1.466e-02</td><td>-4.22</td><td>GO POSITIVE REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>10</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>1.466e-02</td><td>-4.22</td><td>KRISHNAN FURIN TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>10</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>1.466e-02</td><td>-4.22</td><td>GO POSITIVE REGULATION OF FIBROBLAST MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>10</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.466e-02</td><td>-4.22</td><td>GO PHOSPHATASE ACTIVATOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>10</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.466e-02</td><td>-4.22</td><td>HINATA NFKB MATRIX</td><td>MSigDB lists</td><td>&nbsp;</td><td>10</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>1.466e-02</td><td>-4.22</td><td>positive regulation of chemotaxis</td><td>biological process</td><td>GO:0050921</td><td>118</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.473e-02</td><td>-4.22</td><td>GO ENZYME INHIBITOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>353</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, SCG5, PI3</td></tr><tr><td>1.474e-02</td><td>-4.22</td><td>MODULE 171</td><td>MSigDB lists</td><td>&nbsp;</td><td>126</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>1.474e-02</td><td>-4.22</td><td>GAL LEUKEMIC STEM CELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>126</td><td>2</td><td>17621</td><td>26</td><td>
DST, RBPMS</td></tr><tr><td>1.477e-02</td><td>-4.22</td><td>human chr8q24.12</td><td>chromosome location</td><td>human chr8q24.12</td><td>15</td><td>1</td><td>26234</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.496e-02</td><td>-4.20</td><td>KIM RESPONSE TO TSA AND DECITABINE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>127</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>1.496e-02</td><td>-4.20</td><td>GSE6259 33D1 POS DC VS CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>127</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, TFF2</td></tr><tr><td>1.508e-02</td><td>-4.19</td><td>CALR (calreticulin)</td><td>protein interactions</td><td>811</td><td>123</td><td>2</td><td>16330</td><td>25</td><td>
ELF3, THBS1</td></tr><tr><td>1.518e-02</td><td>-4.19</td><td>GSE12963 UNINF VS ENV AND NEF AND VPR DEFICIENT HIV1 INF CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>128</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>FRG1 (FSHD region gene 1)</td><td>protein interactions</td><td>2483</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>INIP (INTS3 and NABP interacting protein)</td><td>protein interactions</td><td>58493</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>ZNF488 (zinc finger protein 488)</td><td>protein interactions</td><td>118738</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>IP6K2 (inositol hexakisphosphate kinase 2)</td><td>protein interactions</td><td>51447</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>POTEKP (POTE ankyrin domain family member K, pseudogene)</td><td>protein interactions</td><td>440915</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>LOR (loricrin)</td><td>protein interactions</td><td>4014</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
PI3</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>TTLL10 (tubulin tyrosine ligase like 10)</td><td>protein interactions</td><td>254173</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.521e-02</td><td>-4.19</td><td>CASP12 (caspase 12 (gene/pseudogene))</td><td>protein interactions</td><td>100506742</td><td>10</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA3</td></tr><tr><td>1.529e-02</td><td>-4.18</td><td>P TREFOIL 1</td><td>prosite domains</td><td>PS00025</td><td>8</td><td>1</td><td>11955</td><td>23</td><td>
TFF2</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>cellular response to cytokine stimulus</td><td>biological process</td><td>GO:0071345</td><td>623</td><td>4</td><td>16543</td><td>26</td><td>
TNFRSF11B, TFF2, CXCL3, THBS1</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>POOLA INVASIVE BREAST CANCER DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>129</td><td>2</td><td>17621</td><td>26</td><td>
DST, INPP4B</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>COULOUARN TEMPORAL TGFB1 SIGNATURE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>129</td><td>2</td><td>17621</td><td>26</td><td>
PCDH1, IGFBP3</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>GSE40274 CTRL VS FOXP3 AND GATA1 TRANSDUCED ACTIVATED CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>129</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>Transglutaminase-like</td><td>interpro domains</td><td>IPR002931</td><td>11</td><td>1</td><td>18428</td><td>26</td><td>
TGM2</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>P trefoil dom</td><td>interpro domains</td><td>IPR000519</td><td>11</td><td>1</td><td>18428</td><td>26</td><td>
TFF2</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>Insulin GF-bd Cys-rich CS</td><td>interpro domains</td><td>IPR017891</td><td>11</td><td>1</td><td>18428</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.541e-02</td><td>-4.17</td><td>Pointed dom</td><td>interpro domains</td><td>IPR003118</td><td>11</td><td>1</td><td>18428</td><td>26</td><td>
ELF3</td></tr><tr><td>1.550e-02</td><td>-4.17</td><td>biological regulation</td><td>biological process</td><td>GO:0065007</td><td>11242</td><td>23</td><td>16543</td><td>26</td><td>
CEACAM6, TNFAIP6, IGFBP6, CXCL3, TGFA, SLPI, ATP1B1, TFF2, ANO1, PI3, THBS1, ELF3, DST, GPR37, SCG5, GPR87, MAGEA3, INPP4B, TNFRSF11B, CEACAM5, TGM2, RBPMS, IGFBP3</td></tr><tr><td>1.551e-02</td><td>-4.17</td><td>sodium:potassium-exchanging ATPase activity</td><td>molecular function</td><td>GO:0005391</td><td>10</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.558e-02</td><td>-4.16</td><td>SAM PNT</td><td>pfam domains</td><td>PF02198</td><td>11</td><td>1</td><td>16832</td><td>24</td><td>
ELF3</td></tr><tr><td>1.558e-02</td><td>-4.16</td><td>Transglut core</td><td>pfam domains</td><td>PF01841</td><td>11</td><td>1</td><td>16832</td><td>24</td><td>
TGM2</td></tr><tr><td>1.561e-02</td><td>-4.16</td><td>negative regulation of response to stimulus</td><td>biological process</td><td>GO:0048585</td><td>1338</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFAIP6, IGFBP6, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>1.561e-02</td><td>-4.16</td><td>sodium ion export from cell</td><td>biological process</td><td>GO:0036376</td><td>10</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.561e-02</td><td>-4.16</td><td>regulation of plasminogen activation</td><td>biological process</td><td>GO:0010755</td><td>10</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.561e-02</td><td>-4.16</td><td>dopamine biosynthetic process</td><td>biological process</td><td>GO:0042416</td><td>10</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>1.561e-02</td><td>-4.16</td><td>positive regulation of mitochondrial calcium ion concentration</td><td>biological process</td><td>GO:0051561</td><td>10</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>1.561e-02</td><td>-4.16</td><td>negative regulation of fibrinolysis</td><td>biological process</td><td>GO:0051918</td><td>10</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.564e-02</td><td>-4.16</td><td>KRAS.AMP.LUNG UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>130</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>1.564e-02</td><td>-4.16</td><td>ALK DN.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>130</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, IGFBP6</td></tr><tr><td>1.574e-02</td><td>-4.15</td><td>human chr7p12.3</td><td>chromosome location</td><td>human chr7p12.3</td><td>16</td><td>1</td><td>26234</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.578e-02</td><td>-4.15</td><td>negative regulation of cellular protein metabolic process</td><td>biological process</td><td>GO:0032269</td><td>965</td><td>5</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>1.580e-02</td><td>-4.15</td><td>GO REGULATION OF CELL DEATH</td><td>MSigDB lists</td><td>&nbsp;</td><td>1429</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, CEACAM5, TGM2, IGFBP3, THBS1</td></tr><tr><td>1.582e-02</td><td>-4.15</td><td>enzyme regulator activity</td><td>molecular function</td><td>GO:0030234</td><td>972</td><td>5</td><td>16652</td><td>26</td><td>
SLPI, ATP1B1, SCG5, PI3, IGFBP3</td></tr><tr><td>1.586e-02</td><td>-4.14</td><td>LIU SOX4 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>131</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>1.586e-02</td><td>-4.14</td><td>DARWICHE SKIN TUMOR PROMOTER UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>131</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGFA</td></tr><tr><td>1.586e-02</td><td>-4.14</td><td>XU GH1 AUTOCRINE TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>131</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>1.586e-02</td><td>-4.14</td><td>NIKOLSKY BREAST CANCER 20Q12 Q13 AMPLICON</td><td>MSigDB lists</td><td>&nbsp;</td><td>131</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>1.590e-02</td><td>-4.14</td><td>GO POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>1431</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>1.601e-02</td><td>-4.13</td><td>sodium:potassium-exchanging ATPase complex</td><td>cellular component</td><td>GO:0005890</td><td>11</td><td>1</td><td>17744</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>DORN ADENOVIRUS INFECTION 32HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO INOSITOL TRISPHOSPHATE PHOSPHATASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO REGULATION OF ODONTOGENESIS OF DENTIN CONTAINING TOOTH</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO PROTEIN O LINKED FUCOSYLATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO MAINTENANCE OF CELL POLARITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO POSITIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO SODIUM POTASSIUM EXCHANGING ATPASE COMPLEX</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO POTASSIUM TRANSPORTING ATPASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO POSITIVE REGULATION OF MACROPHAGE CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO NEGATIVE REGULATION OF BONE RESORPTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>HOFFMAN CLOCK TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.612e-02</td><td>-4.13</td><td>GO MITOCHONDRIAL CALCIUM ION HOMEOSTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>11</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>1.616e-02</td><td>-4.13</td><td>GO NEGATIVE REGULATION OF MOLECULAR FUNCTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>1034</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, SCG5, GPR87, PI3, THBS1</td></tr><tr><td>1.632e-02</td><td>-4.12</td><td>SERVITJA LIVER HNF1A TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>133</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, THBS1</td></tr><tr><td>1.632e-02</td><td>-4.12</td><td>KRAS.PROSTATE UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>133</td><td>2</td><td>17621</td><td>26</td><td>
PI3, IGFBP3</td></tr><tr><td>1.632e-02</td><td>-4.12</td><td>GSE7509 FCGRIIB VS TNFA IL1B IL6 PGE STIM DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>133</td><td>2</td><td>17621</td><td>26</td><td>
DST, TGFA</td></tr><tr><td>1.632e-02</td><td>-4.12</td><td>DARWICHE SQUAMOUS CELL CARCINOMA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>133</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGFA</td></tr><tr><td>1.642e-02</td><td>-4.11</td><td>GO REGULATION OF CELL PROLIFERATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>1441</td><td>6</td><td>17621</td><td>26</td><td>
TNFRSF11B, IGFBP6, CXCL3, TGFA, IGFBP3, THBS1</td></tr><tr><td>1.656e-02</td><td>-4.10</td><td>PID P53 DOWNSTREAM PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, IGFBP3</td></tr><tr><td>1.656e-02</td><td>-4.10</td><td>GO ACTIVATION OF MAPK ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>1.656e-02</td><td>-4.10</td><td>VART KSHV INFECTION ANGIOGENIC MARKERS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>1.656e-02</td><td>-4.10</td><td>GO REGULATION OF ANION TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>1.656e-02</td><td>-4.10</td><td>SMID BREAST CANCER ERBB2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>134</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6</td></tr><tr><td>1.657e-02</td><td>-4.10</td><td>CHYLA CBFA2T3 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>369</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, KRT7, RBPMS</td></tr><tr><td>1.667e-02</td><td>-4.09</td><td>-</td><td>gene3d domains</td><td>4.10.110.10</td><td>11</td><td>1</td><td>10485</td><td>16</td><td>
TFF2</td></tr><tr><td>1.669e-02</td><td>-4.09</td><td>ZHOU INFLAMMATORY RESPONSE LPS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>370</td><td>3</td><td>17621</td><td>26</td><td>
CXCL3, ELF3, IGFBP3</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>KRTAP19-5 (keratin associated protein 19-5)</td><td>protein interactions</td><td>337972</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>TIE1 (tyrosine kinase with immunoglobulin like and EGF like domains 1)</td><td>protein interactions</td><td>7075</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>SBF2 (SET binding factor 2)</td><td>protein interactions</td><td>81846</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>KRT82 (keratin 82)</td><td>protein interactions</td><td>3888</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
ELF3</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>VENTX (VENT homeobox)</td><td>protein interactions</td><td>27287</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>C9orf24 (chromosome 9 open reading frame 24)</td><td>protein interactions</td><td>84688</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>CALCR (calcitonin receptor)</td><td>protein interactions</td><td>799</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>ZC3H10 (zinc finger CCCH-type containing 10)</td><td>protein interactions</td><td>84872</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.672e-02</td><td>-4.09</td><td>SPATA46 (spermatogenesis associated 46)</td><td>protein interactions</td><td>284680</td><td>11</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.679e-02</td><td>-4.09</td><td>BMI1 DN.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>135</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TFF2</td></tr><tr><td>1.703e-02</td><td>-4.07</td><td>KRAS.KIDNEY UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>136</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, SCG5</td></tr><tr><td>1.705e-02</td><td>-4.07</td><td>inositol trisphosphate phosphatase activity</td><td>molecular function</td><td>GO:0046030</td><td>11</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>1.705e-02</td><td>-4.07</td><td>microtubule plus-end binding</td><td>molecular function</td><td>GO:0051010</td><td>11</td><td>1</td><td>16652</td><td>26</td><td>
DST</td></tr><tr><td>1.705e-02</td><td>-4.07</td><td>phosphatase activator activity</td><td>molecular function</td><td>GO:0019211</td><td>11</td><td>1</td><td>16652</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.705e-02</td><td>-4.07</td><td>potassium-transporting ATPase activity</td><td>molecular function</td><td>GO:0008556</td><td>11</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.716e-02</td><td>-4.07</td><td>positive regulation of macrophage chemotaxis</td><td>biological process</td><td>GO:0010759</td><td>11</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.716e-02</td><td>-4.07</td><td>chronic inflammatory response</td><td>biological process</td><td>GO:0002544</td><td>11</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.716e-02</td><td>-4.07</td><td>positive regulation of tumor necrosis factor biosynthetic process</td><td>biological process</td><td>GO:0042535</td><td>11</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.716e-02</td><td>-4.07</td><td>positive regulation of epidermal growth factor-activated receptor activity</td><td>biological process</td><td>GO:0045741</td><td>11</td><td>1</td><td>16543</td><td>26</td><td>
TGFA</td></tr><tr><td>1.718e-02</td><td>-4.06</td><td>GO REGULATION OF PEPTIDASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>374</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, PI3, THBS1</td></tr><tr><td>1.719e-02</td><td>-4.06</td><td>TRANSGLUTAMINASES</td><td>prosite domains</td><td>PS00547</td><td>9</td><td>1</td><td>11955</td><td>23</td><td>
TGM2</td></tr><tr><td>1.719e-02</td><td>-4.06</td><td>P TREFOIL 2</td><td>prosite domains</td><td>PS51448</td><td>9</td><td>1</td><td>11955</td><td>23</td><td>
TFF2</td></tr><tr><td>1.726e-02</td><td>-4.06</td><td>DARWICHE PAPILLOMA RISK HIGH UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>137</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGFA</td></tr><tr><td>1.726e-02</td><td>-4.06</td><td>GOZGIT ESR1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>137</td><td>2</td><td>17621</td><td>26</td><td>
DST, IGFBP3</td></tr><tr><td>1.730e-02</td><td>-4.06</td><td>ODONNELL TFRC TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>375</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, INPP4B, THBS1</td></tr><tr><td>1.750e-02</td><td>-4.05</td><td>regulation of apoptotic process</td><td>biological process</td><td>GO:0042981</td><td>1372</td><td>6</td><td>16543</td><td>26</td><td>
TNFRSF11B, CEACAM5, TGM2, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>1.750e-02</td><td>-4.05</td><td>GSE10500 ARTHRITIC SYNOVIAL FLUID VS HEALTHY MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>138</td><td>2</td><td>17621</td><td>26</td><td>
DST, SCG5</td></tr><tr><td>1.750e-02</td><td>-4.05</td><td>GSE12963 ENV NEF VS ENV NEF AND VPR DEFICIENT HIV1 INF CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>138</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, RBPMS</td></tr><tr><td>1.750e-02</td><td>-4.05</td><td>ATM DN.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>138</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, CXCL3</td></tr><tr><td>1.754e-02</td><td>-4.04</td><td>HAN SATB1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>377</td><td>3</td><td>17621</td><td>26</td><td>
DST, SCG5, PI3</td></tr><tr><td>1.755e-02</td><td>-4.04</td><td>regulation of phosphorylation</td><td>biological process</td><td>GO:0042325</td><td>1373</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO HEMIDESMOSOME ASSEMBLY</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO CELLULAR POTASSIUM ION HOMEOSTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO POSITIVE REGULATION OF MACROPHAGE ACTIVATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>WU ALZHEIMER DISEASE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO DETECTION OF TEMPERATURE STIMULUS INVOLVED IN SENSORY PERCEPTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>JI CARCINOGENESIS BY KRAS AND STK11 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO VOLTAGE GATED CHLORIDE CHANNEL ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>MIZUKAMI HYPOXIA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>DORN ADENOVIRUS INFECTION 24HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>ITO PTTG1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO POLY A BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>PARK OSTEOBLAST DIFFERENTIATION BY PHENYLAMIL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO POSITIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>REACTOME SYNTHESIS OF PIPS AT THE EARLY ENDOSOME MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>LIU TOPBP1 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO DETECTION OF TEMPERATURE STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>GO SODIUM ION EXPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>RAY ALZHEIMERS DISEASE</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>FUNG IL2 SIGNALING 2</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.757e-02</td><td>-4.04</td><td>BIOCARTA PARKIN PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>12</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>1.764e-02</td><td>-4.04</td><td>Hemostasis</td><td>REACTOME pathways</td><td>R-HSA-109582</td><td>632</td><td>4</td><td>10293</td><td>17</td><td>
CEACAM6, CEACAM5, ATP1B1, THBS1</td></tr><tr><td>1.769e-02</td><td>-4.03</td><td>regulation of signal transduction</td><td>biological process</td><td>GO:0009966</td><td>2693</td><td>9</td><td>16543</td><td>26</td><td>
GPR37, IGFBP6, TGFA, MAGEA3, TNFRSF11B, TGM2, RBPMS, THBS1, IGFBP3</td></tr><tr><td>1.770e-02</td><td>-4.03</td><td>human chr2q23.3</td><td>chromosome location</td><td>human chr2q23.3</td><td>18</td><td>1</td><td>26234</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>1.772e-02</td><td>-4.03</td><td>KRIEG HYPOXIA NOT VIA KDM3A</td><td>MSigDB lists</td><td>&nbsp;</td><td>692</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, ATP1B1, TGFA, IGFBP3</td></tr><tr><td>1.790e-02</td><td>-4.02</td><td>PD</td><td>smart domains</td><td>SM00018</td><td>9</td><td>1</td><td>9480</td><td>19</td><td>
TFF2</td></tr><tr><td>1.791e-02</td><td>-4.02</td><td>GO NEGATIVE REGULATION OF HYDROLASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>380</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, PI3, THBS1</td></tr><tr><td>1.797e-02</td><td>-4.02</td><td>V-set</td><td>pfam domains</td><td>PF07686</td><td>145</td><td>2</td><td>16832</td><td>24</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>1.797e-02</td><td>-4.02</td><td>SGTA (small glutamine rich tetratricopeptide repeat containing alpha)</td><td>protein interactions</td><td>6449</td><td>135</td><td>2</td><td>16330</td><td>25</td><td>
SLPI, TGFA</td></tr><tr><td>1.798e-02</td><td>-4.02</td><td>LEE BMP2 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>695</td><td>4</td><td>17621</td><td>26</td><td>
ATP1B1, RBPMS, KRT7, IGFBP6</td></tr><tr><td>1.803e-02</td><td>-4.02</td><td>Type I hemidesmosome assembly</td><td>REACTOME pathways</td><td>R-HSA-446107</td><td>11</td><td>1</td><td>10293</td><td>17</td><td>
DST</td></tr><tr><td>1.803e-02</td><td>-4.02</td><td>Synthesis of IP2, IP, and Ins in the cytosol</td><td>REACTOME pathways</td><td>R-HSA-1855183</td><td>11</td><td>1</td><td>10293</td><td>17</td><td>
INPP4B</td></tr><tr><td>1.804e-02</td><td>-4.02</td><td>MODULE 3</td><td>MSigDB lists</td><td>&nbsp;</td><td>381</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, KRT7, THBS1</td></tr><tr><td>1.814e-02</td><td>-4.01</td><td>regulation of programmed cell death</td><td>biological process</td><td>GO:0043067</td><td>1383</td><td>6</td><td>16543</td><td>26</td><td>
TNFRSF11B, CEACAM5, TGM2, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>1.819e-02</td><td>-4.01</td><td>Chemokine CXC</td><td>interpro domains</td><td>IPR001089</td><td>13</td><td>1</td><td>18428</td><td>26</td><td>
CXCL3</td></tr><tr><td>1.819e-02</td><td>-4.01</td><td>Chemokine CXC CS</td><td>interpro domains</td><td>IPR018048</td><td>13</td><td>1</td><td>18428</td><td>26</td><td>
CXCL3</td></tr><tr><td>1.822e-02</td><td>-4.01</td><td>GO RESPONSE TO TEMPERATURE STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>141</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>1.822e-02</td><td>-4.01</td><td>ADAM12 (ADAM metallopeptidase domain 12)</td><td>protein interactions</td><td>8038</td><td>12</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>1.829e-02</td><td>-4.00</td><td>VECCHI GASTRIC CANCER EARLY UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>383</td><td>3</td><td>17621</td><td>26</td><td>
KRT7, CXCL3, PI3</td></tr><tr><td>1.847e-02</td><td>-3.99</td><td>HALLMARK UV RESPONSE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>142</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, INPP4B</td></tr><tr><td>1.847e-02</td><td>-3.99</td><td>GSE40274 FOXP3 VS FOXP3 AND XBP1 TRANSDUCED ACTIVATED CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>142</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, KRT7</td></tr><tr><td>1.847e-02</td><td>-3.99</td><td>GSE7568 CTRL VS 3H TGFB TREATED MACROPHAGES WITH IL4 AND DEXAMETHASONE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>142</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, GPR87</td></tr><tr><td>1.858e-02</td><td>-3.99</td><td>poly(A) binding</td><td>molecular function</td><td>GO:0008143</td><td>12</td><td>1</td><td>16652</td><td>26</td><td>
RBPMS</td></tr><tr><td>1.858e-02</td><td>-3.99</td><td>voltage-gated chloride channel activity</td><td>molecular function</td><td>GO:0005247</td><td>12</td><td>1</td><td>16652</td><td>26</td><td>
ANO1</td></tr><tr><td>1.858e-02</td><td>-3.99</td><td>sodium ion binding</td><td>molecular function</td><td>GO:0031402</td><td>12</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>positive regulation of macrophage migration</td><td>biological process</td><td>GO:1905523</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>protein O-linked fucosylation</td><td>biological process</td><td>GO:0036066</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>positive regulation of fibroblast migration</td><td>biological process</td><td>GO:0010763</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>negative regulation of bone resorption</td><td>biological process</td><td>GO:0045779</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>cellular potassium ion homeostasis</td><td>biological process</td><td>GO:0030007</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>sodium ion export</td><td>biological process</td><td>GO:0071436</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>negative regulation of fibroblast growth factor receptor signaling pathway</td><td>biological process</td><td>GO:0040037</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>1.870e-02</td><td>-3.98</td><td>positive regulation of SMAD protein import into nucleus</td><td>biological process</td><td>GO:0060391</td><td>12</td><td>1</td><td>16543</td><td>26</td><td>
RBPMS</td></tr><tr><td>1.871e-02</td><td>-3.98</td><td>GO CELL CYCLE ARREST</td><td>MSigDB lists</td><td>&nbsp;</td><td>143</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>1.883e-02</td><td>-3.97</td><td>cellular response to stimulus</td><td>biological process</td><td>GO:0051716</td><td>5931</td><td>15</td><td>16543</td><td>26</td><td>
DST, GPR37, CEACAM6, TNFAIP6, IGFBP6, SCG5, CXCL3, GPR87, INPP4B, TNFRSF11B, ATP1B1, TFF2, TGM2, ANO1, THBS1</td></tr><tr><td>1.896e-02</td><td>-3.97</td><td>GO REGULATION OF LEUKOCYTE MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>144</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>1.896e-02</td><td>-3.97</td><td>SARRIO EPITHELIAL MESENCHYMAL TRANSITION DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>144</td><td>2</td><td>17621</td><td>26</td><td>
DST, CXCL3</td></tr><tr><td>1.896e-02</td><td>-3.97</td><td>P53 DN.V2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>144</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, PCDH1</td></tr><tr><td>1.896e-02</td><td>-3.97</td><td>GO ANCHORED COMPONENT OF MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>144</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO BEHAVIORAL RESPONSE TO PAIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>AMIT EGF RESPONSE 20 MCF10A</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>LY AGING MIDDLE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>MATZUK EARLY ANTRAL FOLLICLE</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>XU HGF TARGETS INDUCED BY AKT1 48HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>VERRECCHIA RESPONSE TO TGFB1 C4</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO POSITIVE REGULATION OF CELLULAR AMINE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO MEMBRANE REPOLARIZATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO ESTABLISHMENT OR MAINTENANCE OF TRANSMEMBRANE ELECTROCHEMICAL GRADIENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO RELAXATION OF CARDIAC MUSCLE</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO NEGATIVE REGULATION OF BONE REMODELING</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>1.902e-02</td><td>-3.96</td><td>GO POSITIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>13</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>1.905e-02</td><td>-3.96</td><td>RUTELLA RESPONSE TO HGF VS CSF2RB AND IL4 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>389</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2, CXCL3</td></tr><tr><td>1.935e-02</td><td>-3.95</td><td>Direct p53 effectors</td><td>Pathway Interaction DB</td><td>p53downstreampathway</td><td>132</td><td>2</td><td>2226</td><td>4</td><td>
TGFA, IGFBP3</td></tr><tr><td>1.946e-02</td><td>-3.94</td><td>FOSTER TOLERANT MACROPHAGE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>146</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>1.956e-02</td><td>-3.93</td><td>RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>713</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, RBPMS, KRT7, THBS1</td></tr><tr><td>1.958e-02</td><td>-3.93</td><td>CXC Chemokine domain</td><td>interpro domains</td><td>IPR033899</td><td>14</td><td>1</td><td>18428</td><td>26</td><td>
CXCL3</td></tr><tr><td>1.958e-02</td><td>-3.93</td><td>Link dom</td><td>interpro domains</td><td>IPR000538</td><td>14</td><td>1</td><td>18428</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>1.960e-02</td><td>-3.93</td><td>positive regulation of cellular protein metabolic process</td><td>biological process</td><td>GO:0032270</td><td>1407</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>1.965e-02</td><td>-3.93</td><td>TP53 Regulates Transcription of Death Receptors and Ligands</td><td>REACTOME pathways</td><td>R-HSA-6803211</td><td>12</td><td>1</td><td>10293</td><td>17</td><td>
IGFBP3</td></tr><tr><td>1.971e-02</td><td>-3.93</td><td>GSE4590 SMALL VS LARGE PRE BCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>147</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, ELF3</td></tr><tr><td>1.971e-02</td><td>-3.93</td><td>negative regulation of protein metabolic process</td><td>biological process</td><td>GO:0051248</td><td>1021</td><td>5</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, IGFBP3, THBS1</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>CYBA (cytochrome b-245 alpha chain)</td><td>protein interactions</td><td>1535</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>TNFSF13 (tumor necrosis factor superfamily member 13)</td><td>protein interactions</td><td>8741</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
TNFRSF11B</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>DHFR (dihydrofolate reductase)</td><td>protein interactions</td><td>1719</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>KIAA1549 (KIAA1549)</td><td>protein interactions</td><td>57670</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>Tubb5 (tubulin, beta 5 class I)</td><td>protein interactions</td><td>22154</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>R3HDM2 (R3H domain containing 2)</td><td>protein interactions</td><td>22864</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>DCTN5 (dynactin subunit 5)</td><td>protein interactions</td><td>84516</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>PLCD1 (phospholipase C delta 1)</td><td>protein interactions</td><td>5333</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>RUSC1 (RUN and SH3 domain containing 1)</td><td>protein interactions</td><td>23623</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>HLA-DRB5 (major histocompatibility complex, class II, DR beta 5)</td><td>protein interactions</td><td>3127</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>1.973e-02</td><td>-3.93</td><td>BOLL (boule homolog, RNA binding protein)</td><td>protein interactions</td><td>66037</td><td>13</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>1.979e-02</td><td>-3.92</td><td>Xlink</td><td>pfam domains</td><td>PF00193</td><td>14</td><td>1</td><td>16832</td><td>24</td><td>
TNFAIP6</td></tr><tr><td>1.996e-02</td><td>-3.91</td><td>GO REGULATION OF MUSCLE CELL DIFFERENTIATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>148</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, IGFBP3</td></tr><tr><td>2.007e-02</td><td>-3.91</td><td>enzyme inhibitor activity</td><td>molecular function</td><td>GO:0004857</td><td>375</td><td>3</td><td>16652</td><td>26</td><td>
SLPI, SCG5, PI3</td></tr><tr><td>2.010e-02</td><td>-3.91</td><td>RUTELLA RESPONSE TO HGF UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>397</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2, CXCL3</td></tr><tr><td>2.021e-02</td><td>-3.90</td><td>NING CHRONIC OBSTRUCTIVE PULMONARY DISEASE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>149</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, KRT7</td></tr><tr><td>2.025e-02</td><td>-3.90</td><td>establishment or maintenance of transmembrane electrochemical gradient</td><td>biological process</td><td>GO:0010248</td><td>13</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.025e-02</td><td>-3.90</td><td>relaxation of cardiac muscle</td><td>biological process</td><td>GO:0055119</td><td>13</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.025e-02</td><td>-3.90</td><td>positive regulation of macrophage activation</td><td>biological process</td><td>GO:0043032</td><td>13</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.025e-02</td><td>-3.90</td><td>positive regulation of potassium ion transmembrane transporter activity</td><td>biological process</td><td>GO:1901018</td><td>13</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.025e-02</td><td>-3.90</td><td>positive regulation of insulin-like growth factor receptor signaling pathway</td><td>biological process</td><td>GO:0043568</td><td>13</td><td>1</td><td>16543</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.025e-02</td><td>-3.90</td><td>regulation of odontogenesis of dentin-containing tooth</td><td>biological process</td><td>GO:0042487</td><td>13</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>GO SODIUM ION BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>SILIGAN TARGETS OF EWS FLI1 FUSION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>GO POTASSIUM ION BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>GO REGULATION OF FIBRINOLYSIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>GO G PROTEIN COUPLED PURINERGIC NUCLEOTIDE RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>DORN ADENOVIRUS INFECTION 48HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>HUMMERICH MALIGNANT SKIN TUMOR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
SLPI</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>GO G PROTEIN COUPLED NUCLEOTIDE RECEPTOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>CASTELLANO NRAS TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>ABBUD LIF SIGNALING 2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.047e-02</td><td>-3.89</td><td>LIM MAMMARY LUMINAL PROGENITOR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>14</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>2.062e-02</td><td>-3.88</td><td>human chr15q13.3</td><td>chromosome location</td><td>human chr15q13.3</td><td>21</td><td>1</td><td>26234</td><td>26</td><td>
SCG5</td></tr><tr><td>2.069e-02</td><td>-3.88</td><td>GO MEMBRANE REGION</td><td>MSigDB lists</td><td>&nbsp;</td><td>1101</td><td>5</td><td>17621</td><td>26</td><td>
DST, ATP1B1, CEACAM5, TGFA, ANO1</td></tr><tr><td>2.072e-02</td><td>-3.88</td><td>GSE45365 NK CELL VS CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>151</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1</td></tr><tr><td>2.072e-02</td><td>-3.88</td><td>MYC UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>151</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>2.072e-02</td><td>-3.88</td><td>TONKS TARGETS OF RUNX1 RUNX1T1 FUSION ERYTHROCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>151</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, SCG5</td></tr><tr><td>2.097e-02</td><td>-3.86</td><td>anchored component of membrane</td><td>cellular component</td><td>GO:0031225</td><td>153</td><td>2</td><td>17744</td><td>26</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>2.097e-02</td><td>-3.86</td><td>IGFBP N 1</td><td>prosite domains</td><td>PS00222</td><td>11</td><td>1</td><td>11955</td><td>23</td><td>
IGFBP3</td></tr><tr><td>2.097e-02</td><td>-3.86</td><td>PNT</td><td>prosite domains</td><td>PS51433</td><td>11</td><td>1</td><td>11955</td><td>23</td><td>
ELF3</td></tr><tr><td>2.098e-02</td><td>-3.86</td><td>GSE13485 CTRL VS DAY3 YF17D VACCINE PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>152</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, PI3</td></tr><tr><td>2.098e-02</td><td>-3.86</td><td>GO REGULATION OF CYCLIC NUCLEOTIDE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>152</td><td>2</td><td>17621</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>2.098e-02</td><td>-3.86</td><td>GSE6269 E COLI VS STREP PNEUMO INF PBMC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>152</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6</td></tr><tr><td>2.098e-02</td><td>-3.86</td><td>DARWICHE PAPILLOMA RISK LOW UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>152</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGFA</td></tr><tr><td>2.104e-02</td><td>-3.86</td><td>3-phosphoinositide degradation</td><td>BIOCYC pathways</td><td>META_PWY-6368</td><td>19</td><td>1</td><td>903</td><td>1</td><td>
INPP4B</td></tr><tr><td>2.106e-02</td><td>-3.86</td><td>response to temperature stimulus</td><td>biological process</td><td>GO:0009266</td><td>143</td><td>2</td><td>16543</td><td>26</td><td>
ANO1, THBS1</td></tr><tr><td>2.106e-02</td><td>-3.86</td><td>activation of MAPK activity</td><td>biological process</td><td>GO:0000187</td><td>143</td><td>2</td><td>16543</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>2.118e-02</td><td>-3.85</td><td>MODULE 60</td><td>MSigDB lists</td><td>&nbsp;</td><td>405</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, RBPMS, IGFBP6</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>CDC42EP1 (CDC42 effector protein 1)</td><td>protein interactions</td><td>11135</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>GLYCTK (glycerate kinase)</td><td>protein interactions</td><td>132158</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>Prkcz (protein kinase C, zeta)</td><td>protein interactions</td><td>18762</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>Tecpr2 (tectonin beta-propeller repeat containing 2)</td><td>protein interactions</td><td>104859</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>JAG1 (jagged 1)</td><td>protein interactions</td><td>182</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>COL17A1 (collagen type XVII alpha 1 chain)</td><td>protein interactions</td><td>1308</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>2.123e-02</td><td>-3.85</td><td>GRAP (GRB2-related adaptor protein)</td><td>protein interactions</td><td>10750</td><td>14</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.145e-02</td><td>-3.84</td><td>LIM MAMMARY STEM CELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>407</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, TGM2, ELF3</td></tr><tr><td>2.150e-02</td><td>-3.84</td><td>KIM WT1 TARGETS 12HR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>154</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, ATP1B1</td></tr><tr><td>2.165e-02</td><td>-3.83</td><td>G-protein coupled purinergic nucleotide receptor activity</td><td>molecular function</td><td>GO:0045028</td><td>14</td><td>1</td><td>16652</td><td>26</td><td>
GPR87</td></tr><tr><td>2.165e-02</td><td>-3.83</td><td>low-density lipoprotein particle binding</td><td>molecular function</td><td>GO:0030169</td><td>14</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>2.165e-02</td><td>-3.83</td><td>G-protein coupled nucleotide receptor activity</td><td>molecular function</td><td>GO:0001608</td><td>14</td><td>1</td><td>16652</td><td>26</td><td>
GPR87</td></tr><tr><td>2.165e-02</td><td>-3.83</td><td>potassium ion binding</td><td>molecular function</td><td>GO:0030955</td><td>14</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.176e-02</td><td>-3.83</td><td>SMIRNOV CIRCULATING ENDOTHELIOCYTES IN CANCER UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>155</td><td>2</td><td>17621</td><td>26</td><td>
THBS1, IGFBP3</td></tr><tr><td>2.176e-02</td><td>-3.83</td><td>GSE45365 BCELL VS CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>155</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.176e-02</td><td>-3.83</td><td>ACCATTT,MIR-522</td><td>MSigDB lists</td><td>&nbsp;</td><td>155</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ANO1</td></tr><tr><td>2.176e-02</td><td>-3.83</td><td>cation-transporting ATPase complex</td><td>cellular component</td><td>GO:0090533</td><td>15</td><td>1</td><td>17744</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>negative regulation of bone remodeling</td><td>biological process</td><td>GO:0046851</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>regulation of fibrinolysis</td><td>biological process</td><td>GO:0051917</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>maintenance of cell polarity</td><td>biological process</td><td>GO:0030011</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
DST</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>detection of temperature stimulus involved in sensory perception</td><td>biological process</td><td>GO:0050961</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
ANO1</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>detection of temperature stimulus involved in sensory perception of pain</td><td>biological process</td><td>GO:0050965</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
ANO1</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>G-protein coupled purinergic nucleotide receptor signaling pathway</td><td>biological process</td><td>GO:0035589</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>negative regulation of interleukin-12 production</td><td>biological process</td><td>GO:0032695</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>positive regulation of sodium ion transmembrane transporter activity</td><td>biological process</td><td>GO:2000651</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.179e-02</td><td>-3.83</td><td>positive regulation of endothelial cell apoptotic process</td><td>biological process</td><td>GO:2000353</td><td>14</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.184e-02</td><td>-3.82</td><td>SAM PNT</td><td>smart domains</td><td>SM00251</td><td>11</td><td>1</td><td>9480</td><td>19</td><td>
ELF3</td></tr><tr><td>2.184e-02</td><td>-3.82</td><td>TGc</td><td>smart domains</td><td>SM00460</td><td>11</td><td>1</td><td>9480</td><td>19</td><td>
TGM2</td></tr><tr><td>2.187e-02</td><td>-3.82</td><td>GO REGULATION OF TRANSMEMBRANE TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>410</td><td>3</td><td>17621</td><td>26</td><td>
ATP1B1, ANO1, THBS1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO CELL COMMUNICATION BY ELECTRICAL COUPLING</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO CXCR CHEMOKINE RECEPTOR BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO CHRONIC INFLAMMATORY RESPONSE</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>PID ERBB NETWORK PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>MODULE 431</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO MHC CLASS II PROTEIN COMPLEX BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO LOW DENSITY LIPOPROTEIN PARTICLE BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>DAVICIONI RHABDOMYOSARCOMA PAX FOXO1 FUSION DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>LOPEZ EPITHELIOID MESOTHELIOMA</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>GO NEGATIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.191e-02</td><td>-3.82</td><td>SANCHEZ MDM2 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>15</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>2.202e-02</td><td>-3.82</td><td>GO INTERMEDIATE FILAMENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>156</td><td>2</td><td>17621</td><td>26</td><td>
DST, KRT7</td></tr><tr><td>2.202e-02</td><td>-3.82</td><td>GO PHAGOCYTOSIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>156</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>2.212e-02</td><td>-3.81</td><td>regulation of proteolysis</td><td>biological process</td><td>GO:0030162</td><td>695</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, PI3, MAGEA3, THBS1</td></tr><tr><td>2.215e-02</td><td>-3.81</td><td>3-phosphoinositide degradation</td><td>BIOCYC pathways</td><td>HUMAN_PWY-6368</td><td>20</td><td>1</td><td>903</td><td>1</td><td>
INPP4B</td></tr><tr><td>2.217e-02</td><td>-3.81</td><td>regulation of ion transmembrane transport</td><td>biological process</td><td>GO:0034765</td><td>387</td><td>3</td><td>16543</td><td>26</td><td>
ATP1B1, ANO1, THBS1</td></tr><tr><td>2.229e-02</td><td>-3.80</td><td>GSE13547 2H VS 12 H ANTI IGM STIM ZFX KO BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>157</td><td>2</td><td>17621</td><td>26</td><td>
DST, SLPI</td></tr><tr><td>2.233e-02</td><td>-3.80</td><td>regulation of response to external stimulus</td><td>biological process</td><td>GO:0032101</td><td>697</td><td>4</td><td>16543</td><td>26</td><td>
TNFAIP6, TGM2, CXCL3, THBS1</td></tr><tr><td>2.255e-02</td><td>-3.79</td><td>GSE37605 TREG VS TCONV NOD FOXP3 FUSION GFP DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>158</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>COL3A1 (collagen type III alpha 1 chain)</td><td>protein interactions</td><td>1281</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>HLA-DRB3 (major histocompatibility complex, class II, DR beta 3)</td><td>protein interactions</td><td>3125</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>SPATA8 (spermatogenesis associated 8)</td><td>protein interactions</td><td>145946</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>CELSR3 (cadherin EGF LAG seven-pass G-type receptor 3)</td><td>protein interactions</td><td>1951</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>MYOZ2 (myozenin 2)</td><td>protein interactions</td><td>51778</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>DPYSL4 (dihydropyrimidinase like 4)</td><td>protein interactions</td><td>10570</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>WDR90 (WD repeat domain 90)</td><td>protein interactions</td><td>197335</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>MORN3 (MORN repeat containing 3)</td><td>protein interactions</td><td>283385</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>2.273e-02</td><td>-3.78</td><td>SERF2 (small EDRK-rich factor 2)</td><td>protein interactions</td><td>10169</td><td>15</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.282e-02</td><td>-3.78</td><td>GSE35825 UNTREATED VS IFNA STIM MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>159</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2</td></tr><tr><td>2.282e-02</td><td>-3.78</td><td>GSE5099 DAY3 VS DAY7 MCSF TREATED MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>159</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>2.285e-02</td><td>-3.78</td><td>LINK 1</td><td>prosite domains</td><td>PS01241</td><td>12</td><td>1</td><td>11955</td><td>23</td><td>
TNFAIP6</td></tr><tr><td>2.289e-02</td><td>-3.78</td><td>Synthesis of PIPs at the early endosome membrane</td><td>REACTOME pathways</td><td>R-HSA-1660516</td><td>14</td><td>1</td><td>10293</td><td>17</td><td>
INPP4B</td></tr><tr><td>2.301e-02</td><td>-3.77</td><td>Ig V-set</td><td>interpro domains</td><td>IPR013106</td><td>167</td><td>2</td><td>18428</td><td>26</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>2.309e-02</td><td>-3.77</td><td>GSE27859 MACROPHAGE VS DC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>160</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2</td></tr><tr><td>2.314e-02</td><td>-3.77</td><td>MODULE 52</td><td>MSigDB lists</td><td>&nbsp;</td><td>419</td><td>3</td><td>17621</td><td>26</td><td>
TGM2, KRT7, THBS1</td></tr><tr><td>2.317e-02</td><td>-3.76</td><td>ErbB receptor signaling network</td><td>Pathway Interaction DB</td><td>erbb_network_pathway</td><td>13</td><td>1</td><td>2226</td><td>4</td><td>
TGFA</td></tr><tr><td>2.325e-02</td><td>-3.76</td><td>skin-hand-carcinoma-squamous cell carcinoma</td><td>COSMIC cancer mutations</td><td>skin-hand-carcinoma-squamous_cell_carcinoma</td><td>420</td><td>3</td><td>17630</td><td>26</td><td>
DST, CEACAM5, INPP4B</td></tr><tr><td>2.331e-02</td><td>-3.76</td><td>regulation of cyclic nucleotide metabolic process</td><td>biological process</td><td>GO:0030799</td><td>151</td><td>2</td><td>16543</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>2.333e-02</td><td>-3.76</td><td>negative regulation of focal adhesion assembly</td><td>biological process</td><td>GO:0051895</td><td>15</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.333e-02</td><td>-3.76</td><td>behavioral response to pain</td><td>biological process</td><td>GO:0048266</td><td>15</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.333e-02</td><td>-3.76</td><td>cell communication by electrical coupling involved in cardiac conduction</td><td>biological process</td><td>GO:0086064</td><td>15</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GSE13485 CTRL VS DAY7 YF17D VACCINE PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>161</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, PI3</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GSE6269 FLU VS STREP PNEUMO INF PBMC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>161</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, PI3</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>DASU IL6 SIGNALING SCAR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO MICROTUBULE PLUS END</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>LEE LIVER CANCER HEPATOBLAST</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO VOLTAGE GATED ANION CHANNEL ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO DETECTION OF TEMPERATURE STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>LEE NAIVE T LYMPHOCYTE</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO CATION TRANSPORTING ATPASE COMPLEX</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO REGULATION OF MACROPHAGE CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO REGULATION OF MONONUCLEAR CELL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>HINATA NFKB IMMU INF</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO NEGATIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO INTRACELLULAR CALCIUM ACTIVATED CHLORIDE CHANNEL ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>PIEPOLI LGI1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO TRANSFORMING GROWTH FACTOR BETA BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.336e-02</td><td>-3.76</td><td>GO POSITIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>16</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.348e-02</td><td>-3.75</td><td>Osteoblast Signaling</td><td>WikiPathways</td><td>WP322</td><td>14</td><td>1</td><td>5314</td><td>9</td><td>
TNFRSF11B</td></tr><tr><td>2.353e-02</td><td>-3.75</td><td>human chr11q13.3</td><td>chromosome location</td><td>human chr11q13.3</td><td>24</td><td>1</td><td>26234</td><td>26</td><td>
ANO1</td></tr><tr><td>2.363e-02</td><td>-3.75</td><td>GSE37301 MULTIPOTENT PROGENITOR VS CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>162</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, SCG5</td></tr><tr><td>2.363e-02</td><td>-3.75</td><td>GSE18791 UNSTIM VS NEWCATSLE VIRUS DC 18H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>162</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CEACAM5</td></tr><tr><td>2.388e-02</td><td>-3.73</td><td>regulation of leukocyte migration</td><td>biological process</td><td>GO:0002685</td><td>153</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>2.398e-02</td><td>-3.73</td><td>regulation of molecular function</td><td>biological process</td><td>GO:0065009</td><td>2830</td><td>9</td><td>16543</td><td>26</td><td>
SCG5, TGFA, GPR87, MAGEA3, SLPI, ATP1B1, PI3, THBS1, IGFBP3</td></tr><tr><td>2.406e-02</td><td>-3.73</td><td>Lactose Degradation</td><td>SMPDB pathways</td><td>SMP00457</td><td>12</td><td>1</td><td>992</td><td>2</td><td>
ATP1B1</td></tr><tr><td>2.406e-02</td><td>-3.73</td><td>Lactose Intolerance</td><td>SMPDB pathways</td><td>SMP00458</td><td>12</td><td>1</td><td>992</td><td>2</td><td>
ATP1B1</td></tr><tr><td>2.417e-02</td><td>-3.72</td><td>GSE29615 DAY3 VS DAY7 LAIV FLU VACCINE PBMC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>164</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, PI3</td></tr><tr><td>2.423e-02</td><td>-3.72</td><td>TWISTNB (TWIST neighbor)</td><td>protein interactions</td><td>221830</td><td>16</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>2.423e-02</td><td>-3.72</td><td>ABCA2 (ATP binding cassette subfamily A member 2)</td><td>protein interactions</td><td>20</td><td>16</td><td>1</td><td>16330</td><td>25</td><td>
PCDH1</td></tr><tr><td>2.423e-02</td><td>-3.72</td><td>LRRC41 (leucine rich repeat containing 41)</td><td>protein interactions</td><td>10489</td><td>16</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.432e-02</td><td>-3.72</td><td>regulation of transmembrane transport</td><td>biological process</td><td>GO:0034762</td><td>401</td><td>3</td><td>16543</td><td>26</td><td>
ATP1B1, ANO1, THBS1</td></tr><tr><td>2.445e-02</td><td>-3.71</td><td>GSE13485 PRE VS POST YF17D VACCINATION PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>165</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, PI3</td></tr><tr><td>2.445e-02</td><td>-3.71</td><td>GO PEPTIDASE INHIBITOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>165</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>2.448e-02</td><td>-3.71</td><td>response to cytokine</td><td>biological process</td><td>GO:0034097</td><td>717</td><td>4</td><td>16543</td><td>26</td><td>
TNFRSF11B, TFF2, CXCL3, THBS1</td></tr><tr><td>2.463e-02</td><td>-3.70</td><td>microtubule plus-end</td><td>cellular component</td><td>GO:0035371</td><td>17</td><td>1</td><td>17744</td><td>26</td><td>
DST</td></tr><tr><td>2.469e-02</td><td>-3.70</td><td>PSMD4 (proteasome 26S subunit, non-ATPase 4)</td><td>protein interactions</td><td>5710</td><td>160</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, THBS1</td></tr><tr><td>2.470e-02</td><td>-3.70</td><td>intracellular chloride channel activity</td><td>molecular function</td><td>GO:0061778</td><td>16</td><td>1</td><td>16652</td><td>26</td><td>
ANO1</td></tr><tr><td>2.470e-02</td><td>-3.70</td><td>intracellular calcium activated chloride channel activity</td><td>molecular function</td><td>GO:0005229</td><td>16</td><td>1</td><td>16652</td><td>26</td><td>
ANO1</td></tr><tr><td>2.470e-02</td><td>-3.70</td><td>transforming growth factor beta binding</td><td>molecular function</td><td>GO:0050431</td><td>16</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>2.470e-02</td><td>-3.70</td><td>MHC class II protein complex binding</td><td>molecular function</td><td>GO:0023026</td><td>16</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.472e-02</td><td>-3.70</td><td>GSE9988 ANTI TREM1 VS ANTI TREM1 AND LPS MONOCYTE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>166</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.472e-02</td><td>-3.70</td><td>GSE9988 LPS VS CTRL TREATED MONOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>166</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.474e-02</td><td>-3.70</td><td>SMALL CYTOKINES CXC</td><td>prosite domains</td><td>PS00471</td><td>13</td><td>1</td><td>11955</td><td>23</td><td>
CXCL3</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO REGULATION OF CATECHOLAMINE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO NEGATIVE REGULATION OF TISSUE REMODELING</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO ATPASE ACTIVATOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO COPULATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
PI3</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>LE NEURONAL DIFFERENTIATION UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO REGULATION OF DOPAMINE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>KOBAYASHI RESPONSE TO ROMIDEPSIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO NEGATIVE REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>SCHWAB TARGETS OF BMYB POLYMORPHIC VARIANTS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>KASLER HDAC7 TARGETS 1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO NEGATIVE REGULATION OF ANOIKIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM5</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>TORCHIA TARGETS OF EWSR1 FLI1 FUSION TOP20 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO NEGATIVE REGULATION OF MYOTUBE DIFFERENTIATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM5</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>KYNG WERNER SYNDROM UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.480e-02</td><td>-3.70</td><td>GO REGULATION OF HYDROGEN PEROXIDE INDUCED CELL DEATH</td><td>MSigDB lists</td><td>&nbsp;</td><td>17</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>membrane repolarization during action potential</td><td>biological process</td><td>GO:0086011</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>copulation</td><td>biological process</td><td>GO:0007620</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
PI3</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>negative regulation of adherens junction organization</td><td>biological process</td><td>GO:1903392</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>regulation of SMAD protein import into nucleus</td><td>biological process</td><td>GO:0060390</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>cardiac muscle cell membrane repolarization</td><td>biological process</td><td>GO:0099622</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>negative regulation of anoikis</td><td>biological process</td><td>GO:2000811</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
CEACAM5</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>regulation of macrophage chemotaxis</td><td>biological process</td><td>GO:0010758</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.486e-02</td><td>-3.69</td><td>membrane repolarization during cardiac muscle cell action potential</td><td>biological process</td><td>GO:0086013</td><td>16</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.500e-02</td><td>-3.69</td><td>GSE2706 LPS VS R848 AND LPS 8H STIM DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>167</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.500e-02</td><td>-3.69</td><td>GSE2706 R848 VS R848 AND LPS 2H STIM DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>167</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.500e-02</td><td>-3.69</td><td>GSE4748 CYANOBACTERIUM LPSLIKE VS LPS AND CYANOBACTERIUM LPSLIKE STIM DC 3H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>167</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CEACAM6</td></tr><tr><td>2.500e-02</td><td>-3.69</td><td>SASAKI ADULT T CELL LEUKEMIA</td><td>MSigDB lists</td><td>&nbsp;</td><td>167</td><td>2</td><td>17621</td><td>26</td><td>
DST, ATP1B1</td></tr><tr><td>2.505e-02</td><td>-3.69</td><td>CREIGHTON ENDOCRINE THERAPY RESISTANCE 5</td><td>MSigDB lists</td><td>&nbsp;</td><td>432</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, CEACAM5, THBS1</td></tr><tr><td>2.505e-02</td><td>-3.69</td><td>SHEDDEN LUNG CANCER POOR SURVIVAL A6</td><td>MSigDB lists</td><td>&nbsp;</td><td>432</td><td>3</td><td>17621</td><td>26</td><td>
GPR37, MAGEA6, MAGEA3</td></tr><tr><td>2.528e-02</td><td>-3.68</td><td>GSE37605 FOXP3 FUSION GFP VS IRES GFP TREG C57BL6 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>168</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, THBS1</td></tr><tr><td>2.545e-02</td><td>-3.67</td><td>positive regulation of protein metabolic process</td><td>biological process</td><td>GO:0051247</td><td>1492</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.556e-02</td><td>-3.67</td><td>GSE9988 LPS VS VEHICLE TREATED MONOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>169</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.556e-02</td><td>-3.67</td><td>PRC2 SUZ12 UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>169</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, SCG5</td></tr><tr><td>2.556e-02</td><td>-3.67</td><td>GSE9988 LOW LPS VS VEHICLE TREATED MONOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>169</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.556e-02</td><td>-3.67</td><td>GSE45365 CD8A DC VS CD11B DC IFNAR KO UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>169</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, SLPI</td></tr><tr><td>2.568e-02</td><td>-3.66</td><td>BUYTAERT PHOTODYNAMIC THERAPY STRESS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>775</td><td>4</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, SCG5, CXCL3</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>TGFA (transforming growth factor alpha)</td><td>protein interactions</td><td>7039</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>CBR3 (carbonyl reductase 3)</td><td>protein interactions</td><td>874</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
ELF3</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>CXCR1 (C-X-C motif chemokine receptor 1)</td><td>protein interactions</td><td>3577</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
CXCL3</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>UQCC2 (ubiquinol-cytochrome c reductase complex assembly factor 2)</td><td>protein interactions</td><td>84300</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM5</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>HRG (histidine rich glycoprotein)</td><td>protein interactions</td><td>3273</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>ACAN (aggrecan)</td><td>protein interactions</td><td>176</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
TNFAIP6</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>BBS2 (Bardet-Biedl syndrome 2)</td><td>protein interactions</td><td>583</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>MAGI2 (membrane associated guanylate kinase, WW and PDZ domain containing 2)</td><td>protein interactions</td><td>9863</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>2.572e-02</td><td>-3.66</td><td>MAP3K12 (mitogen-activated protein kinase kinase kinase 12)</td><td>protein interactions</td><td>7786</td><td>17</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>2.581e-02</td><td>-3.66</td><td>MODULE 24</td><td>MSigDB lists</td><td>&nbsp;</td><td>437</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TGM2, IGFBP3</td></tr><tr><td>2.595e-02</td><td>-3.65</td><td>regulation of muscle cell differentiation</td><td>biological process</td><td>GO:0051147</td><td>160</td><td>2</td><td>16543</td><td>26</td><td>
CEACAM5, IGFBP3</td></tr><tr><td>2.605e-02</td><td>-3.65</td><td>Trehalose Degradation</td><td>SMPDB pathways</td><td>SMP00467</td><td>13</td><td>1</td><td>992</td><td>2</td><td>
ATP1B1</td></tr><tr><td>2.612e-02</td><td>-3.65</td><td>TFAP2 (AP-2) family regulates transcription of growth factors and their receptors</td><td>REACTOME pathways</td><td>R-HSA-8866910</td><td>16</td><td>1</td><td>10293</td><td>17</td><td>
TGFA</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>GSE30971 CTRL VS LPS STIM MACROPHAGE WBP7 KO 2H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGFA</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>GSE36888 UNTREATED VS IL2 TREATED STAT5 AB KNOCKIN TCELL 17H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGFA</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>GSE6259 CD4 TCELL VS CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>GSE9988 LOW LPS VS CTRL TREATED MONOCYTE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>NAGASHIMA NRG1 SIGNALING UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>PTEN DN.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, INPP4B</td></tr><tr><td>2.612e-02</td><td>-3.64</td><td>GSE3920 UNTREATED VS IFNG TREATED FIBROBLAST DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>171</td><td>2</td><td>17621</td><td>26</td><td>
DST, TGM2</td></tr><tr><td>2.623e-02</td><td>-3.64</td><td>voltage-gated anion channel activity</td><td>molecular function</td><td>GO:0008308</td><td>17</td><td>1</td><td>16652</td><td>26</td><td>
ANO1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO REGULATION OF TUMOR NECROSIS FACTOR BIOSYNTHETIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>HUMMERICH BENIGN SKIN TUMOR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
SLPI</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>MAHADEVAN RESPONSE TO MP470 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO MHC PROTEIN COMPLEX BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>XU HGF TARGETS INDUCED BY AKT1 6HR</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO POTASSIUM ION HOMEOSTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO NEGATIVE REGULATION OF ORGANIC ACID TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>ZEMBUTSU SENSITIVITY TO CISPLATIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
PCDH1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>MAHADEVAN IMATINIB RESISTANCE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO POLY PURINE TRACT BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>PLASARI NFIC TARGETS BASAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>DAZARD UV RESPONSE CLUSTER G28</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>YORDY RECIPROCAL REGULATION BY ETS1 AND SP100 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>CLASPER LYMPHATIC VESSELS DURING METASTASIS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO CATECHOLAMINE BIOSYNTHETIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>MOROSETTI FACIOSCAPULOHUMERAL MUSCULAR DISTROPHY UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>KANG CISPLATIN RESISTANCE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>CTACTAG,MIR-325</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>KOBAYASHI EGFR SIGNALING 6HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO GLYCOLIPID BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM5</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>ZEMBUTSU SENSITIVITY TO VINCRISTINE</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>CHEOK RESPONSE TO MERCAPTOPURINE AND LD MTX DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM6</td></tr><tr><td>2.624e-02</td><td>-3.64</td><td>GO CATECHOL CONTAINING COMPOUND BIOSYNTHETIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>18</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>regulation of catecholamine metabolic process</td><td>biological process</td><td>GO:0042069</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>regulation of endothelial cell chemotaxis</td><td>biological process</td><td>GO:2001026</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>catechol-containing compound biosynthetic process</td><td>biological process</td><td>GO:0009713</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>positive regulation of transforming growth factor beta production</td><td>biological process</td><td>GO:0071636</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>catecholamine biosynthetic process</td><td>biological process</td><td>GO:0042423</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>branching involved in salivary gland morphogenesis</td><td>biological process</td><td>GO:0060445</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>cell communication by electrical coupling</td><td>biological process</td><td>GO:0010644</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>negative regulation of hydrogen peroxide-induced cell death</td><td>biological process</td><td>GO:1903206</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>negative regulation of organic acid transport</td><td>biological process</td><td>GO:0032891</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>positive regulation of extrinsic apoptotic signaling pathway via death domain receptors</td><td>biological process</td><td>GO:1902043</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>negative regulation of response to reactive oxygen species</td><td>biological process</td><td>GO:1901032</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>2.640e-02</td><td>-3.63</td><td>regulation of dopamine metabolic process</td><td>biological process</td><td>GO:0042053</td><td>17</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>2.643e-02</td><td>-3.63</td><td>human chr6p12.1</td><td>chromosome location</td><td>human chr6p12.1</td><td>27</td><td>1</td><td>26234</td><td>26</td><td>
DST</td></tr><tr><td>2.644e-02</td><td>-3.63</td><td>HTT (huntingtin)</td><td>protein interactions</td><td>3064</td><td>166</td><td>2</td><td>16330</td><td>25</td><td>
TGM2, MAGEA3</td></tr><tr><td>2.661e-02</td><td>-3.63</td><td>LINK 2</td><td>prosite domains</td><td>PS50963</td><td>14</td><td>1</td><td>11955</td><td>23</td><td>
TNFAIP6</td></tr><tr><td>2.669e-02</td><td>-3.62</td><td>GSE30971 CTRL VS LPS STIM MACROPHAGE WBP7 KO 4H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>173</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGFA</td></tr><tr><td>2.669e-02</td><td>-3.62</td><td>GSE25123 WT VS PPARG KO MACROPHAGE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>173</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>2.669e-02</td><td>-3.62</td><td>GSE2706 UNSTIM VS 2H LPS DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>173</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.679e-02</td><td>-3.62</td><td>Osteoclast Signaling</td><td>WikiPathways</td><td>WP12</td><td>16</td><td>1</td><td>5314</td><td>9</td><td>
TNFRSF11B</td></tr><tr><td>2.698e-02</td><td>-3.61</td><td>GSE2770 TGFB AND IL4 ACT VS ACT CD4 TCELL 2H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6</td></tr><tr><td>2.698e-02</td><td>-3.61</td><td>GSE2706 2H VS 8H R848 STIM DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>2.698e-02</td><td>-3.61</td><td>GSE6269 STAPH AUREUS VS STREP PNEUMO INF PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6</td></tr><tr><td>2.698e-02</td><td>-3.61</td><td>GSE45365 CD8A DC VS CD11B DC IFNAR KO DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, PI3</td></tr><tr><td>2.698e-02</td><td>-3.61</td><td>GO CELL ADHESION MOLECULE BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>2.698e-02</td><td>-3.61</td><td>GSE21360 SECONDARY VS QUATERNARY MEMORY CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>174</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, CXCL3</td></tr><tr><td>2.713e-02</td><td>-3.61</td><td>FN1 (fibronectin 1)</td><td>protein interactions</td><td>2335</td><td>761</td><td>4</td><td>16330</td><td>25</td><td>
TNFRSF11B, TGM2, IGFBP3, THBS1</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>TFPI (tissue factor pathway inhibitor)</td><td>protein interactions</td><td>7035</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>TOR1AIP2 (torsin 1A interacting protein 2)</td><td>protein interactions</td><td>163590</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>ATP6V1G1 (ATPase H+ transporting V1 subunit G1)</td><td>protein interactions</td><td>9550</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>TRIB1 (tribbles pseudokinase 1)</td><td>protein interactions</td><td>10221</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
PCDH1</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>IGFBP5 (insulin like growth factor binding protein 5)</td><td>protein interactions</td><td>3488</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>RDH12 (retinol dehydrogenase 12 (all-trans/9-cis/11-cis))</td><td>protein interactions</td><td>145226</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>BCL6B (B-cell CLL/lymphoma 6B)</td><td>protein interactions</td><td>255877</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>MMP1 (matrix metallopeptidase 1)</td><td>protein interactions</td><td>4312</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>NKD2 (naked cuticle homolog 2)</td><td>protein interactions</td><td>85409</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>CFH (complement factor H)</td><td>protein interactions</td><td>3075</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>SNAP47 (synaptosome associated protein 47)</td><td>protein interactions</td><td>116841</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>BET1 (Bet1 golgi vesicular membrane trafficking protein)</td><td>protein interactions</td><td>10282</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>LRP5 (LDL receptor related protein 5)</td><td>protein interactions</td><td>4041</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.721e-02</td><td>-3.60</td><td>HOXA9 (homeobox A9)</td><td>protein interactions</td><td>3205</td><td>18</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.726e-02</td><td>-3.60</td><td>GSE36888 UNTREATED VS IL2 TREATED STAT5 AB KNOCKIN TCELL 6H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>175</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>2.740e-02</td><td>-3.60</td><td>Longevity(PMID:20834067)</td><td>GWAS genes</td><td>Longevity(PMID:20834067)</td><td>22</td><td>1</td><td>2388</td><td>3</td><td>
TGFA</td></tr><tr><td>2.740e-02</td><td>-3.60</td><td>human chr4q31.21</td><td>chromosome location</td><td>human chr4q31.21</td><td>28</td><td>1</td><td>26234</td><td>26</td><td>
INPP4B</td></tr><tr><td>2.745e-02</td><td>-3.60</td><td>endopeptidase inhibitor activity</td><td>molecular function</td><td>GO:0004866</td><td>166</td><td>2</td><td>16652</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>2.755e-02</td><td>-3.59</td><td>GSE30971 WBP7 HET VS KO MACROPHAGE 4H LPS STIM UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>176</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.755e-02</td><td>-3.59</td><td>VERHAAK AML WITH NPM1 MUTATED UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>176</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>2.755e-02</td><td>-3.59</td><td>GSE3982 DC VS MAC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>176</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, TGFA</td></tr><tr><td>2.755e-02</td><td>-3.59</td><td>GSE32034 UNTREATED VS ROSIGLIZATONE TREATED LY6C LOW MONOCYTE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>176</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, KRT7</td></tr><tr><td>2.755e-02</td><td>-3.59</td><td>ATF2 S UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>176</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, TNFAIP6</td></tr><tr><td>2.757e-02</td><td>-3.59</td><td>Myometrial Relaxation and Contraction Pathways</td><td>WikiPathways</td><td>WP289</td><td>158</td><td>2</td><td>5314</td><td>9</td><td>
IGFBP6, IGFBP3</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>GO PHAGOCYTOSIS ENGULFMENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>GO CELLULAR SODIUM ION HOMEOSTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>GO NEGATIVE REGULATION OF CELL JUNCTION ASSEMBLY</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>NIELSEN GIST VS SYNOVIAL SARCOMA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>chr3q24</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>ZEMBUTSU SENSITIVITY TO MITOMYCIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
PCDH1</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>AMIT EGF RESPONSE 40 MCF10A</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>2.768e-02</td><td>-3.59</td><td>VERRECCHIA RESPONSE TO TGFB1 C1</td><td>MSigDB lists</td><td>&nbsp;</td><td>19</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.772e-02</td><td>-3.59</td><td>LINK</td><td>smart domains</td><td>SM00445</td><td>14</td><td>1</td><td>9480</td><td>19</td><td>
TNFAIP6</td></tr><tr><td>2.775e-02</td><td>-3.58</td><td>ATPase activator activity</td><td>molecular function</td><td>GO:0001671</td><td>18</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.775e-02</td><td>-3.58</td><td>alkali metal ion binding</td><td>molecular function</td><td>GO:0031420</td><td>18</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.782e-02</td><td>-3.58</td><td>endoplasmic reticulum</td><td>cellular component</td><td>GO:0005783</td><td>1633</td><td>6</td><td>17744</td><td>26</td><td>
DST, GPR37, TGM2, TGFA, MAGEA3, THBS1</td></tr><tr><td>2.784e-02</td><td>-3.58</td><td>GSE22611 MUTANT NOD2 VS CTRL TRANSDUCED HEK293T CELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>177</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.784e-02</td><td>-3.58</td><td>GSE19888 ADENOSINE A3R INH VS ACT IN MAST CELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>177</td><td>2</td><td>17621</td><td>26</td><td>
PCDH1, GPR87</td></tr><tr><td>2.784e-02</td><td>-3.58</td><td>GSE37301 COMMON LYMPHOID PROGENITOR VS GRAN MONO PROGENITOR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>177</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, KRT7</td></tr><tr><td>2.784e-02</td><td>-3.58</td><td>GSE10463 CD40L AND VA347 VS CD40L IN DC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>177</td><td>2</td><td>17621</td><td>26</td><td>
PI3, THBS1</td></tr><tr><td>2.784e-02</td><td>-3.58</td><td>GSE2706 UNSTIM VS 2H R848 DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>177</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.784e-02</td><td>-3.58</td><td>GO REGULATION OF CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>177</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>2.793e-02</td><td>-3.58</td><td>ovulation</td><td>biological process</td><td>GO:0030728</td><td>18</td><td>1</td><td>16543</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>2.793e-02</td><td>-3.58</td><td>detection of temperature stimulus</td><td>biological process</td><td>GO:0016048</td><td>18</td><td>1</td><td>16543</td><td>26</td><td>
ANO1</td></tr><tr><td>2.793e-02</td><td>-3.58</td><td>regulation of macrophage migration</td><td>biological process</td><td>GO:1905521</td><td>18</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.793e-02</td><td>-3.58</td><td>potassium ion homeostasis</td><td>biological process</td><td>GO:0055075</td><td>18</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.793e-02</td><td>-3.58</td><td>negative regulation of myotube differentiation</td><td>biological process</td><td>GO:0010832</td><td>18</td><td>1</td><td>16543</td><td>26</td><td>
CEACAM5</td></tr><tr><td>2.804e-02</td><td>-3.57</td><td>Inositol Phosphate Metabolism</td><td>SMPDB pathways</td><td>SMP00462</td><td>14</td><td>1</td><td>992</td><td>2</td><td>
INPP4B</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>GSE36888 UNTREATED VS IL2 TREATED STAT5 AB KNOCKIN TCELL 2H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>GSE9988 ANTI TREM1 VS LOW LPS MONOCYTE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>GSE13411 IGM VS SWITCHED MEMORY BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, RBPMS</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>GSE3982 MAST CELL VS BASOPHIL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, PCDH1</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>GSE22611 NOD2 TRANSD VS CTRL TRANSD HEK293 MDP STIM 2H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ELF3</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>ATF2 UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>FERNANDEZ BOUND BY MYC</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, PI3</td></tr><tr><td>2.813e-02</td><td>-3.57</td><td>GSE22886 NAIVE TCELL VS NEUTROPHIL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>178</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGFA</td></tr><tr><td>2.831e-02</td><td>-3.56</td><td>kidney-carcinoma-papillary renal cell carcinoma</td><td>COSMIC cancer mutations</td><td>kidney-carcinoma-papillary_renal_cell_carcinoma</td><td>6598</td><td>15</td><td>17630</td><td>26</td><td>
DST, GPR37, CEACAM6, PCDH1, TNFAIP6, TGFA, GPR87, INPP4B, ATP1B1, CEACAM5, MAGEA6, ANO1, PI3, THBS1, ELF3</td></tr><tr><td>2.831e-02</td><td>-3.56</td><td>papillary renal cell carcinoma</td><td>COSMIC cancer mutations</td><td>papillary_renal_cell_carcinoma</td><td>6598</td><td>15</td><td>17630</td><td>26</td><td>
DST, GPR37, CEACAM6, PCDH1, TNFAIP6, TGFA, GPR87, INPP4B, ATP1B1, CEACAM5, MAGEA6, ANO1, PI3, THBS1, ELF3</td></tr><tr><td>2.843e-02</td><td>-3.56</td><td>LTE2 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>179</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, TNFRSF11B</td></tr><tr><td>2.843e-02</td><td>-3.56</td><td>GSE22886 TH1 VS TH2 12H ACT DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>179</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, INPP4B</td></tr><tr><td>2.843e-02</td><td>-3.56</td><td>GSE3982 MEMORY CD4 TCELL VS BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>179</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, INPP4B</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>CDC42BPA (CDC42 binding protein kinase alpha)</td><td>protein interactions</td><td>8476</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>COLGALT1 (collagen beta(1-O)galactosyltransferase 1)</td><td>protein interactions</td><td>79709</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>IQUB (IQ motif and ubiquitin domain containing)</td><td>protein interactions</td><td>154865</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>COL7A1 (collagen type VII alpha 1 chain)</td><td>protein interactions</td><td>1294</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>DBI (diazepam binding inhibitor, acyl-CoA binding protein)</td><td>protein interactions</td><td>1622</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
PCDH1</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>TMEM126A (transmembrane protein 126A)</td><td>protein interactions</td><td>84233</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>S100A14 (S100 calcium binding protein A14)</td><td>protein interactions</td><td>57402</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>CD36 (CD36 molecule)</td><td>protein interactions</td><td>948</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>VWF (von Willebrand factor)</td><td>protein interactions</td><td>7450</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
TNFRSF11B</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>CD209 (CD209 molecule)</td><td>protein interactions</td><td>30835</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
CEACAM5</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>ZBTB32 (zinc finger and BTB domain containing 32)</td><td>protein interactions</td><td>27033</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>2.871e-02</td><td>-3.55</td><td>SCARB2 (scavenger receptor class B member 2)</td><td>protein interactions</td><td>950</td><td>19</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>2.872e-02</td><td>-3.55</td><td>GSE37605 FOXP3 FUSION GFP VS IRES GFP TREG C57BL6 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>2</td><td>17621</td><td>26</td><td>
DST, THBS1</td></tr><tr><td>2.872e-02</td><td>-3.55</td><td>GSE13411 PLASMA CELL VS MEMORY BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, IGFBP6</td></tr><tr><td>2.872e-02</td><td>-3.55</td><td>GSE20715 WT VS TLR4 KO 6H OZONE LUNG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6</td></tr><tr><td>2.872e-02</td><td>-3.55</td><td>GSE30971 WBP7 HET VS KO MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>180</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGFA</td></tr><tr><td>2.879e-02</td><td>-3.55</td><td>TGAATGT,MIR-181A,MIR-181B,MIR-181C,MIR-181D</td><td>MSigDB lists</td><td>&nbsp;</td><td>456</td><td>3</td><td>17621</td><td>26</td><td>
TNFRSF11B, ATP1B1, ANO1</td></tr><tr><td>2.882e-02</td><td>-3.55</td><td>Proximal tubule bicarbonate reclamation</td><td>KEGG pathways</td><td>ko04964</td><td>23</td><td>1</td><td>7094</td><td>9</td><td>
ATP1B1</td></tr><tr><td>2.882e-02</td><td>-3.55</td><td>Proximal tubule bicarbonate reclamation</td><td>KEGG pathways</td><td>hsa04964</td><td>23</td><td>1</td><td>7094</td><td>9</td><td>
ATP1B1</td></tr><tr><td>2.899e-02</td><td>-3.54</td><td>protein C-terminus binding</td><td>molecular function</td><td>GO:0008022</td><td>171</td><td>2</td><td>16652</td><td>26</td><td>
DST, ATP1B1</td></tr><tr><td>2.900e-02</td><td>-3.54</td><td>chronic lymphocytic leukaemia-small lymphocytic lymphoma</td><td>COSMIC cancer mutations</td><td>chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</td><td>3650</td><td>10</td><td>17630</td><td>26</td><td>
DST, PCDH1, IGFBP6, SCG5, GPR87, INPP4B, TGM2, CEACAM5, ANO1, IGFBP3</td></tr><tr><td>2.900e-02</td><td>-3.54</td><td>haematopoietic and lymphoid tissue-lymphoid neoplasm-chronic lymphocytic leukaemia-small lymphocytic lymphoma</td><td>COSMIC cancer mutations</td><td>haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma</td><td>3650</td><td>10</td><td>17630</td><td>26</td><td>
DST, PCDH1, IGFBP6, SCG5, GPR87, INPP4B, TGM2, CEACAM5, ANO1, IGFBP3</td></tr><tr><td>2.902e-02</td><td>-3.54</td><td>PIGF UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>181</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, IGFBP6</td></tr><tr><td>2.902e-02</td><td>-3.54</td><td>GSE3982 EOSINOPHIL VS TH2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>181</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, IGFBP3</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>GO G PROTEIN COUPLED PURINERGIC RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>GO ENDOPLASMIC RETICULUM CALCIUM ION HOMEOSTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>MCCABE HOXC6 TARGETS CANCER DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>GO RELAXATION OF MUSCLE</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>DAVICIONI PAX FOXO1 SIGNATURE IN ARMS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>GO ALKALI METAL ION BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>NIELSEN GIST AND SYNOVIAL SARCOMA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>SUZUKI RESPONSE TO TSA AND DECITABINE 1B</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>GO INOSITOL PHOSPHATE PHOSPHATASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>SINGH KRAS DEPENDENCY SIGNATURE </td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>GO SENSORY PERCEPTION OF TEMPERATURE STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>2.912e-02</td><td>-3.54</td><td>AMIT EGF RESPONSE 240 MCF10A</td><td>MSigDB lists</td><td>&nbsp;</td><td>20</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>2.927e-02</td><td>-3.53</td><td>glycolipid binding</td><td>molecular function</td><td>GO:0051861</td><td>19</td><td>1</td><td>16652</td><td>26</td><td>
CEACAM5</td></tr><tr><td>2.927e-02</td><td>-3.53</td><td>MHC protein complex binding</td><td>molecular function</td><td>GO:0023023</td><td>19</td><td>1</td><td>16652</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.927e-02</td><td>-3.53</td><td>inositol phosphate phosphatase activity</td><td>molecular function</td><td>GO:0052745</td><td>19</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>2.927e-02</td><td>-3.53</td><td>poly-purine tract binding</td><td>molecular function</td><td>GO:0070717</td><td>19</td><td>1</td><td>16652</td><td>26</td><td>
RBPMS</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>endopeptidase regulator activity</td><td>molecular function</td><td>GO:0061135</td><td>172</td><td>2</td><td>16652</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE30971 WBP7 HET VS KO MACROPHAGE 2H LPS STIM DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGFA</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE25087 FETAL VS ADULT TCONV UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, CXCL3</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>E2F1 UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGM2</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE3982 MEMORY CD4 TCELL VS TH1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, INPP4B</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE46606 IRF4 KO VS WT CD40L IL2 IL5 3DAY STIMULATED BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, TGFA</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE360 L MAJOR VS B MALAYI HIGH DOSE MAC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE8515 IL1 VS IL6 4H STIM MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.931e-02</td><td>-3.53</td><td>GSE1432 CTRL VS IFNG 1H MICROGLIA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>182</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.935e-02</td><td>-3.53</td><td>phagocytosis</td><td>biological process</td><td>GO:0006909</td><td>171</td><td>2</td><td>16543</td><td>26</td><td>
TGM2, THBS1</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>regulation of tumor necrosis factor biosynthetic process</td><td>biological process</td><td>GO:0042534</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>membrane repolarization</td><td>biological process</td><td>GO:0086009</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>positive regulation of myoblast differentiation</td><td>biological process</td><td>GO:0045663</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>negative regulation of tissue remodeling</td><td>biological process</td><td>GO:0034104</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>positive regulation of sodium ion transmembrane transport</td><td>biological process</td><td>GO:1902307</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>negative regulation of smooth muscle cell migration</td><td>biological process</td><td>GO:0014912</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
IGFBP3</td></tr><tr><td>2.946e-02</td><td>-3.52</td><td>negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway</td><td>biological process</td><td>GO:1902236</td><td>19</td><td>1</td><td>16543</td><td>26</td><td>
MAGEA3</td></tr><tr><td>2.951e-02</td><td>-3.52</td><td>EGF-like CS</td><td>interpro domains</td><td>IPR013032</td><td>191</td><td>2</td><td>18428</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>2.960e-02</td><td>-3.52</td><td>GO REGULATION OF PROTEIN MODIFICATION PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>1645</td><td>6</td><td>17621</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE26351 WNT VS BMP PATHWAY STIM HEMATOPOIETIC PROGENITORS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, TGM2</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE42021 CD24INT VS CD24LOW TREG THYMUS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE19198 1H VS 24H IL21 TREATED TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, ATP1B1</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE26290 CTRL VS AKT INHIBITOR TREATED ANTI CD3 AND IL2 STIM CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE3982 EFF MEMORY CD4 TCELL VS TH2 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
PI3, ELF3</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE13484 12H VS 3H YF17D VACCINE STIM PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>ESC J1 UP LATE.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
PCDH1, KRT7</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>HAMAI APOPTOSIS VIA TRAIL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE22611 MUTANT NOD2 TRANSDUCED VS CTRL HEK293T STIMULATED WITH MDP 6H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ELF3</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GSE14308 TH1 VS NAIVE CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, ANO1</td></tr><tr><td>2.961e-02</td><td>-3.52</td><td>GO PROTEIN C TERMINUS BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>183</td><td>2</td><td>17621</td><td>26</td><td>
DST, ATP1B1</td></tr><tr><td>2.988e-02</td><td>-3.51</td><td>LINKMODULE</td><td>prints domains</td><td>PR01265</td><td>11</td><td>1</td><td>4725</td><td>13</td><td>
TNFAIP6</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE8515 CTRL VS IL1 4H STIM MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE12845 IGD NEG BLOOD VS DARKZONE GC TONSIL BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE17721 LPS VS GARDIQUIMOD 24H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, CXCL3</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>P53 DN.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, IGFBP6</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE40273 EOS KO VS WT TREG UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE27786 BCELL VS CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, SCG5</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE3982 DC VS NEUTROPHIL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, PI3</td></tr><tr><td>2.991e-02</td><td>-3.51</td><td>GSE3039 ALPHAALPHA VS ALPHABETA CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>184</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, CXCL3</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>LACRT (lacritin)</td><td>protein interactions</td><td>90070</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>PACRG (PARK2 coregulated)</td><td>protein interactions</td><td>135138</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
GPR37</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>SERPINF2 (serpin family F member 2)</td><td>protein interactions</td><td>5345</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>SNX4 (sorting nexin 4)</td><td>protein interactions</td><td>8723</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>ARID5A (AT-rich interaction domain 5A)</td><td>protein interactions</td><td>10865</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>COL4A3BP (collagen type IV alpha 3 binding protein)</td><td>protein interactions</td><td>10087</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>CRIP2 (cysteine rich protein 2)</td><td>protein interactions</td><td>1397</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>SH3BP5 (SH3 domain binding protein 5)</td><td>protein interactions</td><td>9467</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>3.019e-02</td><td>-3.50</td><td>ADAM17 (ADAM metallopeptidase domain 17)</td><td>protein interactions</td><td>6868</td><td>20</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE13306 TREG RA VS TCONV RA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, TGFA</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE5542 UNTREATED VS IFNA AND IFNG TREATED EPITHELIAL CELLS 6H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
ELF3, THBS1</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE19401 UNSTIM VS RETINOIC ACID STIM FOLLICULAR DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, THBS1</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE25088 ROSIGLITAZONE VS IL4 AND ROSIGLITAZONE STIM STAT6 KO MACROPHAGE DAY10 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGM2</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE17721 CPG VS GARDIQUIMOD 16H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ANO1</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE2585 CTEC VS THYMIC MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ELF3</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE13484 UNSTIM VS 3H YF17D VACCINE STIM PBMC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE19374 UNINF VS LISTERIA INFECTED MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, RBPMS</td></tr><tr><td>3.021e-02</td><td>-3.50</td><td>GSE46242 TH1 VS ANERGIC TH1 CD4 TCELL WITH EGR2 DELETED UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>185</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, TGFA</td></tr><tr><td>3.026e-02</td><td>-3.50</td><td>peptidase inhibitor activity</td><td>molecular function</td><td>GO:0030414</td><td>175</td><td>2</td><td>16652</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>3.030e-02</td><td>-3.50</td><td>GO MOVEMENT OF CELL OR SUBCELLULAR COMPONENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>1216</td><td>5</td><td>17621</td><td>26</td><td>
DST, CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE7831 UNSTIM VS INFLUENZA STIM PDC 4H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE360 L MAJOR VS T GONDII MAC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TFF2</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE21670 TGFB VS IL6 TREATED CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, TNFAIP6</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE8921 UNSTIM VS TLR1 2 STIM MONOCYTE 12H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
INPP4B, THBS1</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE23502 WT VS HDC KO MYELOID DERIVED SUPPRESSOR CELL COLON TUMOR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGM2</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE9037 CTRL VS LPS 1H STIM BMDM DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGM2</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE1460 DP THYMOCYTE VS NAIVE CD4 TCELL CORD BLOOD DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, INPP4B</td></tr><tr><td>3.051e-02</td><td>-3.49</td><td>GSE1460 NAIVE CD4 TCELL ADULT BLOOD VS THYMIC STROMAL CELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>186</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, THBS1</td></tr><tr><td>3.052e-02</td><td>-3.49</td><td>negative regulation of biological process</td><td>biological process</td><td>GO:0048519</td><td>4518</td><td>12</td><td>16543</td><td>26</td><td>
GPR37, TNFAIP6, IGFBP6, GPR87, MAGEA3, SLPI, TNFRSF11B, CEACAM5, PI3, ELF3, THBS1, IGFBP3</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>WILLERT WNT SIGNALING</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>WANG NEOPLASTIC TRANSFORMATION BY CCND1 MYC</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>VALK AML WITH EVI1</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>GO MICROTUBULE END</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>GO HYALURONIC ACID BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>chr2q23</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>BIOCARTA P53HYPOXIA PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>GO NUCLEOTIDE RECEPTOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>FERRARI RESPONSE TO FENRETINIDE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.055e-02</td><td>-3.49</td><td>GO TRANSFERASE ACTIVITY TRANSFERRING AMINO ACYL GROUPS</td><td>MSigDB lists</td><td>&nbsp;</td><td>21</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE360 DC VS MAC M TUBERCULOSIS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, RBPMS</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE27786 LSK VS NKTCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, TGFA</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE360 T GONDII VS M TUBERCULOSIS MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, INPP4B</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>PEREZ TP53 AND TP63 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, IGFBP3</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE14308 TH1 VS INDUCED TREG UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, IGFBP6</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE2585 CD80 HIGH VS LOW AIRE KO MTEC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, CXCL3</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE22886 IL2 VS IL15 STIM NKCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, THBS1</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE17721 CTRL VS GARDIQUIMOD 24H BMDC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>ALONSO METASTASIS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE17721 POLYIC VS CPG 2H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, TGM2</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE5542 IFNA VS IFNA AND IFNG TREATED EPITHELIAL CELLS 6H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, SLPI</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE13522 WT VS IFNAR KO SKIN UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE36826 WT VS IL1R KO SKIN STAPH AUREUS INF DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TGM2</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>KAECH DAY8 EFF VS DAY15 EFF CD8 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, SCG5</td></tr><tr><td>3.081e-02</td><td>-3.48</td><td>GSE24634 TEFF VS TCONV DAY7 IN CULTURE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>187</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6</td></tr><tr><td>3.092e-02</td><td>-3.48</td><td>TNFR c6</td><td>pfam domains</td><td>PF00020</td><td>22</td><td>1</td><td>16832</td><td>24</td><td>
TNFRSF11B</td></tr><tr><td>3.099e-02</td><td>-3.47</td><td>sensory perception of temperature stimulus</td><td>biological process</td><td>GO:0050951</td><td>20</td><td>1</td><td>16543</td><td>26</td><td>
ANO1</td></tr><tr><td>3.099e-02</td><td>-3.47</td><td>negative regulation of cell junction assembly</td><td>biological process</td><td>GO:1901889</td><td>20</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.099e-02</td><td>-3.47</td><td>phagocytosis, engulfment</td><td>biological process</td><td>GO:0006911</td><td>20</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.099e-02</td><td>-3.47</td><td>G-protein coupled purinergic receptor signaling pathway</td><td>biological process</td><td>GO:0035588</td><td>20</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>3.099e-02</td><td>-3.47</td><td>cellular sodium ion homeostasis</td><td>biological process</td><td>GO:0006883</td><td>20</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.099e-02</td><td>-3.47</td><td>relaxation of muscle</td><td>biological process</td><td>GO:0090075</td><td>20</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE41176 UNSTIM VS ANTI IGM STIM BCELL 1H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE17721 LPS VS CPG 12H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE42088 UNINF VS LEISHMANIA INF DC 8H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, PI3</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE41176 WT VS TAK1 KO UNSTIM BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, TFF2</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE17580 UNINFECTED VS S MANSONI INF TREG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE5099 UNSTIM VS MCSF TREATED MONOCYTE DAY7 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TFF2</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE42021 CD24HI VS CD24LOW TCONV THYMUS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, IGFBP3</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE17721 0.5H VS 4H GARDIQUIMOD BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, TGM2</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE2826 WT VS BTK KO BCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, THBS1</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE9006 HEALTHY VS TYPE 2 DIABETES PBMC AT DX DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE21063 3H VS 16H ANTI IGM STIM NFATC1 KOBCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
ELF3, THBS1</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE15659 NAIVE VS PTPRC NEG CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, RBPMS</td></tr><tr><td>3.111e-02</td><td>-3.47</td><td>GSE14350 IL2RB KO VS WT TREG UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>188</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, SCG5</td></tr><tr><td>3.125e-02</td><td>-3.47</td><td>human chr8p12</td><td>chromosome location</td><td>human chr8p12</td><td>32</td><td>1</td><td>26234</td><td>26</td><td>
RBPMS</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE15659 NAIVE CD4 TCELL VS NONSUPPRESSIVE TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, RBPMS</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE3982 NEUTROPHIL VS NKCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CEACAM5</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE22196 HEALTHY VS OBESE MOUSE SKIN GAMMADELTA TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, TGM2</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE11961 FOLLICULAR BCELL VS MEMORY BCELL DAY40 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, THBS1</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE3039 NKT CELL VS B2 BCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE17721 CPG VS GARDIQUIMOD 4H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, CXCL3</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE19825 NAIVE VS DAY3 EFF CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ANO1</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE2826 WT VS XID BCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE15659 NAIVE CD4 TCELL VS ACTIVATED TREG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, RBPMS</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE22140 GERMFREE VS SPF MOUSE CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE40184 HEALTHY VS HCV INFECTED DONOR PBMC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, IGFBP6</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE4748 CTRL VS CYANOBACTERIUM LPSLIKE STIM DC 1H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, PCDH1</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE14308 TH1 VS TH17 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, IGFBP6</td></tr><tr><td>3.142e-02</td><td>-3.46</td><td>GSE23502 WT VS HDC KO MYELOID DERIVED SUPPRESSOR CELL BM DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>189</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.165e-02</td><td>-3.45</td><td>positive regulation of biological process</td><td>biological process</td><td>GO:0048518</td><td>5099</td><td>13</td><td>16543</td><td>26</td><td>
GPR37, CEACAM6, TNFAIP6, CXCL3, TGFA, TNFRSF11B, ATP1B1, TGM2, RBPMS, ANO1, IGFBP3, ELF3, THBS1</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>TINAGL1 (tubulointerstitial nephritis antigen like 1)</td><td>protein interactions</td><td>64129</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>SIPA1L2 (signal induced proliferation associated 1 like 2)</td><td>protein interactions</td><td>57568</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>CD47 (CD47 molecule)</td><td>protein interactions</td><td>961</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>MGAT5B (mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B)</td><td>protein interactions</td><td>146664</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>SRGAP3 (SLIT-ROBO Rho GTPase activating protein 3)</td><td>protein interactions</td><td>9901</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>ENOPH1 (enolase-phosphatase 1)</td><td>protein interactions</td><td>58478</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>ROR2 (receptor tyrosine kinase like orphan receptor 2)</td><td>protein interactions</td><td>4920</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.168e-02</td><td>-3.45</td><td>BNIP3 (BCL2 interacting protein 3)</td><td>protein interactions</td><td>664</td><td>21</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>CAMP UP.V1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
DST, SCG5</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE1432 6H VS 24H IFNG MICROGLIA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, TGFA</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE17721 CTRL VS CPG 2H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, ELF3</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE19198 CTRL VS IL21 TREATED TCELL 24H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP3</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE22025 TGFB1 VS TGFB1 AND PROGESTERONE TREATED CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, ATP1B1</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE13411 NAIVE VS MEMORY BCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, IGFBP3</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE2770 UNTREATED VS IL4 TREATED ACT CD4 TCELL 6H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, IGFBP6</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE360 T GONDII VS B MALAYI HIGH DOSE MAC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, INPP4B</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE5589 WT VS IL6 KO LPS AND IL6 STIM MACROPHAGE 45MIN DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
PCDH1, IGFBP6</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE360 L DONOVANI VS B MALAYI LOW DOSE DC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, PI3</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE2405 0H VS 3H A PHAGOCYTOPHILUM STIM NEUTROPHIL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, IGFBP3</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE20715 0H VS 6H OZONE TLR4 KO LUNG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, TGFA</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE17721 CTRL VS POLYIC 24H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, TGFA</td></tr><tr><td>3.172e-02</td><td>-3.45</td><td>GSE22103 UNSTIM VS LPS STIM NEUTROPHIL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>190</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, CXCL3</td></tr><tr><td>3.197e-02</td><td>-3.44</td><td>ERBB2 (erb-b2 receptor tyrosine kinase 2)</td><td>protein interactions</td><td>2064</td><td>184</td><td>2</td><td>16330</td><td>25</td><td>
TGFA, ELF3</td></tr><tr><td>3.197e-02</td><td>-3.44</td><td>UBQLN4 (ubiquilin 4)</td><td>protein interactions</td><td>56893</td><td>184</td><td>2</td><td>16330</td><td>25</td><td>
IGFBP6, SCG5</td></tr><tr><td>3.197e-02</td><td>-3.44</td><td>Spectrin repeat</td><td>interpro domains</td><td>IPR002017</td><td>23</td><td>1</td><td>18428</td><td>26</td><td>
DST</td></tr><tr><td>3.197e-02</td><td>-3.44</td><td>Actinin actin-bd CS</td><td>interpro domains</td><td>IPR001589</td><td>23</td><td>1</td><td>18428</td><td>26</td><td>
DST</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GO REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>VIETOR IFRD1 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GO PURINERGIC NUCLEOTIDE RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>LU TUMOR ENDOTHELIAL MARKERS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>HERNANDEZ ABERRANT MITOSIS BY DOCETACEL 4NM UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GO POSITIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GO FUCOSYLATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>BREUHAHN GROWTH FACTOR SIGNALING IN LIVER CANCER</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GO POSITIVE REGULATION OF MYOBLAST DIFFERENTIATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>MISHRA CARCINOMA ASSOCIATED FIBROBLAST DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>NEWMAN ERCC6 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GO INTRINSIC COMPONENT OF EXTERNAL SIDE OF PLASMA MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM5</td></tr><tr><td>3.198e-02</td><td>-3.44</td><td>GRAHAM CML QUIESCENT VS CML DIVIDING UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>22</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE29618 BCELL VS MDC DAY7 FLU VACCINE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
DST, ATP1B1</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE22443 NAIVE VS ACT AND IL2 TREATED CD8 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, ELF3</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE24634 IL4 VS CTRL TREATED NAIVE CD4 TCELL DAY3 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, TGFA</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE29949 MICROGLIA BRAIN VS CD8 POS DC SPLEEN DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, PCDH1</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>ZWANG EGF INTERVAL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ELF3</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE15930 STIM VS STIM AND TRICHOSTATINA 24H CD8 T CELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
GPR37, IGFBP6</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE42021 CD24HI VS CD24INT TREG THYMUS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, IGFBP3</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE45365 HEALTHY VS MCMV INFECTION CD8A DC IFNAR KO DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE43955 10H VS 30H ACT CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, CXCL3</td></tr><tr><td>3.203e-02</td><td>-3.44</td><td>GSE3039 B2 VS B1 BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>191</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, INPP4B</td></tr><tr><td>3.230e-02</td><td>-3.43</td><td>purinergic nucleotide receptor activity</td><td>molecular function</td><td>GO:0001614</td><td>21</td><td>1</td><td>16652</td><td>26</td><td>
GPR87</td></tr><tr><td>3.230e-02</td><td>-3.43</td><td>nucleotide receptor activity</td><td>molecular function</td><td>GO:0016502</td><td>21</td><td>1</td><td>16652</td><td>26</td><td>
GPR87</td></tr><tr><td>3.231e-02</td><td>-3.43</td><td>Spectrin</td><td>pfam domains</td><td>PF00435</td><td>23</td><td>1</td><td>16832</td><td>24</td><td>
DST</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>GSE41978 ID2 KO AND BIM KO VS BIM KO KLRG1 LOW EFFECTOR CD8 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, IGFBP3</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>WANG CISPLATIN RESPONSE AND XPC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, THBS1</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>GSE3982 CTRL VS LPS 48H DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, IGFBP3</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>GSE3982 MAC VS BCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
DST, SCG5</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>GSE22501 PERIPHERAL BLOOD VS CORD BLOOD TREG UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, CXCL3</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>GSE17721 CTRL VS LPS 6H BMDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGFA</td></tr><tr><td>3.234e-02</td><td>-3.43</td><td>GSE13484 12H UNSTIM VS YF17D VACCINE STIM PBMC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>192</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, TGFA</td></tr><tr><td>3.248e-02</td><td>-3.43</td><td>cell migration</td><td>biological process</td><td>GO:0016477</td><td>783</td><td>4</td><td>16543</td><td>26</td><td>
CEACAM6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>3.251e-02</td><td>-3.43</td><td>mitochondrial calcium ion homeostasis</td><td>biological process</td><td>GO:0051560</td><td>21</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>3.251e-02</td><td>-3.43</td><td>endoplasmic reticulum calcium ion homeostasis</td><td>biological process</td><td>GO:0032469</td><td>21</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>3.262e-02</td><td>-3.42</td><td>ovary-carcinoma-adenocarcinoma</td><td>COSMIC cancer mutations</td><td>ovary-carcinoma-adenocarcinoma</td><td>193</td><td>2</td><td>17630</td><td>26</td><td>
TNFAIP6, GPR87</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE19198 CTRL VS IL21 TREATED TCELL 24H UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE14769 UNSTIM VS 240MIN LPS BMDM DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE29618 BCELL VS MDC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
DST, ATP1B1</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE7509 DC VS MONOCYTE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CXCL3</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE20715 0H VS 24H OZONE TLR4 KO LUNG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
ELF3, THBS1</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE17721 CPG VS GARDIQUIMOD 12H BMDC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
PCDH1, TGM2</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE22140 HEALTHY VS ARTHRITIC GERMFREE MOUSE CD4 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>HALLMARK APICAL JUNCTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, PCDH1</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE33374 CD8 ALPHAALPHA VS ALPHABETA CD161 HIGH TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, IGFBP6</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE19941 LPS VS LPS AND IL10 STIM IL10 KO NFKBP50 KO MACROPHAGE DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, INPP4B</td></tr><tr><td>3.265e-02</td><td>-3.42</td><td>GSE23321 CENTRAL VS EFFECTOR MEMORY CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>193</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TGM2</td></tr><tr><td>3.291e-02</td><td>-3.41</td><td>regulation of chemotaxis</td><td>biological process</td><td>GO:0050920</td><td>182</td><td>2</td><td>16543</td><td>26</td><td>
CXCL3, THBS1</td></tr><tr><td>3.296e-02</td><td>-3.41</td><td>GSE15930 NAIVE VS 72H IN VITRO STIM CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>194</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>3.296e-02</td><td>-3.41</td><td>GSE43955 TH0 VS TGFB IL6 TH17 ACT CD4 TCELL 52H DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>194</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, KRT7</td></tr><tr><td>3.296e-02</td><td>-3.41</td><td>GSE17580 TREG VS TEFF S MANSONI INF UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>194</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.311e-02</td><td>-3.41</td><td>GO RESPONSE TO BIOTIC STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>839</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, TNFRSF11B, ATP1B1, CXCL3</td></tr><tr><td>3.316e-02</td><td>-3.41</td><td>intermediate filament</td><td>cellular component</td><td>GO:0005882</td><td>196</td><td>2</td><td>17744</td><td>26</td><td>
DST, KRT7</td></tr><tr><td>3.317e-02</td><td>-3.41</td><td>HEYL (hes related family bHLH transcription factor with YRPW motif-like)</td><td>protein interactions</td><td>26508</td><td>22</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.317e-02</td><td>-3.41</td><td>PDGFB (platelet derived growth factor subunit B)</td><td>protein interactions</td><td>5155</td><td>22</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>3.317e-02</td><td>-3.41</td><td>RAD54L2 (RAD54-like 2 (S. cerevisiae))</td><td>protein interactions</td><td>23132</td><td>22</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.317e-02</td><td>-3.41</td><td>PGLS (6-phosphogluconolactonase)</td><td>protein interactions</td><td>25796</td><td>22</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.318e-02</td><td>-3.41</td><td>ATPase dependent transmembrane transport complex</td><td>cellular component</td><td>GO:0098533</td><td>23</td><td>1</td><td>17744</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.318e-02</td><td>-3.41</td><td>ATPase complex</td><td>cellular component</td><td>GO:1904949</td><td>23</td><td>1</td><td>17744</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.318e-02</td><td>-3.41</td><td>microtubule end</td><td>cellular component</td><td>GO:1990752</td><td>23</td><td>1</td><td>17744</td><td>26</td><td>
DST</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>FOSTER KDM1A TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, KRT7</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE43957 UNTREATED VS NACL TREATED ANTI CD3 CD28 STIM CD4 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, ELF3</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>HALLMARK HYPOXIA</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, IGFBP3</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE20715 0H VS 48H OZONE TLR4 KO LUNG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
ELF3, THBS1</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE11961 GERMINAL CENTER BCELL DAY7 VS PLASMA CELL DAY7 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CXCL3</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE39152 SPLEEN CD103 NEG VS BRAIN CD103 POS MEMORY CD8 TCELL DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, ATP1B1</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE42021 TREG PLN VS CD24HI TREG THYMUS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
CXCL3, ELF3</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE360 CTRL VS L MAJOR DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TNFAIP6</td></tr><tr><td>3.327e-02</td><td>-3.40</td><td>GSE17721 LPS VS CPG 4H BMDC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>195</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1</td></tr><tr><td>3.334e-02</td><td>-3.40</td><td>Prefoldin</td><td>interpro domains</td><td>IPR009053</td><td>24</td><td>1</td><td>18428</td><td>26</td><td>
KRT7</td></tr><tr><td>3.335e-02</td><td>-3.40</td><td>CREIGHTON ENDOCRINE THERAPY RESISTANCE 1</td><td>MSigDB lists</td><td>&nbsp;</td><td>483</td><td>3</td><td>17621</td><td>26</td><td>
DST, RBPMS, INPP4B</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>KEGG PROXIMAL TUBULE BICARBONATE RECLAMATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>GO REGULATION OF ANTIGEN PROCESSING AND PRESENTATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>GO FIBROBLAST GROWTH FACTOR BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>GO REGULATION OF CARDIAC MUSCLE CONTRACTION BY CALCIUM ION SIGNALING</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>GO NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>JEON SMAD6 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>AZARE STAT3 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>OSADA ASCL1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>3.341e-02</td><td>-3.40</td><td>CAIRO PML TARGETS BOUND BY MYC UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>23</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.358e-02</td><td>-3.39</td><td>GSE20715 0H VS 24H OZONE LUNG DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>196</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, ELF3</td></tr><tr><td>3.358e-02</td><td>-3.39</td><td>GO GLYCOSAMINOGLYCAN BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>196</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>3.358e-02</td><td>-3.39</td><td>GSE29949 MICROGLIA VS DC BRAIN UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>196</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, ATP1B1</td></tr><tr><td>3.358e-02</td><td>-3.39</td><td>GSE19401 PLN VS PEYERS PATCH FOLLICULAR DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>196</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, CXCL3</td></tr><tr><td>3.358e-02</td><td>-3.39</td><td>GO INTERMEDIATE FILAMENT CYTOSKELETON</td><td>MSigDB lists</td><td>&nbsp;</td><td>196</td><td>2</td><td>17621</td><td>26</td><td>
DST, KRT7</td></tr><tr><td>3.358e-02</td><td>-3.39</td><td>GSE39152 CD103 NEG VS POS MEMORY CD8 TCELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>196</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, TFF2</td></tr><tr><td>3.381e-02</td><td>-3.39</td><td>hyaluronic acid binding</td><td>molecular function</td><td>GO:0005540</td><td>22</td><td>1</td><td>16652</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>3.390e-02</td><td>-3.38</td><td>GSE360 DC VS MAC M TUBERCULOSIS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>197</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, CXCL3</td></tr><tr><td>3.403e-02</td><td>-3.38</td><td>negative regulation of anion transport</td><td>biological process</td><td>GO:1903792</td><td>22</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.403e-02</td><td>-3.38</td><td>regulation of cardiac muscle contraction by calcium ion signaling</td><td>biological process</td><td>GO:0010882</td><td>22</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.403e-02</td><td>-3.38</td><td>regulation of antigen processing and presentation</td><td>biological process</td><td>GO:0002577</td><td>22</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.403e-02</td><td>-3.38</td><td>purinergic nucleotide receptor signaling pathway</td><td>biological process</td><td>GO:0035590</td><td>22</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>3.403e-02</td><td>-3.38</td><td>positive regulation of neutrophil chemotaxis</td><td>biological process</td><td>GO:0090023</td><td>22</td><td>1</td><td>16543</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.415e-02</td><td>-3.38</td><td>Syndecan interactions</td><td>REACTOME pathways</td><td>R-HSA-3000170</td><td>21</td><td>1</td><td>10293</td><td>17</td><td>
THBS1</td></tr><tr><td>3.421e-02</td><td>-3.38</td><td>GSE24634 TREG VS TCONV POST DAY7 IL4 CONVERSION DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>198</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, IGFBP6</td></tr><tr><td>3.421e-02</td><td>-3.38</td><td>HALLMARK TNFA SIGNALING VIA NFKB</td><td>MSigDB lists</td><td>&nbsp;</td><td>198</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>3.421e-02</td><td>-3.38</td><td>GSE27859 CD11C INT F480 HI MACROPHAGE VS CD11C ING F480 INT DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>198</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, SCG5</td></tr><tr><td>3.453e-02</td><td>-3.37</td><td>GSE360 CTRL VS M TUBERCULOSIS DC DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>199</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, CEACAM5</td></tr><tr><td>3.457e-02</td><td>-3.36</td><td>cytokine-mediated signaling pathway</td><td>biological process</td><td>GO:0019221</td><td>460</td><td>3</td><td>16543</td><td>26</td><td>
TNFRSF11B, TFF2, CXCL3</td></tr><tr><td>3.465e-02</td><td>-3.36</td><td>MAGI3 (membrane associated guanylate kinase, WW and PDZ domain containing 3)</td><td>protein interactions</td><td>260425</td><td>23</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>3.465e-02</td><td>-3.36</td><td>CXCR2 (C-X-C motif chemokine receptor 2)</td><td>protein interactions</td><td>3579</td><td>23</td><td>1</td><td>16330</td><td>25</td><td>
CXCL3</td></tr><tr><td>3.465e-02</td><td>-3.36</td><td>KLHL38 (kelch like family member 38)</td><td>protein interactions</td><td>340359</td><td>23</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>3.465e-02</td><td>-3.36</td><td>Mapre1 (microtubule-associated protein, RP/EB family, member 1)</td><td>protein interactions</td><td>13589</td><td>23</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>3.465e-02</td><td>-3.36</td><td>GORASP1 (golgi reassembly stacking protein 1)</td><td>protein interactions</td><td>64689</td><td>23</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>3.470e-02</td><td>-3.36</td><td>Tyr-kin ephrin A/B rcpt-like</td><td>interpro domains</td><td>IPR011641</td><td>25</td><td>1</td><td>18428</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.470e-02</td><td>-3.36</td><td>TNFR/NGFR Cys rich reg</td><td>interpro domains</td><td>IPR001368</td><td>25</td><td>1</td><td>18428</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.477e-02</td><td>-3.36</td><td>GO RESPONSE TO BACTERIUM</td><td>MSigDB lists</td><td>&nbsp;</td><td>491</td><td>3</td><td>17621</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO REGULATION OF ANOIKIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM5</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>REACTOME BASIGIN INTERACTIONS</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO PROTEIN LIPID COMPLEX BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>MURATA VIRULENCE OF H PILORI</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM6</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO ATPASE COMPLEX</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO REGULATION OF ODONTOGENESIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>IIZUKA LIVER CANCER PROGRESSION L1 G1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>PID INTEGRIN A9B1 PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO POSITIVE REGULATION OF COAGULATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>SMID BREAST CANCER RELAPSE IN PLEURA DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
SLPI</td></tr><tr><td>3.484e-02</td><td>-3.36</td><td>GO DEATH RECEPTOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>24</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.485e-02</td><td>-3.36</td><td>GO PEPTIDASE REGULATOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>200</td><td>2</td><td>17621</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>3.485e-02</td><td>-3.36</td><td>HALLMARK ESTROGEN RESPONSE EARLY</td><td>MSigDB lists</td><td>&nbsp;</td><td>200</td><td>2</td><td>17621</td><td>26</td><td>
TGM2, ELF3</td></tr><tr><td>3.486e-02</td><td>-3.36</td><td>plasma membrane</td><td>cellular component</td><td>GO:0005886</td><td>4933</td><td>12</td><td>17744</td><td>26</td><td>
DST, GPR37, CEACAM6, PCDH1, TGFA, GPR87, TNFRSF11B, CEACAM5, TGM2, ATP1B1, ANO1, THBS1</td></tr><tr><td>3.501e-02</td><td>-3.35</td><td>large cell</td><td>COSMIC cancer mutations</td><td>large_cell</td><td>15499</td><td>26</td><td>17630</td><td>26</td><td>
CEACAM6, PCDH1, TNFAIP6, IGFBP6, KRT7, TGFA, CXCL3, SLPI, ATP1B1, TFF2, ANO1, PI3, THBS1, ELF3, GPR37, DST, SCG5, MAGEA3, GPR87, INPP4B, TNFRSF11B, TGM2, CEACAM5, MAGEA6, RBPMS, IGFBP3</td></tr><tr><td>3.517e-02</td><td>-3.35</td><td>GO POSITIVE REGULATION OF MAP KINASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>201</td><td>2</td><td>17621</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>3.518e-02</td><td>-3.35</td><td>response to lipid</td><td>biological process</td><td>GO:0033993</td><td>803</td><td>4</td><td>16543</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3, THBS1</td></tr><tr><td>3.523e-02</td><td>-3.35</td><td>SMALLCYTKCXC</td><td>prints domains</td><td>PR00437</td><td>13</td><td>1</td><td>4725</td><td>13</td><td>
CXCL3</td></tr><tr><td>3.531e-02</td><td>-3.34</td><td>ENK UV RESPONSE EPIDERMIS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>494</td><td>3</td><td>17621</td><td>26</td><td>
TGFA, GPR87, IGFBP3</td></tr><tr><td>3.532e-02</td><td>-3.34</td><td>lipoprotein particle binding</td><td>molecular function</td><td>GO:0071813</td><td>23</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>3.532e-02</td><td>-3.34</td><td>protein-lipid complex binding</td><td>molecular function</td><td>GO:0071814</td><td>23</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>3.532e-02</td><td>-3.34</td><td>fibroblast growth factor binding</td><td>molecular function</td><td>GO:0017134</td><td>23</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>3.549e-02</td><td>-3.34</td><td>KIM WT1 TARGETS 12HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>202</td><td>2</td><td>17621</td><td>26</td><td>
SCG5, THBS1</td></tr><tr><td>3.555e-02</td><td>-3.34</td><td>regulation of hydrogen peroxide-induced cell death</td><td>biological process</td><td>GO:1903205</td><td>23</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>3.555e-02</td><td>-3.34</td><td>regulation of anoikis</td><td>biological process</td><td>GO:2000209</td><td>23</td><td>1</td><td>16543</td><td>26</td><td>
CEACAM5</td></tr><tr><td>3.555e-02</td><td>-3.34</td><td>negative regulation of adenylate cyclase activity</td><td>biological process</td><td>GO:0007194</td><td>23</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>3.580e-02</td><td>-3.33</td><td>GCANCTGNY V$MYOD Q6</td><td>MSigDB lists</td><td>&nbsp;</td><td>860</td><td>4</td><td>17621</td><td>26</td><td>
DST, ATP1B1, IGFBP6, IGFBP3</td></tr><tr><td>3.585e-02</td><td>-3.33</td><td>MEISSNER NPC HCP WITH H3 UNMETHYLATED</td><td>MSigDB lists</td><td>&nbsp;</td><td>497</td><td>3</td><td>17621</td><td>26</td><td>
KRT7, IGFBP6, ANO1</td></tr><tr><td>3.602e-02</td><td>-3.32</td><td>intrinsic component of external side of plasma membrane</td><td>cellular component</td><td>GO:0031233</td><td>25</td><td>1</td><td>17744</td><td>26</td><td>
CEACAM5</td></tr><tr><td>3.607e-02</td><td>-3.32</td><td>Keratin 2 head</td><td>interpro domains</td><td>IPR032444</td><td>26</td><td>1</td><td>18428</td><td>26</td><td>
KRT7</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>RHOBTB3 (Rho related BTB domain containing 3)</td><td>protein interactions</td><td>22836</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>CPT2 (carnitine palmitoyltransferase 2)</td><td>protein interactions</td><td>1376</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>LGALS9C (galectin 9C)</td><td>protein interactions</td><td>654346</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>LAMB3 (laminin subunit beta 3)</td><td>protein interactions</td><td>3914</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>FNDC11 (fibronectin type III domain containing 11)</td><td>protein interactions</td><td>79025</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>FAM103A1 (family with sequence similarity 103 member A1)</td><td>protein interactions</td><td>83640</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>COG7 (component of oligomeric golgi complex 7)</td><td>protein interactions</td><td>91949</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
KRT7</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>FNTA (farnesyltransferase, CAAX box, alpha)</td><td>protein interactions</td><td>2339</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>ZNFX1 (zinc finger NFX1-type containing 1)</td><td>protein interactions</td><td>57169</td><td>24</td><td>1</td><td>16330</td><td>25</td><td>
PCDH1</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>MCBRYAN PUBERTAL BREAST 3 4WK UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>204</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, ANO1</td></tr><tr><td>3.613e-02</td><td>-3.32</td><td>GO REGULATION OF NUCLEOTIDE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>204</td><td>2</td><td>17621</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>MODULE 307</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO REGULATION OF MACROPHAGE ACTIVATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO DOPAMINE METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>KIM HYPOXIA</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GLI1 UP.V1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>YE METASTATIC LIVER CANCER</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO PURINERGIC RECEPTOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>LU TUMOR ANGIOGENESIS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO NEGATIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM5</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>MODULE 371</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>GO REGULATION OF NEUTROPHIL CHEMOTAXIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.627e-02</td><td>-3.32</td><td>FONTAINE THYROID TUMOR UNCERTAIN MALIGNANCY DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>25</td><td>1</td><td>17621</td><td>26</td><td>
SLPI</td></tr><tr><td>3.645e-02</td><td>-3.31</td><td>Keratin 2 head</td><td>pfam domains</td><td>PF16208</td><td>26</td><td>1</td><td>16832</td><td>24</td><td>
KRT7</td></tr><tr><td>3.645e-02</td><td>-3.31</td><td>GO REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>205</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>3.645e-02</td><td>-3.31</td><td>GO EXTERNAL SIDE OF PLASMA MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>205</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM5, THBS1</td></tr><tr><td>3.645e-02</td><td>-3.31</td><td>BHAT ESR1 TARGETS NOT VIA AKT1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>205</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, TGM2</td></tr><tr><td>3.683e-02</td><td>-3.30</td><td>death receptor activity</td><td>molecular function</td><td>GO:0005035</td><td>24</td><td>1</td><td>16652</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.683e-02</td><td>-3.30</td><td>tumor necrosis factor-activated receptor activity</td><td>molecular function</td><td>GO:0005031</td><td>24</td><td>1</td><td>16652</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.683e-02</td><td>-3.30</td><td>transferase activity, transferring amino-acyl groups</td><td>molecular function</td><td>GO:0016755</td><td>24</td><td>1</td><td>16652</td><td>26</td><td>
TGM2</td></tr><tr><td>3.686e-02</td><td>-3.30</td><td>GO RESPONSE TO LIPID</td><td>MSigDB lists</td><td>&nbsp;</td><td>868</td><td>4</td><td>17621</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3, THBS1</td></tr><tr><td>3.700e-02</td><td>-3.30</td><td>human chr3q25.1</td><td>chromosome location</td><td>human chr3q25.1</td><td>38</td><td>1</td><td>26234</td><td>26</td><td>
GPR87</td></tr><tr><td>3.700e-02</td><td>-3.30</td><td>human chr15q14</td><td>chromosome location</td><td>human chr15q14</td><td>38</td><td>1</td><td>26234</td><td>26</td><td>
THBS1</td></tr><tr><td>3.707e-02</td><td>-3.29</td><td>positive regulation of blood vessel endothelial cell migration</td><td>biological process</td><td>GO:0043536</td><td>24</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.707e-02</td><td>-3.29</td><td>positive regulation of transforming growth factor beta receptor signaling pathway</td><td>biological process</td><td>GO:0030511</td><td>24</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.707e-02</td><td>-3.29</td><td>regulation of fatty acid transport</td><td>biological process</td><td>GO:2000191</td><td>24</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.707e-02</td><td>-3.29</td><td>fucosylation</td><td>biological process</td><td>GO:0036065</td><td>24</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.707e-02</td><td>-3.29</td><td>positive regulation of cellular response to transforming growth factor beta stimulus</td><td>biological process</td><td>GO:1903846</td><td>24</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.743e-02</td><td>-3.29</td><td>Keratin II</td><td>interpro domains</td><td>IPR003054</td><td>27</td><td>1</td><td>18428</td><td>26</td><td>
KRT7</td></tr><tr><td>3.761e-02</td><td>-3.28</td><td>KRTAP12-2 (keratin associated protein 12-2)</td><td>protein interactions</td><td>353323</td><td>25</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.761e-02</td><td>-3.28</td><td>PRR20A (proline rich 20A)</td><td>protein interactions</td><td>122183</td><td>25</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.761e-02</td><td>-3.28</td><td>RIOK3 (RIO kinase 3)</td><td>protein interactions</td><td>8780</td><td>25</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>3.761e-02</td><td>-3.28</td><td>ADAM10 (ADAM metallopeptidase domain 10)</td><td>protein interactions</td><td>102</td><td>25</td><td>1</td><td>16330</td><td>25</td><td>
TGFA</td></tr><tr><td>3.768e-02</td><td>-3.28</td><td>regulation of cysteine-type endopeptidase activity involved in apoptotic process</td><td>biological process</td><td>GO:0043281</td><td>196</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>3.768e-02</td><td>-3.28</td><td>GO MOLECULAR FUNCTION REGULATOR</td><td>MSigDB lists</td><td>&nbsp;</td><td>1289</td><td>5</td><td>17621</td><td>26</td><td>
SLPI, ATP1B1, SCG5, PI3, IGFBP3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>DAZARD UV RESPONSE CLUSTER G24</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
PI3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>GENTLES LEUKEMIC STEM CELL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>BOYAULT LIVER CANCER SUBCLASS G5 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>ST INTERLEUKIN 4 PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
PI3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>WANG BARRETTS ESOPHAGUS AND ESOPHAGUS CANCER UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>MODULE 298</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>GO NEGATIVE REGULATION OF LIPID TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>OLSSON E2F3 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>GO REGULATION OF FATTY ACID TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>MODULE 68</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>JI METASTASIS REPRESSED BY STK11</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
CEACAM6</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>ABRAHAM ALPC VS MULTIPLE MYELOMA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>GO POSITIVE REGULATION OF NEUTROPHIL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>WILLIAMS ESR1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.769e-02</td><td>-3.28</td><td>GO POSITIVE REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>26</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>3.770e-02</td><td>-3.28</td><td>Peptide ligand-binding receptors</td><td>REACTOME pathways</td><td>R-HSA-375276</td><td>188</td><td>2</td><td>10293</td><td>17</td><td>
GPR37, CXCL3</td></tr><tr><td>3.782e-02</td><td>-3.27</td><td>VWC</td><td>pfam domains</td><td>PF00093</td><td>27</td><td>1</td><td>16832</td><td>24</td><td>
THBS1</td></tr><tr><td>3.786e-02</td><td>-3.27</td><td>thyroid</td><td>COSMIC cancer mutations</td><td>thyroid</td><td>10258</td><td>20</td><td>17630</td><td>26</td><td>
CEACAM6, PCDH1, KRT7, TGFA, CXCL3, SLPI, ANO1, PI3, THBS1, ELF3, DST, GPR87, MAGEA3, INPP4B, TNFRSF11B, CEACAM5, TGM2, MAGEA6, RBPMS, IGFBP3</td></tr><tr><td>3.787e-02</td><td>-3.27</td><td>positive regulation of cell proliferation</td><td>biological process</td><td>GO:0008284</td><td>822</td><td>4</td><td>16543</td><td>26</td><td>
CEACAM6, TGM2, TGFA, THBS1</td></tr><tr><td>3.834e-02</td><td>-3.26</td><td>purinergic receptor activity</td><td>molecular function</td><td>GO:0035586</td><td>25</td><td>1</td><td>16652</td><td>26</td><td>
GPR87</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>positive regulation of neutrophil migration</td><td>biological process</td><td>GO:1902624</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>negative regulation of cyclase activity</td><td>biological process</td><td>GO:0031280</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>positive regulation of epithelial cell apoptotic process</td><td>biological process</td><td>GO:1904037</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>dopamine metabolic process</td><td>biological process</td><td>GO:0042417</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>negative regulation of blood vessel endothelial cell migration</td><td>biological process</td><td>GO:0043537</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>positive regulation of granulocyte chemotaxis</td><td>biological process</td><td>GO:0071624</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>positive regulation of hemostasis</td><td>biological process</td><td>GO:1900048</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>negative regulation of lipid transport</td><td>biological process</td><td>GO:0032369</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>regulation of odontogenesis</td><td>biological process</td><td>GO:0042481</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>positive regulation of blood coagulation</td><td>biological process</td><td>GO:0030194</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>regulation of epidermal growth factor-activated receptor activity</td><td>biological process</td><td>GO:0007176</td><td>25</td><td>1</td><td>16543</td><td>26</td><td>
TGFA</td></tr><tr><td>3.859e-02</td><td>-3.25</td><td>SDCBP (syndecan binding protein)</td><td>protein interactions</td><td>6386</td><td>204</td><td>2</td><td>16330</td><td>25</td><td>
GPR37, TGFA</td></tr><tr><td>3.870e-02</td><td>-3.25</td><td>regulation of protein modification process</td><td>biological process</td><td>GO:0031399</td><td>1644</td><td>6</td><td>16543</td><td>26</td><td>
GPR37, TNFRSF11B, RBPMS, TGFA, IGFBP3, THBS1</td></tr><tr><td>3.875e-02</td><td>-3.25</td><td>VERHAAK GLIOBLASTOMA MESENCHYMAL</td><td>MSigDB lists</td><td>&nbsp;</td><td>212</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, THBS1</td></tr><tr><td>3.875e-02</td><td>-3.25</td><td>V$TEF1 Q6</td><td>MSigDB lists</td><td>&nbsp;</td><td>212</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, ELF3</td></tr><tr><td>3.879e-02</td><td>-3.25</td><td>Ets dom</td><td>interpro domains</td><td>IPR000418</td><td>28</td><td>1</td><td>18428</td><td>26</td><td>
ELF3</td></tr><tr><td>3.908e-02</td><td>-3.24</td><td>GO CYTOKINE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>213</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, CXCL3</td></tr><tr><td>3.908e-02</td><td>-3.24</td><td>NR1D2 (nuclear receptor subfamily 1 group D member 2)</td><td>protein interactions</td><td>9975</td><td>26</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.908e-02</td><td>-3.24</td><td>BACE1 (beta-secretase 1)</td><td>protein interactions</td><td>23621</td><td>26</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>3.908e-02</td><td>-3.24</td><td>HEY2 (hes related family bHLH transcription factor with YRPW motif 2)</td><td>protein interactions</td><td>23493</td><td>26</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.908e-02</td><td>-3.24</td><td>BCL7B (BCL tumor suppressor 7B)</td><td>protein interactions</td><td>9275</td><td>26</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>3.908e-02</td><td>-3.24</td><td>DMRT3 (doublesex and mab-3 related transcription factor 3)</td><td>protein interactions</td><td>58524</td><td>26</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>OHM METHYLATED IN ADULT CANCERS</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>GO REGULATION OF FIBROBLAST MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>KYNG NORMAL AGING DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>PLASARI NFIC TARGETS BASAL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>CHEN LUNG CANCER SURVIVAL</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>GO NEGATIVE REGULATION OF LYASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>TIAN TNF SIGNALING VIA NFKB</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>SAKAI TUMOR INFILTRATING MONOCYTES UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>3.911e-02</td><td>-3.24</td><td>MODULE 226</td><td>MSigDB lists</td><td>&nbsp;</td><td>27</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>3.916e-02</td><td>-3.24</td><td>EGF-like dom</td><td>interpro domains</td><td>IPR000742</td><td>223</td><td>2</td><td>18428</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>3.920e-02</td><td>-3.24</td><td>Ets</td><td>pfam domains</td><td>PF00178</td><td>28</td><td>1</td><td>16832</td><td>24</td><td>
ELF3</td></tr><tr><td>3.925e-02</td><td>-3.24</td><td>external side of plasma membrane</td><td>cellular component</td><td>GO:0009897</td><td>215</td><td>2</td><td>17744</td><td>26</td><td>
CEACAM5, THBS1</td></tr><tr><td>3.975e-02</td><td>-3.23</td><td>AACTGGA,MIR-145</td><td>MSigDB lists</td><td>&nbsp;</td><td>215</td><td>2</td><td>17621</td><td>26</td><td>
TNFRSF11B, RBPMS</td></tr><tr><td>3.979e-02</td><td>-3.22</td><td>regulation of purine nucleotide metabolic process</td><td>biological process</td><td>GO:1900542</td><td>202</td><td>2</td><td>16543</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>3.984e-02</td><td>-3.22</td><td>phosphatidylinositol bisphosphate phosphatase activity</td><td>molecular function</td><td>GO:0034593</td><td>26</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>3.994e-02</td><td>-3.22</td><td>Joubert syndrome</td><td>SMPDB pathways</td><td>SMP00582</td><td>20</td><td>1</td><td>992</td><td>2</td><td>
INPP4B</td></tr><tr><td>3.994e-02</td><td>-3.22</td><td>Phosphatidylinositol Phosphate Metabolism</td><td>SMPDB pathways</td><td>SMP00463</td><td>20</td><td>1</td><td>992</td><td>2</td><td>
INPP4B</td></tr><tr><td>4.000e-02</td><td>-3.22</td><td>GO NEGATIVE REGULATION OF RESPONSE TO STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>1310</td><td>5</td><td>17621</td><td>26</td><td>
GPR37, TNFAIP6, IGFBP6, IGFBP3, THBS1</td></tr><tr><td>4.003e-02</td><td>-3.22</td><td>glycosaminoglycan binding</td><td>molecular function</td><td>GO:0005539</td><td>204</td><td>2</td><td>16652</td><td>26</td><td>
TNFAIP6, THBS1</td></tr><tr><td>4.010e-02</td><td>-3.22</td><td>positive regulation of potassium ion transmembrane transport</td><td>biological process</td><td>GO:1901381</td><td>26</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.010e-02</td><td>-3.22</td><td>positive regulation of coagulation</td><td>biological process</td><td>GO:0050820</td><td>26</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.010e-02</td><td>-3.22</td><td>regulation of transforming growth factor beta production</td><td>biological process</td><td>GO:0071634</td><td>26</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.010e-02</td><td>-3.22</td><td>regulation of fibroblast growth factor receptor signaling pathway</td><td>biological process</td><td>GO:0040036</td><td>26</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.012e-02</td><td>-3.22</td><td>response to bacterium</td><td>biological process</td><td>GO:0009617</td><td>488</td><td>3</td><td>16543</td><td>26</td><td>
SLPI, TNFRSF11B, CXCL3</td></tr><tr><td>4.015e-02</td><td>-3.22</td><td>Spectrin/alpha-actinin</td><td>interpro domains</td><td>IPR018159</td><td>29</td><td>1</td><td>18428</td><td>26</td><td>
DST</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>LOPES METHYLATED IN COLON CANCER DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>GO NEGATIVE REGULATION OF CELL MATRIX ADHESION</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>GILDEA METASTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
KRT7</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>BERENJENO TRANSFORMED BY RHOA REVERSIBLY DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>WEINMANN ADAPTATION TO HYPOXIA UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>GO CALCIUM ACTIVATED CATION CHANNEL ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
ANO1</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>GNF2 CDH3</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>MODULE 488</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>MODULE 281</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>4.053e-02</td><td>-3.21</td><td>GO PURINERGIC RECEPTOR SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>28</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>TNFSF10 (tumor necrosis factor superfamily member 10)</td><td>protein interactions</td><td>8743</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
TNFRSF11B</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>MMP3 (matrix metallopeptidase 3)</td><td>protein interactions</td><td>4314</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
IGFBP3</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>FGA (fibrinogen alpha chain)</td><td>protein interactions</td><td>2243</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>GPATCH2L (G-patch domain containing 2 like)</td><td>protein interactions</td><td>55668</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>EVPL (envoplakin)</td><td>protein interactions</td><td>2125</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
PI3</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>RTP5 (receptor transporter protein 5 (putative))</td><td>protein interactions</td><td>285093</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.055e-02</td><td>-3.21</td><td>CRBN (cereblon)</td><td>protein interactions</td><td>51185</td><td>27</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.076e-02</td><td>-3.20</td><td>MARKEY RB1 ACUTE LOF DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>218</td><td>2</td><td>17621</td><td>26</td><td>
KRT7, IGFBP3</td></tr><tr><td>4.082e-02</td><td>-3.20</td><td>human chr1q24.2</td><td>chromosome location</td><td>human chr1q24.2</td><td>42</td><td>1</td><td>26234</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.087e-02</td><td>-3.20</td><td>negative regulation of apoptotic signaling pathway</td><td>biological process</td><td>GO:2001234</td><td>205</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>4.092e-02</td><td>-3.20</td><td>cell periphery</td><td>cellular component</td><td>GO:0071944</td><td>5042</td><td>12</td><td>17744</td><td>26</td><td>
DST, GPR37, CEACAM6, PCDH1, TGFA, GPR87, TNFRSF11B, CEACAM5, ATP1B1, TGM2, ANO1, THBS1</td></tr><tr><td>4.110e-02</td><td>-3.19</td><td>SHETH LIVER CANCER VS TXNIP LOSS PAM1</td><td>MSigDB lists</td><td>&nbsp;</td><td>219</td><td>2</td><td>17621</td><td>26</td><td>
TFF2, TGM2</td></tr><tr><td>4.134e-02</td><td>-3.19</td><td>FLECHNER BIOPSY KIDNEY TRANSPLANT REJECTED VS OK DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>526</td><td>3</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, RBPMS</td></tr><tr><td>4.146e-02</td><td>-3.18</td><td>Integrated Pancreatic Cancer Pathway</td><td>WikiPathways</td><td>WP2377</td><td>197</td><td>2</td><td>5314</td><td>9</td><td>
IGFBP3, THBS1</td></tr><tr><td>4.146e-02</td><td>-3.18</td><td>EGFR (epidermal growth factor receptor)</td><td>protein interactions</td><td>1956</td><td>870</td><td>4</td><td>16330</td><td>25</td><td>
ATP1B1, KRT7, TGFA, ELF3</td></tr><tr><td>4.152e-02</td><td>-3.18</td><td>TNFR NGFR 2</td><td>prosite domains</td><td>PS50050</td><td>22</td><td>1</td><td>11955</td><td>23</td><td>
TNFRSF11B</td></tr><tr><td>4.161e-02</td><td>-3.18</td><td>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</td><td>biological process</td><td>GO:0051482</td><td>27</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>4.161e-02</td><td>-3.18</td><td>regulation of neutrophil chemotaxis</td><td>biological process</td><td>GO:0090022</td><td>27</td><td>1</td><td>16543</td><td>26</td><td>
CXCL3</td></tr><tr><td>4.161e-02</td><td>-3.18</td><td>negative regulation of lyase activity</td><td>biological process</td><td>GO:0051350</td><td>27</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>4.161e-02</td><td>-3.18</td><td>response to arsenic-containing substance</td><td>biological process</td><td>GO:0046685</td><td>27</td><td>1</td><td>16543</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>4.161e-02</td><td>-3.18</td><td>positive regulation of insulin secretion involved in cellular response to glucose stimulus</td><td>biological process</td><td>GO:0035774</td><td>27</td><td>1</td><td>16543</td><td>26</td><td>
ANO1</td></tr><tr><td>4.173e-02</td><td>-3.18</td><td>MASSARWEH TAMOXIFEN RESISTANCE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>528</td><td>3</td><td>17621</td><td>26</td><td>
CEACAM6, KRT7, INPP4B</td></tr><tr><td>4.177e-02</td><td>-3.18</td><td>human chr2p13.3</td><td>chromosome location</td><td>human chr2p13.3</td><td>43</td><td>1</td><td>26234</td><td>26</td><td>
TGFA</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>DAZARD UV RESPONSE CLUSTER G2</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GNF2 SERPINB5</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
GPR87</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO POTASSIUM ION IMPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>MODULE 500</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
TFF2</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>LU TUMOR VASCULATURE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
TNFAIP6</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO RESPONSE TO PAIN</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>chr5q32</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
PCDH1</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO PROTEOGLYCAN BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO MEMBRANE INVAGINATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>PARK TRETINOIN RESPONSE AND PML RARA FUSION</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO RESPONSE TO ARSENIC CONTAINING SUBSTANCE</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO PHOSPHATIDYLINOSITOL PHOSPHATE PHOSPHATASE ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO REGULATION OF CGMP METABOLIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>GO HSP70 PROTEIN BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>YANAGIHARA ESX1 TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>4.195e-02</td><td>-3.17</td><td>chr8p12</td><td>MSigDB lists</td><td>&nbsp;</td><td>29</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>4.196e-02</td><td>-3.17</td><td>regulation of transmembrane receptor protein serine/threonine kinase signaling pathway</td><td>biological process</td><td>GO:0090092</td><td>208</td><td>2</td><td>16543</td><td>26</td><td>
RBPMS, THBS1</td></tr><tr><td>4.203e-02</td><td>-3.17</td><td>CSTA (cystatin A)</td><td>protein interactions</td><td>1475</td><td>28</td><td>1</td><td>16330</td><td>25</td><td>
PI3</td></tr><tr><td>4.203e-02</td><td>-3.17</td><td>HP (haptoglobin)</td><td>protein interactions</td><td>3240</td><td>28</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>4.203e-02</td><td>-3.17</td><td>ATPAF2 (ATP synthase mitochondrial F1 complex assembly factor 2)</td><td>protein interactions</td><td>91647</td><td>28</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.203e-02</td><td>-3.17</td><td>ACOT7 (acyl-CoA thioesterase 7)</td><td>protein interactions</td><td>11332</td><td>28</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.203e-02</td><td>-3.17</td><td>CNNM3 (cyclin and CBS domain divalent metal cation transport mediator 3)</td><td>protein interactions</td><td>26505</td><td>28</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.208e-02</td><td>-3.17</td><td>Cytokine-cytokine receptor interaction</td><td>KEGG pathways</td><td>ko04060</td><td>265</td><td>2</td><td>7094</td><td>9</td><td>
TNFRSF11B, CXCL3</td></tr><tr><td>4.208e-02</td><td>-3.17</td><td>Cytokine-cytokine receptor interaction</td><td>KEGG pathways</td><td>hsa04060</td><td>265</td><td>2</td><td>7094</td><td>9</td><td>
TNFRSF11B, CXCL3</td></tr><tr><td>4.212e-02</td><td>-3.17</td><td>Basigin interactions</td><td>REACTOME pathways</td><td>R-HSA-210991</td><td>26</td><td>1</td><td>10293</td><td>17</td><td>
ATP1B1</td></tr><tr><td>4.212e-02</td><td>-3.17</td><td>OSWALD HEMATOPOIETIC STEM CELL IN COLLAGEN GEL UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>222</td><td>2</td><td>17621</td><td>26</td><td>
TNFAIP6, CXCL3</td></tr><tr><td>4.228e-02</td><td>-3.16</td><td>GO REGULATION OF RESPONSE TO EXTERNAL STIMULUS</td><td>MSigDB lists</td><td>&nbsp;</td><td>907</td><td>4</td><td>17621</td><td>26</td><td>
TNFAIP6, ATP1B1, CXCL3, THBS1</td></tr><tr><td>4.232e-02</td><td>-3.16</td><td>regulation of nucleotide metabolic process</td><td>biological process</td><td>GO:0006140</td><td>209</td><td>2</td><td>16543</td><td>26</td><td>
GPR87, THBS1</td></tr><tr><td>4.246e-02</td><td>-3.16</td><td>UDAYAKUMAR MED1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>223</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, ELF3</td></tr><tr><td>4.252e-02</td><td>-3.16</td><td>DOUGLAS BMI1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>532</td><td>3</td><td>17621</td><td>26</td><td>
TNFAIP6, ATP1B1, INPP4B</td></tr><tr><td>4.281e-02</td><td>-3.15</td><td>CHICAS RB1 TARGETS GROWING</td><td>MSigDB lists</td><td>&nbsp;</td><td>224</td><td>2</td><td>17621</td><td>26</td><td>
ANO1, IGFBP3</td></tr><tr><td>4.292e-02</td><td>-3.15</td><td>peptidase regulator activity</td><td>molecular function</td><td>GO:0061134</td><td>212</td><td>2</td><td>16652</td><td>26</td><td>
SLPI, PI3</td></tr><tr><td>4.292e-02</td><td>-3.15</td><td>FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>534</td><td>3</td><td>17621</td><td>26</td><td>
DST, TNFRSF11B, RBPMS</td></tr><tr><td>4.306e-02</td><td>-3.15</td><td>negative regulation of cell migration</td><td>biological process</td><td>GO:0030336</td><td>211</td><td>2</td><td>16543</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>4.307e-02</td><td>-3.14</td><td>basal plasma membrane</td><td>cellular component</td><td>GO:0009925</td><td>30</td><td>1</td><td>17744</td><td>26</td><td>
DST</td></tr><tr><td>4.312e-02</td><td>-3.14</td><td>purinergic receptor signaling pathway</td><td>biological process</td><td>GO:0035587</td><td>28</td><td>1</td><td>16543</td><td>26</td><td>
GPR87</td></tr><tr><td>4.312e-02</td><td>-3.14</td><td>regulation of cGMP metabolic process</td><td>biological process</td><td>GO:0030823</td><td>28</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.312e-02</td><td>-3.14</td><td>import across plasma membrane</td><td>biological process</td><td>GO:0098739</td><td>28</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.312e-02</td><td>-3.14</td><td>plasma membrane invagination</td><td>biological process</td><td>GO:0099024</td><td>28</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.331e-02</td><td>-3.14</td><td>Death</td><td>pfam domains</td><td>PF00531</td><td>31</td><td>1</td><td>16832</td><td>24</td><td>
TNFRSF11B</td></tr><tr><td>4.336e-02</td><td>-3.14</td><td>ACTININ 2</td><td>prosite domains</td><td>PS00020</td><td>23</td><td>1</td><td>11955</td><td>23</td><td>
DST</td></tr><tr><td>4.336e-02</td><td>-3.14</td><td>ACTININ 1</td><td>prosite domains</td><td>PS00019</td><td>23</td><td>1</td><td>11955</td><td>23</td><td>
DST</td></tr><tr><td>4.336e-02</td><td>-3.14</td><td>TNFR NGFR 1</td><td>prosite domains</td><td>PS00652</td><td>23</td><td>1</td><td>11955</td><td>23</td><td>
TNFRSF11B</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO ATPASE REGULATOR ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>VALK AML CLUSTER 10</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>chr15q13</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>SIMBULAN PARP1 TARGETS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP6</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>HATADA METHYLATED IN LUNG CANCER DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO PEPTIDE HORMONE PROCESSING</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>RODRIGUES NTN1 AND DCC TARGETS</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>REACTOME SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
INPP4B</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>WANG IMMORTALIZED BY HOXA9 AND MEIS1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO SODIUM ION HOMEOSTASIS</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO EPIDERMAL GROWTH FACTOR RECEPTOR BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO REGULATION OF NEUTROPHIL MIGRATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
CXCL3</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>GO LAMININ BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.337e-02</td><td>-3.14</td><td>HERNANDEZ MITOTIC ARREST BY DOCETAXEL 1 UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>30</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>4.349e-02</td><td>-3.14</td><td>COL4A1 (collagen type IV alpha 1 chain)</td><td>protein interactions</td><td>1282</td><td>29</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>4.349e-02</td><td>-3.14</td><td>PITX1 (paired like homeodomain 1)</td><td>protein interactions</td><td>5307</td><td>29</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.349e-02</td><td>-3.14</td><td>Ckap5 (cytoskeleton associated protein 5)</td><td>protein interactions</td><td>75786</td><td>29</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.349e-02</td><td>-3.14</td><td>FAM124B (family with sequence similarity 124 member B)</td><td>protein interactions</td><td>79843</td><td>29</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.349e-02</td><td>-3.14</td><td>HNRNPLL (heterogeneous nuclear ribonucleoprotein L like)</td><td>protein interactions</td><td>92906</td><td>29</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.349e-02</td><td>-3.14</td><td>LAPTM5 (lysosomal protein transmembrane 5)</td><td>protein interactions</td><td>7805</td><td>29</td><td>1</td><td>16330</td><td>25</td><td>
KRT7</td></tr><tr><td>4.366e-02</td><td>-3.13</td><td>Neutrophil degranulation</td><td>REACTOME pathways</td><td>R-HSA-6798695</td><td>487</td><td>3</td><td>10293</td><td>17</td><td>
SLPI, CEACAM6, TNFAIP6</td></tr><tr><td>4.372e-02</td><td>-3.13</td><td>Ig sub2</td><td>interpro domains</td><td>IPR003598</td><td>237</td><td>2</td><td>18428</td><td>26</td><td>
CEACAM6, CEACAM5</td></tr><tr><td>4.385e-02</td><td>-3.13</td><td>MULLIGHAN MLL SIGNATURE 1 DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>227</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, RBPMS</td></tr><tr><td>4.420e-02</td><td>-3.12</td><td>V$ZF5 B</td><td>MSigDB lists</td><td>&nbsp;</td><td>228</td><td>2</td><td>17621</td><td>26</td><td>
DST, RBPMS</td></tr><tr><td>4.434e-02</td><td>-3.12</td><td>phosphatidylinositol phosphate phosphatase activity</td><td>molecular function</td><td>GO:0052866</td><td>29</td><td>1</td><td>16652</td><td>26</td><td>
INPP4B</td></tr><tr><td>4.434e-02</td><td>-3.12</td><td>laminin binding</td><td>molecular function</td><td>GO:0043236</td><td>29</td><td>1</td><td>16652</td><td>26</td><td>
THBS1</td></tr><tr><td>4.454e-02</td><td>-3.11</td><td>positive regulation of MAP kinase activity</td><td>biological process</td><td>GO:0043406</td><td>215</td><td>2</td><td>16543</td><td>26</td><td>
TGFA, THBS1</td></tr><tr><td>4.455e-02</td><td>-3.11</td><td>SENESE HDAC1 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>229</td><td>2</td><td>17621</td><td>26</td><td>
RBPMS, KRT7</td></tr><tr><td>4.463e-02</td><td>-3.11</td><td>regulation of macrophage activation</td><td>biological process</td><td>GO:0043030</td><td>29</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>GROSS ELK3 TARGETS DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
SLPI</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>SIMBULAN UV RESPONSE IMMORTALIZED DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>ROZANOV MMP14 TARGETS SUBSET</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>GO BASAL PLASMA MEMBRANE</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>GO SALIVARY GLAND DEVELOPMENT</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
TGM2</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>chr7p13</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>4.478e-02</td><td>-3.11</td><td>GO NEGATIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION</td><td>MSigDB lists</td><td>&nbsp;</td><td>31</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.496e-02</td><td>-3.10</td><td>STRBP (spermatid perinuclear RNA binding protein)</td><td>protein interactions</td><td>55342</td><td>30</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.496e-02</td><td>-3.10</td><td>FAM168A (family with sequence similarity 168 member A)</td><td>protein interactions</td><td>23201</td><td>30</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.496e-02</td><td>-3.10</td><td>ACO2 (aconitase 2)</td><td>protein interactions</td><td>50</td><td>30</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>4.496e-02</td><td>-3.10</td><td>LIN37 (lin-37 DREAM MuvB core complex component)</td><td>protein interactions</td><td>55957</td><td>30</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.496e-02</td><td>-3.10</td><td>GCH1 (GTP cyclohydrolase 1)</td><td>protein interactions</td><td>2643</td><td>30</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>4.515e-02</td><td>-3.10</td><td>TNFR</td><td>smart domains</td><td>SM00208</td><td>23</td><td>1</td><td>9480</td><td>19</td><td>
TNFRSF11B</td></tr><tr><td>4.515e-02</td><td>-3.10</td><td>TSPN</td><td>smart domains</td><td>SM00210</td><td>23</td><td>1</td><td>9480</td><td>19</td><td>
THBS1</td></tr><tr><td>4.550e-02</td><td>-3.09</td><td>regulation of response to stress</td><td>biological process</td><td>GO:0080134</td><td>1274</td><td>5</td><td>16543</td><td>26</td><td>
GPR37, TNFAIP6, TGM2, MAGEA3, THBS1</td></tr><tr><td>4.560e-02</td><td>-3.09</td><td>V$CDC5 01</td><td>MSigDB lists</td><td>&nbsp;</td><td>232</td><td>2</td><td>17621</td><td>26</td><td>
GPR87, INPP4B</td></tr><tr><td>4.560e-02</td><td>-3.09</td><td>V$MYOD Q6</td><td>MSigDB lists</td><td>&nbsp;</td><td>232</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, PCDH1</td></tr><tr><td>4.569e-02</td><td>-3.09</td><td>Ion channel transport</td><td>REACTOME pathways</td><td>R-HSA-983712</td><td>209</td><td>2</td><td>10293</td><td>17</td><td>
ATP1B1, ANO1</td></tr><tr><td>4.584e-02</td><td>-3.08</td><td>calcium activated cation channel activity</td><td>molecular function</td><td>GO:0005227</td><td>30</td><td>1</td><td>16652</td><td>26</td><td>
ANO1</td></tr><tr><td>4.588e-02</td><td>-3.08</td><td>cytokine activity</td><td>molecular function</td><td>GO:0005125</td><td>220</td><td>2</td><td>16652</td><td>26</td><td>
TNFRSF11B, CXCL3</td></tr><tr><td>4.604e-02</td><td>-3.08</td><td>regulation of cysteine-type endopeptidase activity</td><td>biological process</td><td>GO:2000116</td><td>219</td><td>2</td><td>16543</td><td>26</td><td>
MAGEA3, THBS1</td></tr><tr><td>4.607e-02</td><td>-3.08</td><td>TRIM28 (tripartite motif containing 28)</td><td>protein interactions</td><td>10155</td><td>225</td><td>2</td><td>16330</td><td>25</td><td>
MAGEA6, MAGEA3</td></tr><tr><td>4.613e-02</td><td>-3.08</td><td>potassium ion import</td><td>biological process</td><td>GO:0010107</td><td>30</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.613e-02</td><td>-3.08</td><td>negative regulation of striated muscle cell differentiation</td><td>biological process</td><td>GO:0051154</td><td>30</td><td>1</td><td>16543</td><td>26</td><td>
CEACAM5</td></tr><tr><td>4.613e-02</td><td>-3.08</td><td>negative regulation of cell-matrix adhesion</td><td>biological process</td><td>GO:0001953</td><td>30</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.613e-02</td><td>-3.08</td><td>salivary gland morphogenesis</td><td>biological process</td><td>GO:0007435</td><td>30</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>4.613e-02</td><td>-3.08</td><td>positive regulation of calcium ion transmembrane transporter activity</td><td>biological process</td><td>GO:1901021</td><td>30</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.613e-02</td><td>-3.08</td><td>regulation of fibroblast migration</td><td>biological process</td><td>GO:0010762</td><td>30</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>GO REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>GO REGULATION OF BONE RESORPTION</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>PID SYNDECAN 4 PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>MCBRYAN PUBERTAL BREAST 3 4WK DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>PID INTEGRIN A4B1 PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>CHESLER BRAIN HIGHEST GENETIC VARIANCE</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
SCG5</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>FARDIN HYPOXIA 11</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>GO NEGATIVE REGULATION OF ANION TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.619e-02</td><td>-3.07</td><td>GO A BAND</td><td>MSigDB lists</td><td>&nbsp;</td><td>32</td><td>1</td><td>17621</td><td>26</td><td>
DST</td></tr><tr><td>4.631e-02</td><td>-3.07</td><td>V$PITX2 Q2</td><td>MSigDB lists</td><td>&nbsp;</td><td>234</td><td>2</td><td>17621</td><td>26</td><td>
DST, RBPMS</td></tr><tr><td>4.643e-02</td><td>-3.07</td><td>SH3RF2 (SH3 domain containing ring finger 2)</td><td>protein interactions</td><td>153769</td><td>31</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.643e-02</td><td>-3.07</td><td>PPP4R3B (protein phosphatase 4 regulatory subunit 3B)</td><td>protein interactions</td><td>57223</td><td>31</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>4.643e-02</td><td>-3.07</td><td>PER1 (period circadian clock 1)</td><td>protein interactions</td><td>5187</td><td>31</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.643e-02</td><td>-3.07</td><td>KMT2B (lysine methyltransferase 2B)</td><td>protein interactions</td><td>9757</td><td>31</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>4.662e-02</td><td>-3.07</td><td>negative regulation of cell death</td><td>biological process</td><td>GO:0060548</td><td>879</td><td>4</td><td>16543</td><td>26</td><td>
GPR37, CEACAM5, MAGEA3, THBS1</td></tr><tr><td>4.680e-02</td><td>-3.06</td><td>cellular response to tumor necrosis factor</td><td>biological process</td><td>GO:0071356</td><td>221</td><td>2</td><td>16543</td><td>26</td><td>
TNFRSF11B, THBS1</td></tr><tr><td>4.691e-02</td><td>-3.06</td><td>Death domain</td><td>interpro domains</td><td>IPR000488</td><td>34</td><td>1</td><td>18428</td><td>26</td><td>
TNFRSF11B</td></tr><tr><td>4.733e-02</td><td>-3.05</td><td>Hsp70 protein binding</td><td>molecular function</td><td>GO:0030544</td><td>31</td><td>1</td><td>16652</td><td>26</td><td>
GPR37</td></tr><tr><td>4.733e-02</td><td>-3.05</td><td>epidermal growth factor receptor binding</td><td>molecular function</td><td>GO:0005154</td><td>31</td><td>1</td><td>16652</td><td>26</td><td>
TGFA</td></tr><tr><td>4.750e-02</td><td>-3.05</td><td>intermediate filament cytoskeleton</td><td>cellular component</td><td>GO:0045111</td><td>239</td><td>2</td><td>17744</td><td>26</td><td>
DST, KRT7</td></tr><tr><td>4.756e-02</td><td>-3.05</td><td>negative regulation of cell motility</td><td>biological process</td><td>GO:2000146</td><td>223</td><td>2</td><td>16543</td><td>26</td><td>
IGFBP3, THBS1</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>SARTIPY NORMAL AT INSULIN RESISTANCE UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO SNRNA BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>REACTOME ION TRANSPORT BY P TYPE ATPASES</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO ATPASE ACTIVITY COUPLED TO TRANSMEMBRANE MOVEMENT OF IONS PHOSPHORYLATIVE MECHANISM</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO NEGATIVE REGULATION OF RESPONSE TO OXIDATIVE STRESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>WESTON VEGFA TARGETS 12HR</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO PHENOL CONTAINING COMPOUND BIOSYNTHETIC PROCESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO NEGATIVE REGULATION OF CELLULAR RESPONSE TO OXIDATIVE STRESS</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
GPR37</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GROSS HYPOXIA VIA ELK3 ONLY UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
SLPI</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO PHOSPHATIDYLSERINE BINDING</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>PETRETTO CARDIAC HYPERTROPHY</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
IGFBP3</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>DORN ADENOVIRUS INFECTION 12HR DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
ELF3</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>MODULE 522</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>4.760e-02</td><td>-3.04</td><td>GO POSITIVE REGULATION OF SODIUM ION TRANSPORT</td><td>MSigDB lists</td><td>&nbsp;</td><td>33</td><td>1</td><td>17621</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>phenol-containing compound biosynthetic process</td><td>biological process</td><td>GO:0046189</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
GPR37</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>negative regulation of endothelial cell proliferation</td><td>biological process</td><td>GO:0001937</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway</td><td>biological process</td><td>GO:1902235</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
MAGEA3</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>sodium ion homeostasis</td><td>biological process</td><td>GO:0055078</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
ATP1B1</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>response to pain</td><td>biological process</td><td>GO:0048265</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
THBS1</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>regulation of neutrophil migration</td><td>biological process</td><td>GO:1902622</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
CXCL3</td></tr><tr><td>4.763e-02</td><td>-3.04</td><td>peptide hormone processing</td><td>biological process</td><td>GO:0016486</td><td>31</td><td>1</td><td>16543</td><td>26</td><td>
SCG5</td></tr><tr><td>4.767e-02</td><td>-3.04</td><td>Keratinization</td><td>REACTOME pathways</td><td>R-HSA-6805567</td><td>214</td><td>2</td><td>10293</td><td>17</td><td>
KRT7, PI3</td></tr><tr><td>4.774e-02</td><td>-3.04</td><td>VERHAAK AML WITH NPM1 MUTATED DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>238</td><td>2</td><td>17621</td><td>26</td><td>
CEACAM6, RBPMS</td></tr><tr><td>4.782e-02</td><td>-3.04</td><td>CAGGTG V$E12 Q6</td><td>MSigDB lists</td><td>&nbsp;</td><td>2336</td><td>7</td><td>17621</td><td>26</td><td>
GPR37, DST, ATP1B1, PCDH1, IGFBP6, SCG5, GPR87</td></tr><tr><td>4.789e-02</td><td>-3.04</td><td>TRMT2A (tRNA methyltransferase 2 homolog A)</td><td>protein interactions</td><td>27037</td><td>32</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>4.789e-02</td><td>-3.04</td><td>KCTD9 (potassium channel tetramerization domain containing 9)</td><td>protein interactions</td><td>54793</td><td>32</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.789e-02</td><td>-3.04</td><td>DIDO1 (death inducer-obliterator 1)</td><td>protein interactions</td><td>11083</td><td>32</td><td>1</td><td>16330</td><td>25</td><td>
KRT7</td></tr><tr><td>4.789e-02</td><td>-3.04</td><td>MMP9 (matrix metallopeptidase 9)</td><td>protein interactions</td><td>4318</td><td>32</td><td>1</td><td>16330</td><td>25</td><td>
THBS1</td></tr><tr><td>4.789e-02</td><td>-3.04</td><td>PRKD2 (protein kinase D2)</td><td>protein interactions</td><td>25865</td><td>32</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>4.789e-02</td><td>-3.04</td><td>STAMBPL1 (STAM binding protein like 1)</td><td>protein interactions</td><td>57559</td><td>32</td><td>1</td><td>16330</td><td>25</td><td>
MAGEA6</td></tr><tr><td>4.810e-02</td><td>-3.03</td><td>V$TCF11 01</td><td>MSigDB lists</td><td>&nbsp;</td><td>239</td><td>2</td><td>17621</td><td>26</td><td>
ATP1B1, THBS1</td></tr><tr><td>4.843e-02</td><td>-3.03</td><td>Aldosterone-regulated sodium reabsorption</td><td>KEGG pathways</td><td>hsa04960</td><td>39</td><td>1</td><td>7094</td><td>9</td><td>
ATP1B1</td></tr><tr><td>4.843e-02</td><td>-3.03</td><td>Aldosterone-regulated sodium reabsorption</td><td>KEGG pathways</td><td>ko04960</td><td>39</td><td>1</td><td>7094</td><td>9</td><td>
ATP1B1</td></tr><tr><td>4.845e-02</td><td>-3.03</td><td>TNFs bind their physiological receptors</td><td>REACTOME pathways</td><td>R-HSA-5669034</td><td>30</td><td>1</td><td>10293</td><td>17</td><td>
TNFRSF11B</td></tr><tr><td>4.868e-02</td><td>-3.02</td><td>A band</td><td>cellular component</td><td>GO:0031672</td><td>34</td><td>1</td><td>17744</td><td>26</td><td>
DST</td></tr><tr><td>4.882e-02</td><td>-3.02</td><td>V$AREB6 02</td><td>MSigDB lists</td><td>&nbsp;</td><td>241</td><td>2</td><td>17621</td><td>26</td><td>
PCDH1, GPR87</td></tr><tr><td>4.898e-02</td><td>-3.02</td><td>Ephrin rec like</td><td>smart domains</td><td>SM01411</td><td>25</td><td>1</td><td>9480</td><td>19</td><td>
TNFRSF11B</td></tr><tr><td>4.901e-02</td><td>-3.02</td><td>CERIBELLI PROMOTERS INACTIVE AND BOUND BY NFY</td><td>MSigDB lists</td><td>&nbsp;</td><td>34</td><td>1</td><td>17621</td><td>26</td><td>
TFF2</td></tr><tr><td>4.901e-02</td><td>-3.02</td><td>DACOSTA ERCC3 ALLELE XPCS VS TTD DN</td><td>MSigDB lists</td><td>&nbsp;</td><td>34</td><td>1</td><td>17621</td><td>26</td><td>
RBPMS</td></tr><tr><td>4.901e-02</td><td>-3.02</td><td>GO POSITIVE REGULATION OF ERBB SIGNALING PATHWAY</td><td>MSigDB lists</td><td>&nbsp;</td><td>34</td><td>1</td><td>17621</td><td>26</td><td>
TGFA</td></tr><tr><td>4.901e-02</td><td>-3.02</td><td>LOPEZ TRANSLATION VIA FN1 SIGNALING</td><td>MSigDB lists</td><td>&nbsp;</td><td>34</td><td>1</td><td>17621</td><td>26</td><td>
THBS1</td></tr><tr><td>4.913e-02</td><td>-3.01</td><td>blood vessel remodeling</td><td>biological process</td><td>GO:0001974</td><td>32</td><td>1</td><td>16543</td><td>26</td><td>
TGM2</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>INCA1 (inhibitor of CDK, cyclin A1 interacting protein 1)</td><td>protein interactions</td><td>388324</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>Ppp6c (protein phosphatase 6, catalytic subunit)</td><td>protein interactions</td><td>67857</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>UBFD1 (ubiquitin family domain containing 1)</td><td>protein interactions</td><td>56061</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>AP3S1 (adaptor related protein complex 3 sigma 1 subunit)</td><td>protein interactions</td><td>1176</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
KRT7</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>VPS37C (VPS37C, ESCRT-I subunit)</td><td>protein interactions</td><td>55048</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>MOB1B (MOB kinase activator 1B)</td><td>protein interactions</td><td>92597</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
DST</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>DOK3 (docking protein 3)</td><td>protein interactions</td><td>79930</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>FBXL18 (F-box and leucine rich repeat protein 18)</td><td>protein interactions</td><td>80028</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>DDAH2 (dimethylarginine dimethylaminohydrolase 2)</td><td>protein interactions</td><td>23564</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
ATP1B1</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>NAPRT (nicotinate phosphoribosyltransferase)</td><td>protein interactions</td><td>93100</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
RBPMS</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>ELF3 (E74 like ETS transcription factor 3)</td><td>protein interactions</td><td>1999</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
ELF3</td></tr><tr><td>4.935e-02</td><td>-3.01</td><td>PLOD3 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 3)</td><td>protein interactions</td><td>8985</td><td>33</td><td>1</td><td>16330</td><td>25</td><td>
TGM2</td></tr><tr><td>4.955e-02</td><td>-3.00</td><td>V$TST1 01</td><td>MSigDB lists</td><td>&nbsp;</td><td>243</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, INPP4B</td></tr><tr><td>4.971e-02</td><td>-3.00</td><td>Extracellular vesicle-mediated signaling in recipient cells</td><td>WikiPathways</td><td>WP2870</td><td>30</td><td>1</td><td>5314</td><td>9</td><td>
TGFA</td></tr><tr><td>4.991e-02</td><td>-3.00</td><td>DAVICIONI TARGETS OF PAX FOXO1 FUSIONS UP</td><td>MSigDB lists</td><td>&nbsp;</td><td>244</td><td>2</td><td>17621</td><td>26</td><td>
IGFBP6, THBS1</td></tr></TABLE>